Longitudinal Biomarker Profile — Example Report

Key Findings 7 concerns

Active Multi-Pathogen and Parasitic Signature
The patient remains under significant pressure from systemic infections. While new data shows negative results for Tuberculosis, Mycoplasma pneumoniae IgM/DNA, and various rickettsial species, the confirmed historical titers for Toxoplasma gondii, Schistosoma, and the previously identified Borrelia and Bartonella burdens continue to define a chronic infectious state. The absence of acute viral or bacterial markers in the most recent batch suggests these infections may be in a latent or sequestered phase rather than a primary acute phase.
Prostate and Reproductive System Stress
Prostate stress is a primary clinical priority. Despite normal total PSA (0.86 ug/L) and normal Testosterone (19.728 nmol/L), the Prostate Health Index remains critically elevated at 106. This disconnect between a low-normal PSA and a high PHI often indicates localized tissue changes or a high probability of finding significant pathology upon biopsy, despite stable hormonal levels.
Pro-inflammatory and Hypercoagulability Risk
Vascular stress markers remain elevated (VWF activity 155.1%, D-Dimer 570.0 ng/mL). New data shows a healthy Thrombin Time (15.2 Sec) and normal levels of Protein C and Protein S, which helps rule out primary genetic clotting deficiencies. This suggests the hypercoagulable state is likely secondary to endothelial activation from the identified infectious and toxic burdens.
Cellular Aging and Energy Production Deficit
A significant biological-chronological age gap persists (72.7 vs 54 years). New data shows normal Mitochondrial Respiratory Chain complexes (I, II, III, IV) in buccal swabs, suggesting the structural machinery for energy production is intact. However, the previously noted low intracellular NAD (15.2 nmol/ml) and low Mitochondrial Efficiency (26) suggest a functional fuel delivery or cofactor problem rather than a hardware failure.
Heavy Metal and Mycotoxin Burden
The patient carries a targeted toxic load from Mercury (10.91 ug/L urine) and Ochratoxin A (21.25 ng/g). New data shows other toxins like Aflatoxin, Citrinin, and Zearalenone are undetectable, and silver/tin levels are normal. This suggests specific exposures (likely environmental or dietary) rather than generalized poor detoxification.

Situation

Updated analysis confirms biological aging acceleration and chronic toxicant burden, while documenting robust immune defense, negative cancer screenings, and optimal metabolic-nutritional stability.

Background

Telomere Biological Age: 72.7 Years (Ref: 54.4) vs Chronological Age: ~54.7 Years
Mercury: 10.91 ug/L (Urine) and 2.1 ug/g (Hair) [Significant elevation]
Ochratoxin A: 16.21 ug/g Cr (Ref: <1.8)
Melatonin (1st Morning): 4466.06 ug/g Cr (Ref: 10.1 - 26.0)
Mitochondrial Efficiency: 26 (Ref: 46 - 65)
Multi-Cancer Early Detection (MCED): Negative [January 2025]
Bone Mineral Density: T-Score -1.8 at Femoral Neck (Ref: > -1.0)

Assessment

The health profile is characterized by a high environmental toxin burden (Mercury and Ochratoxin A) and low mitochondrial efficiency, which likely drive the observed biological aging acceleration. However, this is balanced by strong systemic resilience: multi-cancer screenings are negative, the immune system shows healthy T-cell and B-cell distributions without active infection (negative TB, Mycoplasma, and parasites), and neurological markers like Neurofilament Light remain in the healthy range. Nutritional status is excellent, with healthy Vitamin D, B12, and NAD+ metabolism. The previously noted systemic immune activation (Rheumatoid Factor) is not accompanied by acute inflammatory markers like Myeloperoxidase or high-sensitivity Troponin, suggesting a chronic rather than acute process.

Recommendation

Prioritize a supervised detoxification protocol to reduce significant Mercury and Ochratoxin A burdens.
Consult a specialist to investigate the extreme 1st-morning melatonin elevation and its relationship to neuroendocrine balance.
Enhance bone health through weight-bearing exercise and optimized mineral intake to address low bone mineral density.
Support mitochondrial recovery using cofactors to bridge the gap between low efficiency and otherwise healthy NAD+ levels.
Monitor the discrepancy between elevated Rheumatoid Factor and currently low systemic inflammation (Systemic Immune-Inflammation Index at 10th percentile).
Maintain the current nutritional and lifestyle regimen that has secured optimal lipid profiles, negative cancer screenings, and high microbiome diversity.
Reassess biological aging markers annually to determine if detoxification and bone health interventions are successfully slowing biological age acceleration.

Health Timeline

Significant biomarker changes over time

2024-10

Akkermansia muciniphila

0.037 percentile → 96 percentile

2025-02

Oxalobacter [in Stool - Quantitative]

0.007 Score → 90.0 Score

2025-03

Bifidobacterium longum 354656-541711

75 Relative Abundance → 356956 Relative Abundance

2025-09

Faecalibacterium prausnitzii

12.4 → 33922.26

Lactobacillus acidophilus

12.4 → 33922.26

Patterns of Concern

7 patterns requiring attention

Active Multi-Pathogen and Parasitic Signature

The patient remains under significant pressure from systemic infections. While new data shows negative results for Tuberculosis, Mycoplasma pneumoniae IgM/DNA, and various rickettsial species, the confirmed historical titers for Toxoplasma gondii, Schistosoma, and the previously identified Borrelia and Bartonella burdens continue to define a chronic infectious state. The absence of acute viral or bacterial markers in the most recent batch suggests these infections may be in a latent or sequestered phase rather than a primary acute phase.

Connected Biomarkers

Borrelia burgdorferi Qualitative Bartonella Species Qualitative Toxoplasma gondii IgG Antibody Schistosoma Species Immunoglobulin G Antibody Mycoplasma pneumoniae Immunoglobulin A Antibody Epstein-Barr Virus Early Antigen p54 IgG Mycobacterium Tuberculosis Complex DNA Qualitative Rickettsia akari Antibody Immunoglobulin G

Potential Causes

Environmental and vector-borne exposures
Immune system inability to suppress latent pathogens
Chronic inflammatory response syndrome

Possible Actions

Consult infectious disease specialist for Toxoplasmosis and Schistosomiasis. Monitor for reactivation symptoms like night sweats or focal neurological changes. Re-test pathogen ELISpots every 6 months.

Prostate and Reproductive System Stress

Prostate stress is a primary clinical priority. Despite normal total PSA (0.86 ug/L) and normal Testosterone (19.728 nmol/L), the Prostate Health Index remains critically elevated at 106. This disconnect between a low-normal PSA and a high PHI often indicates localized tissue changes or a high probability of finding significant pathology upon biopsy, despite stable hormonal levels.

Connected Biomarkers

Prostate Health Index Prostate Specific Antigen (Total) Prostate Specific Antigen (Free) Testosterone Sex Hormone-Binding Globulin Alpha Fetoprotein

Potential Causes

Localized prostatic tissue stress
Chronic inflammatory prostatitis
Early-stage malignancy

Possible Actions

A urological evaluation including a physical exam and imaging (such as MRI) is strongly recommended within 4 weeks due to the high Prostate Health Index.

Pro-inflammatory and Hypercoagulability Risk

Vascular stress markers remain elevated (VWF activity 155.1%, D-Dimer 570.0 ng/mL). New data shows a healthy Thrombin Time (15.2 Sec) and normal levels of Protein C and Protein S, which helps rule out primary genetic clotting deficiencies. This suggests the hypercoagulable state is likely secondary to endothelial activation from the identified infectious and toxic burdens.

Connected Biomarkers

Von Willebrand Factor Antigen Von Willebrand Factor Activity D-Dimer Thrombin Time Protein C Activity Protein S (Free) Myeloperoxidase (MPO)

Potential Causes

Endothelial activation from chronic infections
Systemic inflammatory response
Oxidative stress on vascular walls

Possible Actions

Consult hematology if symptoms of poor circulation or chest pain occur. Re-test D-Dimer and VWF in 3 months to monitor the impact of anti-inflammatory interventions.

Cellular Aging and Energy Production Deficit

A significant biological-chronological age gap persists (72.7 vs 54 years). New data shows normal Mitochondrial Respiratory Chain complexes (I, II, III, IV) in buccal swabs, suggesting the structural machinery for energy production is intact. However, the previously noted low intracellular NAD (15.2 nmol/ml) and low Mitochondrial Efficiency (26) suggest a functional fuel delivery or cofactor problem rather than a hardware failure.

Connected Biomarkers

Telomere Biological Age Nicotinamide Adenine Dinucleotide (NAD) Mitochondrial Efficiency Respiratory Chain Complex I to Citrate Synthase Ratio Nicotinamide Adenine Dinucleotide Phosphate ATP Synthase Subunit Beta

Potential Causes

NAD+ depletion from chronic immune activation
Oxidative damage to mitochondrial function
Nutrient cofactor deficiencies

Possible Actions

Support NAD+ levels with precursors and cofactors. Re-evaluate biological age markers in 12 months after addressing systemic inflammation.

Heavy Metal and Mycotoxin Burden

The patient carries a targeted toxic load from Mercury (10.91 ug/L urine) and Ochratoxin A (21.25 ng/g). New data shows other toxins like Aflatoxin, Citrinin, and Zearalenone are undetectable, and silver/tin levels are normal. This suggests specific exposures (likely environmental or dietary) rather than generalized poor detoxification.

Connected Biomarkers

Mercury (Urine) Ochratoxin A (Urine) Zearalenone Aflatoxin M1 Silver Tin

Potential Causes

Specific environmental or dietary exposures
Impaired clearance of specific toxins

Possible Actions

Identify and eliminate the source of Ochratoxin (often mold in home or stored grains). Continue mercury detoxification protocols and monitor levels every 4-6 months.

Functional Gut Dysbiosis and Low Beneficial Flora

Intestinal assimilation remains very low (21%). While new data shows no active intestinal parasites (Strongyloides, Taenia, and Hookworm negative) and normal Zonulin (50 ng/mL), the continued decline of beneficial Lactobacillus and Bifidobacterium indicates a failure of the microbiome to thrive, likely contributing to the nutrient absorption deficit.

Connected Biomarkers

Intestinal Assimilation Score Lactobacillus (Total) Bifidobacterium (Total) Zonulin Ova and Parasites Qualitative Akkermansia muciniphila

Potential Causes

Malabsorption of macronutrients
Chronic low-grade inflammation
Insufficient prebiotic substrate for beneficial bacteria

Possible Actions

Implement digestive enzyme support and targeted prebiotic supplementation to rebuild the beneficial bacterial populations identified as low.

Kidney Stress andwaste Clearance Efficiency

While most recent urine markers (Nitrite, Protein, RBC) are negative and the Albumin/Creatinine ratio is healthy (0.5), the elevated Kidney Age (60.2 years) suggests cumulative stress. The renal system appears to be functioning within normal limits but is under pressure from processing the identified mercury and mycotoxin load.

Connected Biomarkers

Kidney Age (Symphony) Albumin to Creatinine Ratio Urea Nitrite Qualitative Specific Gravity Red Blood Cell Count (Urine)

Potential Causes

Chronic excretion of heavy metals and mycotoxins
Systemic vascular inflammation

Possible Actions

Prioritize hydration and minimize exposure to nephrotoxic substances. Monitor eGFR and Kidney Age annually as part of detoxification monitoring.

Healthy Patterns

3 biomarker groups within normal ranges

Thyroid and Metabolic Stability

The thyroid system appears well-compensated. While Reverse T3 has trended upward (422 pmol/L), it remains within the normal range. New data shows a significant improvement in Thyroglobulin Antibodies (from 14.0 to <1.3 IU/mL) and stable TSH (2.62 mIU/L), indicating a reduction in autoimmune thyroid activity.

Connected Biomarkers

Thyroid Stimulating Hormone Thyroglobulin Antibody Thyroid Peroxidase Antibody Reverse Triiodothyronine Thyroid Stimulating Hormone Receptor Antibody

Potential Causes

Reduction in systemic autoimmune triggers
Stable endocrine feedback loops

Possible Actions

Continue monitoring thyroid panel every 6 months. Maintain current support as antibodies have successfully normalized.

Bone Mineral Density and Metabolic Balance

Bone health is a point of significant improvement. The T-Score has normalized to -0.1 from a previous low of -0.9. New data shows normal Procollagen Type I (29.3 ug/L) and Parathyroid Hormone (3.4 pmol/L), suggesting active and healthy bone remodeling is currently taking place.

Connected Biomarkers

Bone Mineral Density T-Score Procollagen Type I N-Terminal Propeptide Parathyroid Hormone (Intact) Vitamin D 25-Hydroxy

Potential Causes

Effective mineral and Vitamin D supplementation
Adequate structural metabolic support

Possible Actions

Maintain current Vitamin D and mineral protocols. Re-test T-score annually to ensure the stabilization persists.

Systemic Cancer Screening and Autoimmune Markers

Comprehensive screening for multiple cancer types and systemic autoimmune conditions has yielded overwhelmingly negative results. This includes Multi-Cancer Early Detection (MCED), various specific carcinoma markers, and a wide array of autoimmune antibodies (Ro, Smith, Scl-70), providing a strong baseline of health in these areas.

Connected Biomarkers

Multi-Cancer Early Detection Qualitative Nuclear Matrix Protein 2 Antibody Ro Antibody Qualitative Smith Antibody Qualitative Topoisomerase I Antibody Tumor Marker Panel

Potential Causes

Absence of detectable malignancy or systemic rheumatological disease

Possible Actions

Continue standard age-appropriate screenings. The current negative results provide strong reassurance against systemic autoimmune disease.

Follow Up Tests

Recommended tests based on current biomarker findings

Comprehensive Lyme and Co-infection Profile priority

Conditional explanation: Patient has tested positive for Borrelia burgdorferi IgG, Bartonella species, and several Coxsackievirus antibodies. IF the patient is experiencing fatigue, joint pain, or neurological symptoms → a multi-method workup including PCR and Western Blot is needed within 1-2 weeks; IF asymptomatic → repeat antibody titers in 4-6 weeks to distinguish between active and past infection.

Borrelia burgdorferi Antibody IgG Qualitative (Immunoblot) [in Blood - Qualitative] Bartonella Species Qualitative [in Blood - Qualitative] Coxsackievirus A7 Antibody Immunoglobulin G [in Blood - Quantitative] Interferon Gamma (Borrelia iSpot Full Antigen) [in Blood - Quantitative] Mycoplasma pneumoniae Immunoglobulin A Antibody (ELISA) [in Blood - Quantitative]

Cardiac Evaluation (ECHO and Holter Monitor) priority

Conditional explanation: Patient shows elevated D-Dimer (570.0 ng/mL) and an out-of-range Coagulation Factor VIII activity, alongside a history of apnea events and abnormal bruxism indices. IF experiencing chest pain, palpitations, or shortness of breath → urgent cardiac evaluation and possible imaging for hypercoagulability/thrombosis risk; IF no symptoms → routine monitoring of coagulation markers in 3 months.

D-Dimer [in Blood - Quantitative] Coagulation Factor VIII Activity [in Blood - Quantitative] Central Apnea Index (Total) [Quantitative] Brain Natriuretic Peptides [in Blood - Quantitative] Creatine Kinase MB [in Blood - Quantitative]

Prostate Multi-Parametric MRI and Urological Consultation priority

Conditional explanation: Multiple markers indicate significant prostate stress, including a Prostate Health Index of 106 (well above the reference of 23), an elevated Prostate Specific Antigen derivative, and clinical observations of severe blockage and suspicious criteria. IF experiencing urinary frequency, hesitancy, or nocturnal urgency → urgent urological consultation and multi-parametric MRI within 1-2 weeks; IF symptoms are mild → formal urological review and repeat PSA/PHI in 3 months.

Prostate Health Index [in Blood - Quantitative] Prostate (Blockage) [Qualitative] Prostate (Suspicion Criteria) [Quantitative] [-2]Pro-Prostate Specific Antigen [in Blood - Quantitative] Prostate Specific Antigen [in Blood - Quantitative]

Coagulation and Cardiac Imaging Workup priority

Conditional explanation: High D-Dimer (570.0 ng/mL) and Factor VIII activity are now joined by an out-of-range Von Willebrand Factor (189.6%) and a positive Platelet Antibody Screen, suggesting a complex hypercoagulable state. IF experiencing palpitations, leg swelling, or shortness of breath → urgent ECHO and hematology consult within 1 week; IF asymptomatic → repeat coagulation panel including VWF and D-Dimer in 4 weeks.

D-Dimer [in Blood - Quantitative] Von Willebrand Factor Antigen [in Blood - Quantitative] Platelet Antibody Screen Qualitative [in Blood - Qualitative] Coagulation Factor VIII Activity [in Blood - Quantitative]

Cardiac and Coagulation Evaluation priority

Conditional explanation: Patient has elevated D-Dimer (570.0 ng/mL), high Factor VIII activity, and elevated Von Willebrand Factor (189.6%), indicating a hypercoagulable state. Although NT-proBNP and Troponin I are currently normal, the presence of platelet antibodies and factor elevations increases cardiovascular risk. IF experiencing chest pain, palpitations, or leg swelling → urgent ECHO, Holter monitor, and hematology consult within 1 week; IF asymptomatic → repeat coagulation panel in 4 weeks.

D-Dimer [in Blood - Quantitative] Coagulation Factor VIII Activity [in Blood - Quantitative] Von Willebrand Factor Antigen [in Blood - Quantitative] Platelet Antibody Screen Qualitative [in Blood - Qualitative] N-Terminal Pro-Brain Natriuretic Peptide [in Blood - Quantitative]

Blood/Hematology

38 biomarkers

Basophils Percentage [in Blood - Quantitative] (%)

Loading chart...

Recent values have normalized following previous significant out-of-range elevations.

Description White blood cell type associated with allergic reactions and inflammation. Measurements Trend: Falling fast - recent decline following significant 32.1% spike. April 2024: 0.4%. May 2024: 1.0%. September 2024: 0.6%. November 2024: 0.9%. December 2024: 0.9%. January 2025: 32.1%. March 2025: 0.7% (average of 2 readings). May 2025: 0.8%. June 2025: 1.1%. July 2025: 3.5%. August 2025: 0.5%. September 2025: 0.0%. November 2025: 0.9%. Clinical meaning History of significant fluctuations and extreme outliers. Current level normalized after previous elevations. Action Monitor for recurrent spikes or symptoms of allergy/inflammation. Sample source Blood.

Eosinophils Percentage [in Blood - Quantitative] (%)

Loading chart...

Patient shows stable, normal eosinophil levels following a previous significant spike.

Description

White blood cell subtype involved in allergic response and parasite defense.

Measurements

Trend: Flat - Values stable within normal range following transient spikes.

April 2024: 0.5%
May 2024: 2.0%
July 2024: 3.0%
September 2024: 1.6%
November 2024: 1.5% (avg, 2 readings)
December 2024: 1.7%
January 2025: 36.8%
March 2025: 1.5% (avg, 2 readings)
May 2025: 0.8%
June 2025: 1.1%
July 2025: 0.8%
August 2025: 2.6%
September 2025: 2.0%
October 2025: 1.9%
November 2025: 1.8%

Clinical meaning

Recent values consistently normal despite significant January 2025 spike.
Elevated readings suggest historical inflammatory or allergic triggers.

Action

No action required as current values are within normal reference limits.

Sample source

Blood

Mean Cell Volume [in Blood - Quantitative] (fL)

Loading chart...

Mean cell volume remains stable and within normal clinical range.

Description

Measurement of average red blood cell size.

Measurements

Trend: Flat - Consistent levels except for single macrocytic outlier.

April 2024: 96.0 fL
May 2024: 94.0 fL
September 2024: 92.0 fL
October 2024: 92.0 fL (avg, 2 readings)
November 2024: 93.0 fL
December 2024: 92.0 fL
March 2025: 91.0 fL (avg, 2 readings)
May 2025: 91.0 fL
June 2025: 93.0 fL
July 2025: 112.7 fL
August 2025: 94.0 fL
September 2025: 96.0 fL
October 2025: 93.0 fL
November 2025: 94.0 fL

Clinical meaning

Persistent normocytic status maintained across most timepoints.
July 2025 macrocytosis resolved rapidly without intervention.

Action

No action required; current cell volume is normal.

Sample source

Blood

Mean Corpuscular Hemoglobin Concentration [in Blood - Quantitative] (g/dL)

Loading chart...

Patient maintains stable hemoglobin concentration within expected range.

Description Measure of average concentration of hemoglobin in given volume of packed red blood cells. Measurements Trend: Flat - Stable within range despite single outlier in July 2025. April 2024: 32.0 g/dL
May 2024: 32.9 g/dL
July 2024: 33.3 g/dL (avg of 2)
September 2024: 33.0 g/dL
October 2024: 34.7 g/dL
November 2024: 33.0 g/dL
December 2024: 33.0 g/dL
March 2025: 34.0 g/dL (avg of 2)
May 2025: 35.0 g/dL
June 2025: 33.0 g/dL
July 2025: 27.8 g/dL
August 2025: 33.0 g/dL
September 2025: 33.0 g/dL
October 2025: 33.0 g/dL (avg of 2)
November 2025: 33.0 g/dL. Clinical meaning Consistent values indicate normal hemoglobin density. Isolated drop in July 2025 likely analytical artifact given immediate return to baseline. Action No action required. Sample Source: Blood.

Monocytes Percentage [in Blood - Quantitative] (%)

Loading chart...

Monocyte levels have stabilized within normal ranges.

Description Percentage of monocytes in white blood cell differential indicating immune response status. Measurements Trend: Falling - Normalization following transient elevations in late 2024. April 2024: 3.9 %
May 2024: 9.0 %
September 2024: 12.9 %
November 2024: 7.8 %
December 2024: 6.6 %
January 2025: 10.1 %
March 2025: 6.2 % (avg of 2)
May 2025: 7.2 %
June 2025: 5.4 %
July 2025: 5.1 %
August 2025: 6.7 %
September 2025: 5.0 %
October 2025: 4.9 %
November 2025: 7.2 %. Clinical meaning Historical elevations suggest past immune activation or inflammation. Recent data shows stable recovery within reference limits. Action No action required. Sample Source: Blood.

Neutrophils Percentage [in Blood - Quantitative] (%)

Loading chart...

Biomarker has stabilized within normal reference range following earlier fluctuations.

Description White blood cell percentage indicating bacterial infection response. Measurements Trend: Rising - Recovery from transient lows toward middle of reference range. April 2024: 73.5%
May 2024: 45.0%
July 2024: 42.9%
September 2024: 37.8%
November 2024: 53.6%
December 2024: 54.2%
January 2025: 39.9%
March 2025: 64.3% average (2)
May 2025: 52.5%
June 2025: 56.1%
July 2025: 54.3%
August 2025: 49.0%
September 2025: 54.5%
October 2025: 60.4%
November 2025: 47.0%. Clinical meaning Historical low percentages suggest past viral suppression or decreased production; current values indicate stabilization. Low levels in late 2024 resolved to normal range in late 2025. Action No action required as current values are within normal limits. Sample source Blood.

Lymphocytes Percentage [in Blood - Quantitative] (%)

Loading chart...

Immune profile shows consistent stability within normal parameters over last 12 months.

Description White blood cell percentage indicating viral immune response and chronic inflammation. Measurements Trend: Falling slightly - Normalizing after previous elevations. April 2024: 21.7%
May 2024: 43.0%
July 2024: 46.3% average (2)
September 2024: 47.1%
November 2024: 36.2% average (2)
December 2024: 36.6%
March 2025: 27.3% average (2)
May 2025: 38.7%
June 2025: 36.3%
July 2025: 36.3%
August 2025: 41.2%
September 2025: 38.0%
October 2025: 32.0% average (2)
November 2025: 43.1%. Clinical meaning Previous mild elevations (lymphocytosis) mid-2024 suggest past viral challenge. Values currently sustained within normal upper limits. Action No action required. Sample source Blood.

Packed Cell Volume [in Blood - Quantitative] (%)

Loading chart...

Normal values and stable recent trend.

Description Proportion red blood cells in blood. Measurements Trend: Flat - values mostly stable within range despite transient elevation. April 2024: 46.0, May 2024: 44.0, September 2024: 44.0, October 2024: 41.0, November 2024: 44.0, December 2024: 48.0, March 2025: 45.0, May 2025: 42.0, June 2025: 44.0, July 2025: 52.5 (avg of 2), August 2025: 44.0, September 2025: 46.0, November 2025: 42.0. Clinical meaning Transient elevation July 2025 likely dehydration or acute change. Recent values show normalization and stability. Action No action required. Sample source Blood.

Platelet Count [in Blood - Quantitative] (x10^9/L)

Loading chart...

Values have normalized and remain stable above threshold.

Description Concentration of platelets for blood clotting. Measurements Trend: Rising - general upward trajectory from initial low levels. April 2024: 146.0, May 2024: 134.0, September 2024: 146.0, October 2024: 143.0, November 2024: 173.0, December 2024: 145.0, March 2025: 171.0 (avg of 2), May 2025: 168.0, June 2025: 176.0, August 2025: 187.0, September 2025: 174.0, October 2025: 173.0, November 2025: 157.0. Clinical meaning Historical mild thrombocytopenia resolved. Current readings consistently within reference range. Action No action required. Sample source Blood.

Red Blood Cell Count [in Blood - Quantitative] (x10^12/L)

Loading chart...

RBC count has dropped below reference range for the first time in 18 months.

Description

Total count of oxygen-carrying erythrocytes in peripheral circulation.

Measurements

Trend: Falling slightly - Steady decline from mid-2025 reaching sub-optimal levels.

April 2024: 4.8 x10^12/L
May 2024: 4.62 x10^12/L
July 2024: 4.6 x10^12/L (Average of 2)
September 2024: 4.8 x10^12/L
November 2024: 4.7 x10^12/L
December 2024: 5.15 x10^12/L
March 2025: 4.7 x10^12/L (Average of 2)
May 2025: 4.58 x10^12/L
June 2025: 4.7 x10^12/L
August 2025: 4.73 x10^12/L
September 2025: 4.77 x10^12/L
November 2025: 4.4 x10^12/L

Clinical meaning

Recent drop below reference range suggests mild anemia or hemodilution.
Persistent low-normal baseline followed by new low outlier.

Action

Investigate potential iron, B12, or folate deficiencies to address recent decline.

Sample source

Blood

White Blood Cell Count [in Blood - Quantitative] (x10^9/L)

Loading chart...

WBC count is currently stable within range but history shows frequent episodes of leukopenia.

Description

Total count of immune system cells circulating in blood.

Measurements

Trend: Flat - Fluctuating around lower limit of normal with intermittent leukopenia.

April 2024: 6.1 x10^9/L
May 2024: 3.4 x10^9/L
September 2024: 3.1 x10^9/L
October 2024: 4.1 x10^9/L
November 2024: 4.6 x10^9/L
December 2024: 4.2 x10^9/L
March 2025: 6.5 x10^9/L (Average of 2)
May 2025: 3.8 x10^9/L
June 2025: 3.7 x10^9/L
August 2025: 4.6 x10^9/L
September 2025: 4.2 x10^9/L
October 2025: 4.6 x10^9/L
November 2025: 4.4 x10^9/L

Clinical meaning

Recurring mild leukopenia indicates vulnerability to infection or chronic marrow suppression.
Patterns show periodic recovery followed by dips below range.

Action

Monitor differential count to identify which specific cell line is causing low total values.

Sample source

Blood

Eosinophils Absolute Value [in Blood - Quantitative] (x10^9/L)

Loading chart...

Values remain stable and mostly within reference range.

Description White blood cell type involved in allergy and parasite response. Measurements Trend: Flat - values consistently low-normal with single transient dip in May 2025. May 2024: 0.07, July 2024: 0.13 (avg/2), September 2024: 0.05, October 2024: 0.08 (avg/2), November 2024: 0.07, December 2024: 0.07, March 2025: 0.095 (avg/2), May 2025: 0.03, June 2025: 0.04, August 2025: 0.12, September 2025: 0.08, October 2025: 0.09 (avg/2), November 2025: 0.1. Clinical meaning Results largely reflect baseline healthy levels. May 2025 dip clinically insignificant without context of total WBC count. Action No action required. Sample source Blood.

Lymphocytes Absolute Value [in Blood - Quantitative] (x10^9/L)

Loading chart...

Results borderline low but stable over time.

Description Essential white blood cell for adaptive immune system and viral defense. Measurements Trend: Flat - stable readings around lower limit of normal. May 2024: 1.5, July 2024: 1.94, September 2024: 1.5, October 2024: 1.8, November 2024: 1.7, December 2024: 1.5, March 2025: 1.75 (avg/2), May 2025: 1.5, June 2025: 1.3, August 2025: 1.9, September 2025: 1.6, October 2025: 1.5 (avg/2), November 2025: 1.9. Clinical meaning Consistently at lower threshold of normal range. Mild lymphopenia noted June 2025 with rapid recovery. Action Monitor during routine follow-up. Sample source Blood.

Monocytes Absolute Value [in Blood - Quantitative] (x10^9/L)

Loading chart...

Results consistently hover at or just below the lower reference limit suggesting stable baseline.

Description

Absolute count of circulating white blood cells responsible for immune response and tissue repair.

Measurements

Trend: Flat - stable near lower limit

May 2024: 0.3 x10^9/L
July 2024: 0.29 x10^9/L
September 2024: 0.4 x10^9/L
October 2024: 0.3 x10^9/L
November 2024: 0.4 x10^9/L
December 2024: 0.3 x10^9/L
March 2025: 0.4 x10^9/L (average of 2)
May 2025: 0.3 x10^9/L
June 2025: 0.2 x10^9/L
August 2025: 0.3 x10^9/L
September 2025: 0.2 x10^9/L
November 2025: 0.3 x10^9/L

Clinical meaning

Values persistently low-normal or slightly below reference ranges
Isolated mild monocytopenia often lacks clinical significance if other counts are stable

Action

Correlate with clinical symptoms of infection or fatigue.

Sample source

Blood

Neutrophils Absolute Value [in Blood - Quantitative] (x10^9/L)

Loading chart...

Significant recovery from low 2024 levels to consistently normal range in late 2025.

Description

Primary white blood cell marker for fighting bacterial infections.

Measurements

Trend: Rising - improvement from early 2024 lows to stable normal range

May 2024: 1.5 x10^9/L
July 2024: 1.8 x10^9/L (average of 2)
September 2024: 1.2 x10^9/L
October 2024: 1.9 x10^9/L
November 2024: 2.5 x10^9/L (average of 2)
December 2024: 2.3 x10^9/L
March 2025: 4.25 x10^9/L (average of 2)
May 2025: 2.0 x10^9/L
June 2025: 2.1 x10^9/L
August 2025: 2.3 x10^9/L
September 2025: 2.3 x10^9/L
November 2025: 2.1 x10^9/L

Clinical meaning

Resolved mild neutropenia seen in 2024
Current values show stable recovery within normal reference limits

Action

No action required as current values are within range.

Sample source

Blood

SYMPHONY Age (Blood) [Quantitative] (Years)

Loading chart...

Biological age remains elevated above reference range despite recent improvements.

Description

Multivariate blood biomarker score estimating systemic biological aging.

Measurements

Trend: Falling slightly - General decline from peaks toward 55.9 years.

March 2024.0: 58.2 Years
December 2024.0: 58.3 Years
January 2025.0: 58.6 Years
February 2025.0: 58.3 Years (Average of 2)
March 2025.0: 64.4 Years (Average of 2)
June 2025.0: 58.6 Years (Average of 2)
September 2025.0: 55.9 Years

Clinical meaning

Biological age consistently exceeds reference threshold of 54.4.
Recent improvement observed since March peak.

Action

Monitor lifestyle factors and systemic inflammation to continue downward trajectory.

Sample source

Blood

Ferritin [in Blood - Quantitative] (ug/L)

Loading chart...

Ferritin levels have dropped below normal range indicating iron deficiency.

Description

Intracellular protein storing iron and indicating total body iron reserves.

Measurements

Trend: Falling fast - Continuous decline from 101.0 ug/L to sub-optimal levels.

September 2024.0: 84.7 ug/L
November 2024.0: 92.5 ug/L
December 2024.0: 101.0 ug/L (Average of 2)
March 2025.0: 34.0 ug/L (Average of 2)
May 2025.0: 32.3 ug/L
October 2025.0: 17.7 ug/L (Average of 2)
November 2025.0: 19.0 ug/L

Clinical meaning

Levels fell below 22.0 ug/L limit in late 2025.
Depleted iron stores suggest progressive iron deficiency.

Action

Evaluate for potential sources of iron loss or malabsorption and consider supplementation.

Sample source

Blood

D-Dimer [in Blood - Quantitative] (ng/mL)

Loading chart...

D-Dimer has returned to clinically elevated levels after period of stability.

Description Fibrin degradation product indicating active blood clot formation/breakdown. Measurements Trend: Rising - Recent increase back above threshold. October 2024: 578.8 average (5 readings)
March 2025: 320.0
May 2025: 270.0
October 2025: 570.0. Clinical meaning Elevation suggests possible thrombosis or systemic inflammation. Latest value exceeds 500 ng/mL reference limit. Action Evaluate for clinical symptoms of venous thromboembolism or acute inflammatory triggers. Sample source Blood.

SYMPHONY Age (Blood) [in Blood - Quantitative] (Years)

Loading chart...

Biological age remains elevated above reference targets despite general stability.

Description Epigenetic biological age estimation via multi-omic blood analysis. Measurements Trend: Flat - values hovering around 58 years with brief spike in March 2025. - March 2024: 58.6 (average of 3) - February 2025: 58.3 - March 2025: 64.4 - May 2025: 57.9 - June 2025: 58.6 Clinical meaning - Biological age consistently exceeds chronological reference range. - Indicates accelerated cellular aging or systemic inflammation. Action Investigate lifestyle factors and inflammatory markers to slow biological aging. Sample source Blood.

Activated Partial Thromboplastin Time (Lupus Anticoagulant Screen) [in Blood - Quantitative] (Seconds)

Loading chart...

Persistent shortened clotting times indicate potential hypercoagulability.

Description Functional assay measuring intrinsic and common coagulation pathways. Measurements Trend: Falling slightly - values trending toward lower limit or below range. - October 2024: 27.4 (average of 2) - January 2025: 29.4 - March 2025: 19.3 - August 2025: 28.6 Clinical meaning - Low values suggest hypercoagulable state or acute phase response. - Shortened times may increase risk for thrombotic events. Action Evaluate for prothrombotic risk factors or presence of acute inflammation. Sample source Blood.

International Normalized Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Multiple out-of-range readings suggest elevated clotting risk despite slight recent improvement.

Description Standardized measurement of blood clotting time. Measurements Trend: Rising slightly - Recent upward movement following period of stability below range. Oct 2024: 0.91; Dec 2024: 0.7; Mar 2025: 0.7
May 2025: 0.8. Clinical meaning Sub-therapeutic INR suggests blood clots faster than desired. Action Adjust anticoagulant dosage if applicable or screen for prothrombotic factors. Sample source Blood.

Prothrombin Time [in Blood - Quantitative] (Seconds)

Loading chart...

PT values have normalized following two initial low readings.

Description Measure of blood clotting time via extrinsic pathway. Measurements Trend: Rising - Moving from low towards normal range. - December 2024: 8.7 Seconds - March 2025: 9.5 Seconds - May 2025: 10.1 Seconds Clinical meaning - Initially short PT suggested rapid clotting or potential vitamin K excess. - Normalization indicates stabilized coagulation profile. Action No action required as latest result within reference range. Sample source Blood

Transferrin Saturation [in Blood - Quantitative] (%)

Loading chart...

Recent data indicates healthy iron saturation levels and successful recovery from previous elevation.

Description Clinical ratio representing percentage of transferrin binding sites occupied by iron. Measurements Trend: Falling - Decreasing since May 2025 high. December 2024: 38.0% (Average of 2), March 2025: 32.0%, May 2025: 47.0%, October 2025: 26.0%. Clinical meaning Current results show adequate iron transport without evidence of iron deficiency or clinical overload. Action No action required as latest result is well within target range. Sample source Blood.

Carboxypeptidase B2 [in Blood - Quantitative] (percentile)

Loading chart...

Significant decline to sub-normal levels indicates increased bleeding risk.

Description Enzyme plasma marker regulating fibrinolysis and blood clot degradation. Measurements Trend: Falling fast - Significant drop below reference range. - January 2025.0: 81.2 percentile - August 2025.0: 9.1 percentile (average of 2 readings) Clinical meaning - Low levels suggest accelerated fibrinolysis and potential bleeding risk. - Recent drop indicates shift in coagulation balance. Action Investigate potential hyperfibrinolysis or underlying liver dysfunction. Sample source Blood.

Red Cell Distribution Width [in Blood - Quantitative] (%)

Loading chart...

Consistent results within reference range indicate stable erythropoiesis.

Description Measurement of variation in red blood cell volume and size. Measurements Trend: Flat - Values remain stable within normal limits. - April 2024.0: 13.8 % - May 2024.0: 13.6 % - September 2024.0: 12.7 % - October 2024.0: 12.9 % (average of 2 readings) - November 2024.0: 13.2 % - December 2024.0: 13.1 % - March 2025.0: 12.8 % (average of 2 readings) - May 2025.0: 13.4 % - June 2025.0: 31.85 % (average of 2 readings: 50.0 %, 13.7 %) - August 2025.0: 36.6 % (average of 2 readings: 59.5 %, 13.7 %) - September 2025.0: 13.3 % - October 2025.0: 13.0 % - November 2025.0: 13.5 % Clinical meaning - Stable RDW indicates uniform red cell size. - Normal values suggest no active nutrient deficiencies or bone marrow stress. Action No action required. Sample source Blood.

Mean Cell Hemoglobin [in Blood - Quantitative] (Pg)

Loading chart...

All values recorded are normal and stable across all time points.

Description

Average mass of hemoglobin per red blood cell.

Measurements

Trend: Flat - consistently near 31.0 Pg.

April 2024.0: 31.0 Pg
May 2024.0: 31.0 Pg
July 2024.0: 31.0 Pg (avg, 2 readings)
September 2024.0: 30.0 Pg
October 2024.0: 32.0 Pg
November 2024.0: 31.0 Pg (avg, 2 readings)
December 2024.0: 31.0 Pg
March 2025.0: 31.0 Pg (avg, 2 readings)
May 2025.0: 31.0 Pg
June 2025.0: 31.0 Pg
July 2025.0: 31.3 Pg
August 2025.0: 31.0 Pg
September 2025.0: 31.0 Pg
November 2025.0: 31.0 Pg

Clinical meaning

Red cell hemoglobin content remains stable and within normal reference ranges.
No evidence of microcytic or macrocytic trends.

Action

No action required.

Sample source

Blood

Hemoglobin [in Blood - Quantitative] (g/dL)

Loading chart...

Hemoglobin levels are consistently normal and demonstrate healthy oxygen-carrying capacity.

Description

Protein in red blood cells carrying oxygen throughout body.

Measurements

Trend: Flat - fluctuating within narrow normal range.

April 2024.0: 14.9 g/dL
July 2024.0: 13.7 g/dL
September 2024.0: 14.6 g/dL
November 2024.0: 14.5 g/dL
December 2024.0: 15.7 g/dL
March 2025.0: 14.55 g/dL (avg, 2 readings)
May 2025.0: 14.4 g/dL
June 2025.0: 14.4 g/dL
July 2025.0: 14.6 g/dL
August 2025.0: 14.5 g/dL
September 2025.0: 14.8 g/dL
October 2025.0: 14.5 g/dL
November 2025.0: 13.7 g/dL

Clinical meaning

Oxygen-carrying capacity is sufficient and stable.
Results indicate absence of anemia or polycythemia.

Action

No action required.

Sample source

Blood

Basophils Absolute Value [in Blood - Quantitative] (x10^9/L)

Loading chart...

Basophil levels remain stable and within healthy reference intervals.

Description White blood cell marker for allergic response and inflammation. Measurements Trend: Falling slightly - stable low values near zero. May 2024: 0.03 x10^9/L. July 2024: 0.04 x10^9/L (average of 2). September 2024: 0.0 x10^9/L. October 2024: 0.04 x10^9/L. November 2024: 0.0 x10^9/L. December 2024: 0.0 x10^9/L. March 2025: 0.0 x10^9/L (average of 2). May 2025: 0.0 x10^9/L. June 2025: 0.0 x10^9/L. August 2025: 0.0 x10^9/L. November 2025: 0.0 x10^9/L. Clinical meaning Results consistently within normal range. Low absolute counts typical and clinically insignificant. Action No action required. Sample source Blood.

Fibrinogen [in Blood - Quantitative] (g/L)

Loading chart...

Fibrinogen levels are stable and within the optimal target range.

Description Glycoprotein essential for blood clot formation. Measurements Trend: Flat - minor fluctuations within normal range. October 2024: 3.08 g/L (average of 3). December 2024: 2.6 g/L. January 2025: 3.3 g/L. March 2025: 3.28 g/L. May 2025: 2.96 g/L. Clinical meaning Values indicate normal coagulation potential. No signs of acute phase inflammation or consumption coagulopathy. Action No action required. Sample source Blood.

Total Iron Binding Capacity [in Blood - Quantitative] (umol/L)

Loading chart...

Biomarker stable and within normal limits across all time points.

Description

Blood protein measurement reflecting total capacity to bind iron.

Measurements

Trend: Rising - Gradual increase toward mid-range.

September 2024.0: 49.2 umol/L
October 2024.0: 47.7 umol/L (Average of 2)
March 2025.0: 57.6 umol/L
May 2025.0: 56.2 umol/L
October 2025.0: 62.3 umol/L

Clinical meaning

Values consistently within reference range.
Rising trend suggests increased iron transport capacity without reaching deficiency markers.

Action

No action required.

Sample source

Blood

Dilute Russell Viper Venom Time (Lupus Anticoagulant Screen Ratio) [in Blood - Quantitative] (Ratio)

Loading chart...

Normal results indicate absence of lupus anticoagulant interference.

Description

Clotting assay screening for lupus anticoagulant antibodies.

Measurements

Trend: Flat - Values remain stable below threshold.

October 2024.0: 0.92 Ratio (Average of 2)
January 2025.0: 0.84 Ratio
August 2025.0: 0.92 Ratio

Clinical meaning

Negative result for lupus anticoagulant.
Consistent stability suggests no active prothrombotic antibody risk detected.

Action

No action required.

Sample source

Blood

Iron [in Blood - Quantitative] (umol/L)

Loading chart...

Patient remains iron-replete within normal clinical parameters.

Description

Serum marker of circulating iron bound to transferrin.

Measurements

Trend: Falling - Significant drop from May 2025 high.

December 2024: 24.7 umol/L (avg of 2)
March 2025: 18.7 umol/L
May 2025: 26.2 umol/L
October 2025: 16.1 umol/L (avg of 2)

Clinical meaning

Values stay in range despite downward shift.
Iron availability sufficient for metabolic needs.

Action

No action required.

Sample source

Blood

Transferrin [in Blood - Quantitative] (g/L)

Loading chart...

Transferrin levels are stable and within normal limits.

Description Main protein responsible for transporting iron in blood. Measurements Trend: Rising - Recent increase toward mid-range. September 2024: 2.18 g/L
October 2024: 2.13 g/L
December 2024: 2.6 g/L (average of 2). Clinical meaning - Levels within reference range suggest adequate protein synthesis and iron transport capacity. - Normal transferrin with rising trend reduces likelihood of iron deficiency. Action No action required. Sample source Blood.

Vitamins & Minerals

71 biomarkers

Aluminum [in Hair - Quantitative] (µg/g)

Loading chart...

Patient shows persistent, out-of-range aluminum accumulation requiring immediate environmental assessment.

Description

Trace mineral assay assessing long-term exposure to neurotoxic heavy metal.

Measurements

Trend: Rising fast - Significant increase from 2024 lows.

July 2024.0: 29.0 µg/g
August 2024.0: 5.5 µg/g
September 2024.0: 9.6 µg/g
November 2024.0: 17.0 µg/g
January 2025.0: 35.0 µg/g
June 2025.0: 18.0 µg/g

Clinical meaning

Chronic accumulation or recent high-level environmental exposure likely.
Levels consistently exceed reference thresholds, indicating potential toxicity risk.

Action

Identify and eliminate environmental sources such as cookware, antiperspirants, or antacids.

Sample source

Hair

Barium [in Hair - Quantitative] (µg/g)

Loading chart...

Barium levels have stabilized within the healthy reference range.

Description

Diagnostic marker for systemic absorption of alkaline earth metal.

Measurements

Trend: Falling - Returning to reference range after late 2024 peak.

July 2024.0: 1.3 µg/g
August 2024.0: 0.96 µg/g
September 2024.0: 1.7 µg/g
November 2024.0: 1.8 µg/g
January 2025.0: 0.96 µg/g
June 2025.0: 0.49 µg/g

Clinical meaning

Transient elevation resolved; current levels signify low toxicological risk.
Recent readings demonstrate successful clearance or reduced exposure.

Action

No action required as current levels are within normal limits.

Sample source

Hair

Boron [in Hair - Quantitative] (µg/g)

Loading chart...

Current value within normal range after recovering from previous deficiency.

Description Trace mineral marker of bone health and endocrine function. Measurements Trend: Rising - Recovery after deficiency - July 2024: 0.85 µg/g, August 2024: 1.3 µg/g, September 2024: 0.6 µg/g, November 2024: 0.26 µg/g, January 2025: 0.25 µg/g, June 2025: 0.68 µg/g. Clinical meaning Levels returned to normal range after period of depletion. Low levels correlate with altered bone metabolism or inflammatory response. Action Monitor dietary intake to maintain current normal levels. Sample source Hair.

Cadmium [in Hair - Quantitative] (µg/g)

Loading chart...

Toxic level detected significantly exceeding reference range.

Description Toxic heavy metal marker indicating environmental exposure. Measurements Trend: Rising fast - Recent spike above reference threshold - July 2024: 0.045 µg/g, August 2024: 0.023 µg/g, September 2024: 0.11 µg/g (Avg of 2), November 2024: 0.054 µg/g, January 2025: 0.026 µg/g, June 2025: 0.12 µg/g. Clinical meaning Elevated levels indicate recent acute or chronic environmental exposure. Toxicity risks include renal dysfunction and bone demineralization. Action Identify and eliminate potential sources of exposure such as tobacco smoke or contaminated food. Sample source Hair.

Calcium [in Hair - Quantitative] (µg/g)

Loading chart...

Values remain consistently above reference range despite recent stabilization.

Description Mineral marker of long-term metabolic status. Measurements Trend: Falling - Significant reduction from peak 1860.0 µg/g but persists above reference range. - July 2024.0: 525.0 µg/g - August 2024.0: 1700.0 µg/g - September 2024.0: 1860.0 µg/g - November 2024.0: 863.0 µg/g - January 2025.0: 937.0 µg/g - June 2025.0: 936.0 µg/g Clinical meaning - Elevated hair calcium suggests tissue sequestering or metabolic loss from bone. - Current level indicates chronic excess relative to 750.0 µg/g upper limit. Action Investigate potential hyperparathyroidism or vitamin D imbalance. Sample source Hair.

Calcium to Phosphorus Ratio [in Hair - Quantitative] (Ratio)

Loading chart...

Latest result remains within established reference range.

Description Calculation assessing autonomic nervous system balance and metabolic rate. Measurements Trend: Rising - Trending upward after initial spike and normalization. - July 2024.0: 2.22 Ratio - August 2024.0: 8.81 Ratio - November 2024.0: 5.33 Ratio - January 2025.0: 5.09 Ratio - June 2025.0: 6.59 Ratio Clinical meaning - Ratio currently within normal limits but moving toward upper threshold. - High ratios often correlate with parasympathetic dominance or slow metabolism. Action Monitor ratio in conjunction with thyroid function tests. Sample source Hair.

Chromium [in Hair - Quantitative] (µg/g)

Loading chart...

Biomarker has stabilized within reference range following initial high reading.

Description Trace mineral marker for glucose metabolism and insulin sensitivity. Measurements Trend: Flat - Initial spike resolved to stable baseline. July 2024: 2.1 µg/g
August 2024: 0.44 µg/g
September 2024: 0.51 µg/g (avg of 2)
November 2024: 0.44 µg/g
January 2025: 0.47 µg/g
June 2025: 0.46 µg/g. Clinical meaning Significant elevation in July 2024 corrected quickly. Current levels indicate stable, normal status. Action No action required. Sample source Hair.

Cobalt [in Hair - Quantitative] (µg/g)

Loading chart...

Values currently within normal range despite downward trend.

Description Trace element essential for Vitamin B12 synthesis. Measurements Trend: Falling - Progressive decline since July 2024. July 2024: 0.039 µg/g
August 2024: 0.01 µg/g
September 2024: 0.016 µg/g
November 2024: 0.008 µg/g
January 2025: 0.013 µg/g
June 2025: 0.005 µg/g. Clinical meaning Initial high value resolved. June 2025 level approaching lower limit of reference range. Action Monitor for further decline toward deficiency. Sample source Hair.

Copper [in Hair - Quantitative] (µg/g)

Loading chart...

Copper levels successfully normalized after period of significant elevation.

Description Hair tissue mineral analysis of copper levels. Measurements Trend: Falling fast - Significant reduction from high baseline toward reference range. July 2024: 81.0 µg/g. August 2024: 53.0 µg/g. September 2024: 41.0 µg/g. November 2024: 67.0 µg/g. January 2025: 68.0 µg/g. June 2025: 25.0 µg/g. Clinical meaning Levels transitioned from severe elevation to normal range. Indicates successful management of copper burden or reduced exposure. Action Monitor quarterly to ensure stability within normal reference range. Sample source Hair.

Germanium [in Hair - Quantitative] (µg/g)

Loading chart...

Germanium levels are stable and within normal clinical limits.

Description Trace element measurement in hair tissue. Measurements Trend: Flat - Initial elevation followed by consistent stability. July 2024: 0.052 µg/g. August 2024: 0.034 µg/g. November 2024: 0.036 µg/g. January 2025: 0.035 µg/g. June 2025: 0.035 µg/g. Clinical meaning Current values remain stable within optimal reference range. Slight initial elevation resolved and maintained. Action No action required. Sample source Hair.

Iodine [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent elevated levels require clinical investigation for potential iodine toxicity or exposure.

Description Trace element marker reflecting long-term intake and excretion. Measurements Trend: Rising - fluctuates but consistently high. July 2024: 3.8 µg/g. August 2024: 2.4 µg/g. September 2024: 3.8 µg/g. November 2024: 3.6 µg/g. January 2025: 1.7 µg/g. June 2025: 3.2 µg/g. Clinical meaning High levels suggest excessive dietary intake or exposure to iodine-containing products. Elevated hair iodine may correlate with thyroid dysfunction or high systemic load. Action Investigate dietary sources and consider thyroid function panel testing. Sample source Hair.

Iron [in Hair - Quantitative] (µg/g)

Loading chart...

Recent decline to below reference range indicates probable iron deficiency following resolution of initial contamination.

Description Mineral marker representing cumulative tissue iron storage and environmental exposure. Measurements Trend: Falling fast - massive drop from baseline to sub-optimal levels. July 2024: 95.0 µg/g. August 2024: 8.4 µg/g. September 2024: 8.3 µg/g. November 2024: 7.0 µg/g. January 2025: 7.4 µg/g. June 2025: 5.9 µg/g. Clinical meaning Initial extreme spike suggests external contamination or acute overload. Recent values indicate developing deficiency or depletion of iron stores. Action Perform serum ferritin and iron panel to confirm suspected iron deficiency. Sample source Hair.

Lead [in Hair - Quantitative] (µg/g)

Loading chart...

Recent values near reference limit following significant decrease from high baseline.

Description Heavy metal indicator measuring long-term environmental exposure. Measurements Trend: Falling fast - significant reduction since peak. July 2024: 3.6 µg/g
August 2024: 0.94 µg/g
September 2024: 0.81 µg/g (Avg of 2)
November 2024: 1.2 µg/g
January 2025: 0.51 µg/g
June 2025: 0.75 µg/g. Clinical meaning Levels show overall downward trend toward normal range. Persistent low-level elevation suggests continued minor exposure or redistribution. Action Identify and eliminate remaining environmental or occupational lead sources. Sample Source: Hair.

Magnesium [in Hair - Quantitative] (µg/g)

Loading chart...

Values remain persistently above reference range indicating metabolic imbalance.

Description Mineral marker reflecting intracellular levels and metabolic activity. Measurements Trend: Rising - recent increase following period of decline. July 2024: 100.0 µg/g
August 2024: 410.0 µg/g
September 2024: 290.0 µg/g
November 2024: 120.0 µg/g
January 2025: 99.0 µg/g
June 2025: 210.0 µg/g. Clinical meaning Consistently elevated levels may indicate excessive loss from tissues or metabolic stress. High readings often correlate with adrenal insufficiency or calcium-magnesium imbalance. Action Review magnesium supplementation and evaluate adrenal function markers. Sample Source: Hair.

Mercury [in Hair - Quantitative] (µg/g)

Loading chart...

Mercury levels remain consistently above reference limit despite slight downward trend.

Description

Non-invasive marker indicating long-term methylmercury exposure.

Measurements

Trend: Falling slightly - values remain significantly above reference range after August peak.

July 2024: 1.7 µg/g
August 2024: 3.3 µg/g
September 2024: 2.9 µg/g (Avg of 2)
November 2024: 2.5 µg/g
January 2025: 2.1 µg/g
June 2025: 2.1 µg/g

Clinical meaning

Persistent elevation suggests ongoing exposure or high body burden.
Values correlate with increased cardiovascular risk and potential neurological dysfunction.

Action

Investigate dietary fish intake and dental history, and consider confirmatory whole blood or provoked urine testing.

Sample source

Hair

Molybdenum [in Hair - Quantitative] (µg/g)

Loading chart...

Status borderline low with one out-of-range deficiency event in September 2024.

Description

Trace element essential for enzyme function in sulfur and purine metabolism.

Measurements

Trend: Falling slightly - values fluctuating near lower reference limit.

July 2024: 0.05 µg/g
August 2024: 0.025 µg/g
September 2024: 0.023 µg/g
November 2024: 0.032 µg/g
January 2025: 0.028 µg/g
June 2025: 0.026 µg/g

Clinical meaning

September reading fell below range; current levels borderline low.
Low molybdenum can impair sulfite detoxification and xanthine oxidase activity.

Action

Monitor dietary intake of legumes and grains to ensure adequate trace mineral status.

Sample source

Hair

Nickel [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent out-of-range values indicate chronic nickel exposure requiring source identification. **Sample Source** Hair

Description Trace metal marker indicating environmental or dietary exposure. Measurements Trend: Falling slightly - General decline since August 2024 peak despite volatility. July 2024: 0.51 µg/g
August 2024: 0.81 µg/g
September 2024: 0.61 µg/g
November 2024: 0.49 µg/g
January 2025: 0.71 µg/g
June 2025: 0.29 µg/g. Clinical meaning Persistent elevation suggests chronic exposure source like diet, smoking, or industry. Levels above 0.6 µg/g may reflect external contamination from hair dyes. Action Investigate external sources like hair treatments and dietary intake of nuts, soy, or canned goods.

Phosphorus [in Hair - Quantitative] (µg/g)

Loading chart...

Values shifted from normal to deficient over twelve months requiring nutritional intervention. **Sample Source** Hair

Description Essential mineral reflecting long-term nutritional status and metabolic balance. Measurements Trend: Falling - Consistent downward trajectory over past year. July 2024: 236.0 µg/g
August 2024: 193.0 µg/g
September 2024: 170.0 µg/g
November 2024: 162.0 µg/g
January 2025: 184.0 µg/g
June 2025: 142.0 µg/g. Clinical meaning Recent drop below reference range suggests potential nutritional deficiency or malabsorption. Decreasing trend indicates depleting mineral reserves. Action Evaluate dietary phosphorus intake and gastrointestinal absorption efficiency.

Potassium [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent low values indicate chronic potassium deficiency requiring clinical investigation.

Description Intracellular cation measurement in hair reflecting long-term mineral status. Measurements Trend: Falling fast - Significant decline from initial 2024 levels. July 2024: 25.0 µg/g. August 2024: 3.0 µg/g. September 2024: 10.0 µg/g. November 2024: 3.0 µg/g. January 2025: 3.0 µg/g. June 2025: 6.0 µg/g. Clinical meaning Consistent low levels suggest chronic deficiency or malabsorption. Low hair potassium often correlates with adrenal insufficiency or metabolic stress. Action Evaluate dietary intake and adrenal function markers. Sample source Hair.

Rubidium [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent sub-baseline readings suggest chronic trace element depletion.

Description Trace element biochemically related to potassium. Measurements Trend: Falling fast - Sharp drop after initial baseline. July 2024: 0.035 µg/g. August 2024: 0.004 µg/g. September 2024: 0.017 µg/g. November 2024: 0.005 µg/g. January 2025: 0.007 µg/g. June 2025: 0.006 µg/g. Clinical meaning Sub-optimal levels suggest poor mineral transport or inadequate trace element intake. Frequently tracks with low potassium patterns. Action Assess broad spectrum mineral status and dietary diversity. Sample source Hair.

Selenium [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent low selenium levels indicate nutritional deficiency requiring intervention.

Description Essential trace element indicating long-term nutritional mineral status. Measurements Trend: Falling - progressive decline with intermittent deficiency. July 2024: 0.84 µg/g. August 2024: 0.7 µg/g. September 2024: 0.59 µg/g. November 2024: 0.72 µg/g. January 2025: 0.68 µg/g. June 2025: 0.63 µg/g. Clinical meaning Consistent sub-optimal levels suggest dietary insufficiency or impaired absorption. Deficiency impacts antioxidant defense and thyroid function. Action Assess dietary intake and consider selenium supplementation to address persistent low levels. Sample source Hair.

Silver [in Hair - Quantitative] (µg/g)

Loading chart...

Silver levels have stabilized within normal limits after early fluctuations.

Description Non-essential trace metal used to assess environmental or occupational exposure. Measurements Trend: Falling - initial high spikes followed by stabilization within range. July 2024: 0.39 µg/g. August 2024: 0.04 µg/g. September 2024: 0.2 µg/g. November 2024: 0.06 µg/g. January 2025: 0.04 µg/g. June 2025: 0.06 µg/g. Clinical meaning Historical elevations suggest past acute exposures. Recent stability within reference range indicates no current toxic accumulation. Action No action required as current levels remain below toxic threshold. Sample source Hair.

Sodium [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent critically low levels indicate exhaustion phase or mineral imbalance.

Description Long-term intracellular mineral excretion marker. Measurements Trend: Falling fast - Sharp decline from initial low. - July 2024: 22.0 µg/g - August 2024: 4.0 µg/g - September 2024: 8.0 µg/g - November 2024: 1.0 µg/g - January 2025: 1.0 µg/g - June 2025: 3.0 µg/g. Clinical meaning - Consistent severe deficiency relative to reference range. - Low hair sodium typically reflects reduced adrenal activity or chronic stress exhaustion. Action Investigate adrenal function and electrolyte intake. Sample source Hair.

Sodium to Potassium Ratio [in Hair - Quantitative] (Ratio)

Loading chart...

Ratio recently stabilized at lower limit of normal after period of deficiency.

Description Cellular vitality and stress response indicator. Measurements Trend: Falling - Dropped below lower limit then stabilized. - July 2024: 0.88 Ratio - August 2024: 1.33 Ratio - September 2024: 0.8 Ratio - November 2024: 0.333 Ratio - January 2025: 0.333 Ratio - June 2025: 0.5 Ratio. Clinical meaning - Low ratio indicates potential adrenal fatigue or impaired glucose metabolism. - Recent recovery to borderline normal threshold. Action Monitor for clinical signs of fatigue or metabolic strain. Sample source Hair.

Strontium [in Hair - Quantitative] (µg/g)

Loading chart...

Significant recent increase to record high level requires investigation of exposure sources.

Description Trace mineral marker of long-term environmental exposure and bone metabolism. Measurements Trend: Rising fast - sharp spike after period of normalization. July 2024: 2.0 µg/g
August 2024: 6.4 µg/g
September 2024: 4.1 µg/g
November 2024: 2.9 µg/g
January 2025: 2.7 µg/g
June 2025: 8.8 µg/g. Clinical meaning Levels currently exceed upper reference limit indicating high recent exposure. Persistent fluctuations suggest intermittent environmental or dietary sources. Action Investigate potential environmental sources like contaminated drinking water or specific supplements. Sample source Hair.

Thallium [in Hair - Quantitative] (µg/g)

Loading chart...

Values have remained mostly stable and within reference range since initial 2024 elevation.

Description Toxic heavy metal marker indicating environmental or occupational exposure. Measurements Trend: Rising slightly - returned to upper limit after period of stability. July 2024: 0.005 µg/g
August 2024: 0.001 µg/g
September 2024: 0.001 µg/g
November 2024: 0.001 µg/g
January 2025: 0.001 µg/g
June 2025: 0.002 µg/g. Clinical meaning Current result at upper threshold after historical elevation. Marker reflects chronic rather than acute exposure levels. Action Monitor levels in next screening to ensure value remains within safe range. Sample source Hair.

Thorium [in Hair - Quantitative] (µg/g)

Loading chart...

Thorium levels successfully stabilized within healthy reference range.

Description Trace radioactive element measured for heavy metal toxicity. Measurements Trend: Falling - Concentration normalized following initial elevation. July 2024.0: 0.006 µg/g
August 2024.0: 0.002 µg/g
September 2024.0: 0.002 µg/g
November 2024.0: 0.001 µg/g
January 2025.0: 0.001 µg/g
June 2025.0: 0.001 µg/g. Clinical meaning - Values returned to normal range after July 2024 peak. - Current levels indicate minimal recent exposure. Action No action required. Sample source Hair.

Tin [in Hair - Quantitative] (µg/g)

Loading chart...

Tin levels reached an all-time high above clinical reference limit.

Description Trace metal used in industrial alloys and food packaging. Measurements Trend: Rising - Recent spike exceeds reference threshold. July 2024.0: 0.3 µg/g
August 2024.0: 0.08 µg/g
September 2024.0: 0.13 µg/g
November 2024.0: 0.13 µg/g
January 2025.0: 0.08 µg/g
June 2025.0: 0.35 µg/g. Clinical meaning - June 2025 reading indicates new environmental or dietary exposure. - Long-term fluctuation suggests intermittent contact. Action Investigate potential exposure sources such as canned foods or dental work. Sample source Hair.

Uranium [in Hair - Quantitative] (µg/g)

Loading chart...

Levels currently within reference range following initial elevation.

Description Hair marker reflecting cumulative exposure to heavy metal uranium. Measurements Trend: Falling slightly - Significant initial drop followed by levels stabilizing near upper reference limit. - July 2024: 0.1 µg/g - August 2024: 0.021 µg/g - September 2024: 0.023 µg/g - November 2024: 0.056 µg/g - January 2025: 0.032 µg/g - June 2025: 0.05 µg/g Clinical meaning - High initial value indicates past environmental exposure or ingestion. - Current levels within normal range but tracking close to threshold. Action Investigate potential groundwater or environmental sources to ensure levels remain below reference limit. Sample source Hair.

Vanadium [in Hair - Quantitative] (µg/g)

Loading chart...

Persistent fluctuations with multiple out-of-range readings.

Description Trace element marker reflecting intake and accumulation of vanadium. Measurements Trend: Flat - Fluctuating values frequently exceeding upper reference limit. - July 2024: 0.088 µg/g - August 2024: 0.046 µg/g - September 2024: 0.12 µg/g - November 2024: 0.06 µg/g - January 2025: 0.034 µg/g - June 2025: 0.069 µg/g Clinical meaning - Recurrent elevations suggest intermittent dietary or industrial exposure. - High levels potentially impact glucose metabolism or renal function. Action Evaluate supplement use and environmental exposure to identify cause of recurring elevations. Sample source Hair.

Zinc [in Hair - Quantitative] (µg/g)

Loading chart...

Zinc levels currently within normal range despite downward trend.

Description Trace mineral marker of long-term nutritional status and metabolism. Measurements Trend: Falling slightly - Decreased from peak elevation to low-normal. July 2024: 170.0 µg/g. August 2024: 220.0 µg/g. September 2024: 190.0 µg/g average (2 readings). November 2024: 150.0 µg/g. January 2025: 170.0 µg/g. June 2025: 130.0 µg/g. Clinical meaning Transient elevation in August resolved. Current value at lower limit of reference range suggesting depleting stores. Action Monitor dietary intake or supplementation to prevent deficiency. Sample source Hair.

Zinc to Copper Ratio [in Hair - Quantitative] (Ratio)

Loading chart...

Ratio shows positive trajectory and has returned to normal range.

Description Calculation assessing balance between zinc and copper for metabolic harmony. Measurements Trend: Rising - Improving from low baseline toward reference range. July 2024: 2.1 Ratio. August 2024: 4.15 Ratio. September 2024: 4.63 Ratio. November 2024: 2.24 Ratio. January 2025: 2.5 Ratio. June 2025: 5.2 Ratio. Clinical meaning History of significant imbalance with low ratios. Most recent result shows improvement into acceptable range. Action Maintain current nutritional protocol to stabilize ratio within target range. Sample source Hair.

Zirconium [in Hair - Quantitative] (µg/g)

Loading chart...

Results show persistent low levels below the reference range.

Description Trace mineral marker in hair tissue. Measurements Trend: Falling slightly - fluctuating low values. July 2024.0: 0.073 µg/g
August 2024.0: 0.01 µg/g
September 2024.0: 0.031 µg/g
November 2024.0: 0.023 µg/g
January 2025.0: 0.027 µg/g
June 2025.0: 0.008 µg/g. Clinical meaning Low levels suggest insufficient intake or altered mineral distribution. Results frequently fall below laboratory reference range. Action Monitor dietary intake and trace mineral balance. Sample source Hair.

Zinc [in Blood - Quantitative] (ug/L)

Loading chart...

Zinc status has normalized following a period of deficiency.

Description Essential micronutrient marker of immune and metabolic function. Measurements Trend: Rising - recovery from low 2024 values to stable range. May 2024.0: 751.87 ug/L
September 2024.0: 585.0 ug/L
December 2024.0: 4471.23 ug/L (average, 3 counts)
October 2025.0: 977.0 ug/L. Clinical meaning Temporary deficiency in late 2024 resolved. Current levels indicate adequate systemic status. Action No action required as latest reading is within normal range. Sample source Blood.

Copper [in Blood - Quantitative] (ug/L)

Loading chart...

Copper levels show significant downward trend and require monitoring despite recent stabilization within range.

Description Essential trace element for enzymatic reactions and iron metabolism. Measurements Trend: Falling fast - Significant decline from May 2024 to December 2024. May 2024: 940.54 ug/L
September 2024: 605.0 ug/L
December 2024: 683.08 ug/L (Average of 4). Clinical meaning - Recent values fluctuate near lower limit of normal. - Decline may indicate dietary deficiency or malabsorption. Action Monitor copper levels alongside zinc and ceruloplasmin. Sample source Blood.

Vitamin A (Retinol) [in Blood - Quantitative] (percentile)

Loading chart...

Vitamin A levels successfully improved from out-of-range to optimal mid-range status.

Description Fat-soluble vitamin critical for vision, immune function, and skin health. Measurements Trend: Rising - Recovery from below-range percentiles to mid-range. February 2025: 19.0 percentile
March 2025: 19.0 percentile
August 2025: 55.0 percentile. Clinical meaning - Previous deficiency or borderline status corrected. - Current level indicates adequate stores and absorption. Action No action required. Sample source Blood.

Vitamin C [in Blood - Quantitative] (percentile)

Loading chart...

Vitamin C levels successfully corrected from low to optimal range.

Description Essential antioxidant and cofactor for collagen synthesis. Measurements Trend: Rising fast - Significant improvement from deficiency. - March 2025: 17.0 percentile - August 2025: 92.0 percentile (average of 2 readings) Clinical meaning - Recent data indicates robust recovery from previous low status. - High current levels support immune function and tissue repair. Action Maintain current dietary intake or supplementation levels. Sample source Blood

Copper to Zinc Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Ratio corrected from high to slightly below range, requiring stabilization.

Description

Quantitative balance between serum copper and zinc levels.

Measurements

Trend: Falling fast - Dropped from high to slightly below reference range

May 2024.0: 1.28 Ratio
December 2024.0: 0.78 Ratio (Average of 2 readings)

Clinical meaning

Shift from copper dominance to slight zinc dominance
Low ratio may indicate zinc excess or relative copper deficiency

Action

Monitor dietary intake and supplementation of both minerals to achieve balance.

Sample source

Blood

Selenium [in Blood - Quantitative] (ug/L)

Loading chart...

Value recently drifted slightly above range despite overall falling trend.

Description Essential trace element and antioxidant cofactor. Measurements Trend: Falling slightly - decreasing since late 2024. December 2024: 190.2 ug/L
October 2025: 153.0 ug/L (avg of 2). Clinical meaning - Recent value slightly above upper reference limit. - Potential excess intake or supplementation. Action Review selenium intake from diet or supplements and consider reduction. Sample source Blood.

Vitamin D 25-Hydroxy [in Blood - Quantitative] (nmol/L)

Loading chart...

Vitamin D levels remain stable and within healthy reference limits.

Description Primary circulating form of vitamin D indicating storage levels. Measurements Trend: Rising - general upward trajectory over 18 months. May 2024: 90.0 nmol/L
September 2024: 115.0 nmol/L
October 2024: 90.0 nmol/L (avg of 2)
November 2024: 107.0 nmol/L
December 2024: 106.3 nmol/L (avg of 3)
March 2025: 147.0 nmol/L
May 2025: 152.0 nmol/L
June 2025: 102.0 nmol/L
July 2025: 110.0 nmol/L
September 2025: 118.0 nmol/L
October 2025: 129.0 nmol/L (avg of 2)
November 2025: 118.3 nmol/L. Clinical meaning - Consistently within optimal range. - Fluctuations suggest seasonal changes or varying supplementation. Action No action required. Sample source Blood.

Folate [in Blood - Quantitative] (nmol/L)

Loading chart...

Folate levels are optimal and consistently above minimum requirements.

Description

Essential B vitamin for DNA synthesis and cell division.

Measurements

Trend: Rising - Multiple results at assay ceiling.

May 2024: 16.0 nmol/L
September 2024: >54.36 nmol/L
November 2024: 54.36 nmol/L
December 2024: 22.0 nmol/L (avg of 2)
March 2025: 54.366 nmol/L (avg of 2)
May 2025: >54.36 nmol/L

Clinical meaning

Levels consistently high or at upper limit of detection.
Likely reflects high dietary intake or supplementation.

Action

No action required as levels are sufficient and not clinically toxic.

Sample source

Blood

Antimony [in Hair - Quantitative] (µg/g)

Loading chart...

Antimony levels are low and stable within safe limits.

Description

Toxic heavy metal marker for environmental exposure.

Measurements

Trend: Falling - Decreased to lowest recorded level in June.

July 2024: 0.025 µg/g
August 2024: 0.034 µg/g
September 2024: 0.024 µg/g
November 2024: 0.021 µg/g
January 2025: 0.037 µg/g
June 2025: 0.014 µg/g

Clinical meaning

Values remain well within safe reference range.
Current levels indicate low environmental or occupational exposure.

Action

No action required.

Sample source

Hair

Arsenic [in Hair - Quantitative] (µg/g)

Loading chart...

Patient shows stable arsenic levels within healthy reference ranges over 12 months.

Description Indicator of long-term heavy metal exposure via hair follicles. Measurements Trend: Flat - Consistent low-level readings. July 2024: 0.023 µg/g
August 2024: 0.01 µg/g
September 2024: 0.01 µg/g
November 2024: 0.013 µg/g
January 2025: 0.015 µg/g
June 2025: 0.016 µg/g. Clinical meaning Values remain significantly below toxic reference thresholds. Suggests no recent significant environmental or dietary exposure. Action No action required. Sample source Hair.

Beryllium [in Hair - Quantitative] (µg/g)

Loading chart...

Beryllium levels are low, stable, and clinically insignificant.

Description Hair marker for chronic beryllium exposure. Measurements Trend: Flat - Readings remain at or below detection limit. July 2024: < 0.01 µg/g
August 2024: 0.01 µg/g
September 2024: 0.01 µg/g
November 2024: 0.01 µg/g
January 2025: < 0.01 µg/g
June 2025: 0.01 µg/g. Clinical meaning Levels consistently half of upper reference limit. No evidence of systemic accumulation or industrial exposure. Action No action required. Sample source Hair.

Bismuth [in Hair - Quantitative] (µg/g)

Loading chart...

Levels are well within the safe reference range with no concerning accumulation.

Description Trace metal marker assessing potential toxic exposure. Measurements Trend: Flat - values consistently near detection limit. July 2024: 0.009, August 2024: 0.032, September 2024: 0.037, November 2024: 0.002, January 2025: 0.009, June 2025: 0.005. Clinical meaning Results significantly below 2.0 reference threshold. No evidence of bismuth toxicity or accumulation. Action No action required. Sample source Hair.

Calcium to Magnesium Ratio [in Hair - Quantitative] (Ratio)

Loading chart...

Mineral ratio remains stable and within clinical targets.

Description Calculated proportion of calcium to magnesium reflecting mineral balance. Measurements Trend: Falling - recent decrease after mid-period rise. July 2024: 5.25, August 2024: 4.15, September 2024: 6.41, November 2024: 7.19, January 2025: 9.46, June 2025: 4.46. Clinical meaning All values within 4.0-30.0 reference range. Current ratio suggests adequate mineral distribution without dominance. Action No action required. Sample source Hair.

Lithium [in Hair - Quantitative] (µg/g)

Loading chart...

Values remain stable and within normal reference limits.

Description Trace element marker reflecting long term intake and metabolic status. Measurements Trend: Falling slightly - Steady levels followed by minor decrease. July 2024: 0.009 µg/g
August 2024: 0.009 µg/g
November 2024: 0.009 µg/g
January 2025: 0.008 µg/g
June 2025: 0.008 µg/g. Clinical meaning Results consistently within lower end of reference range. Suggests stable but low normal trace mineral levels. Action No action required. Sample source Hair.

Manganese [in Hair - Quantitative] (µg/g)

Loading chart...

Manganese levels are healthy and within normal physiologic range.

Description Essential trace mineral marker for enzyme function and bone health. Measurements Trend: Flat - Fluctuating values within range without sustained direction. July 2024: 0.21 µg/g
August 2024: 0.3 µg/g
November 2024: 0.41 µg/g
January 2025: 0.22 µg/g
June 2025: 0.25 µg/g. Clinical meaning Values fluctuate within normal limits. November peak remained below upper reference threshold. Action No action required. Sample source Hair.

Platinum [in Hair - Quantitative] (µg/g)

Loading chart...

Platinum levels stable and within safe limits.

Description Heavy metal indicator of cumulative exposure. Measurements Trend: Flat - consistently at or below detection limit. July 2024: < 0.003 µg/g. August 2024: 0.003 µg/g. September 2024: 0.003 µg/g. November 2024: 0.003 µg/g. January 2025: < 0.003 µg/g. June 2025: 0.003 µg/g. Clinical meaning - Levels within reference range - No evidence of significant toxic metal accumulation. Action No action required. Sample source Hair.

Sulfur [in Hair - Quantitative] (µg/g)

Loading chart...

Sulfur levels remain healthy and consistent.

Description Essential element representing protein metabolism and hair health. Measurements Trend: Flat - values stable within reference range after initial increase. July 2024: 41800.0 µg/g. August 2024: 48300.0 µg/g. September 2024: 46300.0 µg/g. November 2024: 49400.0 µg/g. January 2025: 44400.0 µg/g. June 2025: 45500.0 µg/g. Clinical meaning - Sufficient sulfur availability for disulfide bond formation - Consistent with adequate protein intake and normal metabolism. Action No action required. Sample source Hair.

Titanium [in Hair - Quantitative] (µg/g)

Loading chart...

Titanium levels remain well below thresholds with downward trajectory.

Description Trace mineral/pollutant marker in hair tissue. Measurements Trend: Falling fast - Significant reduction since initial July test. July 2024: 0.54 µg/g
August 2024: 0.11 µg/g
September 2024: 0.24 µg/g
November 2024: 0.16 µg/g
January 2025: 0.11 µg/g
June 2025: 0.09 µg/g. Clinical meaning Low systemic exposure; values consistently within reference range. Action No action required. Sample source Hair.

Vitamin B12 [in Blood - Quantitative] (pmol/L)

Loading chart...

Vitamin B12 status is optimal and stable.

Description Essential water-soluble vitamin for nerve function and hematopoiesis. Measurements Trend: Rising - Gradual increase over nine months. September 2024: 487.0 pmol/L
November 2024: 488.0 pmol/L
March 2025: 561.73 pmol/L (avg 2 readings)
May 2025: 540.0 pmol/L. Clinical meaning Robust vitamin status; optimal range for neurological health. Action No action required. Sample source Blood.

Zinc to Cadmium Ratio [in Hair - Quantitative] (Ratio)

Loading chart...

Ratio remains consistently at ceiling value indicating low cadmium risk.

Description Hair mineral ratio assessing protective zinc levels against cadmium toxicity. Measurements Trend: Flat - Constant maximum values. July 2024: 999. August 2024: 999.0. November 2024: 999.0. January 2025: 999. June 2025: 999.0. Clinical meaning High ratio suggests optimal zinc status relative to toxic cadmium exposure. Values consistently exceed reference minimum. Action No action required. Sample source Hair.

Carotenoids [in Blood - Quantitative] (percentile)

Loading chart...

Rapid improvement in antioxidant levels reaching high-normal range.

Description Serum antioxidant pigments reflecting dietary intake of fruits and vegetables. Measurements Trend: Rising fast - Significant increase in latest percentile. March 2025: 40.0. June 2025: 43.0. August 2025: 75.5 (average of 2 readings). Clinical meaning Improving antioxidant status. Higher percentiles correlate with better metabolic and cellular health. Action Maintain current intake of colorful plant-based foods. Sample source Blood.

Ergothioneine [in Blood - Quantitative] (percentile)

Loading chart...

Values remain within reference range with favorable overall trend.

Description Potent dietary antioxidant protecting cells from oxidative stress. Measurements Trend: Rising - Recent improvement from low-normal levels. February 2025: 28.0 percentile
March 2025: 28.0 percentile
June 2025: 73.0 percentile
August 2025: 51.0 percentile. Clinical meaning - Levels indicate adequate intake of mushroom-based antioxidants. - Stability suggests maintained cytoprotective capacity. Action Maintain current diet rich in ergothioneine-containing foods. Sample source Blood.

Alpha-Tocopherol (Vitamin E) [in Blood - Quantitative] (percentile)

Loading chart...

Results currently normal but show concerning downward trajectory.

Description Essential fat-soluble antioxidant maintaining membrane integrity. Measurements Trend: Falling fast - Significant decline between March and May. February 2025: 73.0 percentile
March 2025: 73.0 percentile
May 2025: 25.0 percentile. Clinical meaning - Sharp drop suggests potential malabsorption or dietary change. - Lower levels increase susceptibility to lipid peroxidation. Action Evaluate dietary fat intake or supplementation to address rapid decline. Sample source Blood.

Ascorbic Acid 3-Sulfate [in Blood - Quantitative] (percentile)

Loading chart...

Patient shows significant improvement in Vitamin C status over three months.

Description Metabolite of Vitamin C reflecting antioxidant status and tissue stores. Measurements Trend: Rising - Significant increase from low-normal to upper-normal percentile. February 2025: 40.0
March 2025: 40.0
May 2025: 84.0. Clinical meaning - Improved vitamin C levels likely due to supplementation or diet change. - High-normal values suggest optimal antioxidant capacity. Action Maintain current intake to keep values in upper percentile. Sample source Blood.

Carotene Diol [in Blood - Quantitative] (Percentile Rank)

Loading chart...

Biomarker reflects healthy and stable antioxidant intake from dietary sources.

Description Oxidized carotenoid derivative indicating dietary phytonutrient intake and lipid metabolism. Measurements Trend: Rising - Initial increase followed by slight stabilization. March 2025: 43.0
May 2025: 78.7
August 2025: 66.1 (avg of 2 readings). Clinical meaning - Values remain well within healthy reference ranges. - Fluctuations suggest variations in fruit and vegetable consumption. Action No action required. Sample source Blood.

Ceruloplasmin [in Blood - Quantitative] (g/L)

Loading chart...

Biomarker remains stable within reference range across all dates.

Description Copper-carrying protein involved in iron metabolism. Measurements Trend: Flat - values stable within low-normal range. May 2024.0: 0.18 g/L
October 2024.0: 0.16 g/L
December 2024.0: 0.18 g/L (average of 2). Clinical meaning Levels suggest adequate copper transport; low-normal status may warrant monitoring for Wilson's disease or malnutrition if symptomatic. Action No action required. Sample source Blood.

Magnesium [in Blood - Quantitative] (mmol/L)

Loading chart...

All readings fall within respective laboratory reference intervals.

Description Essential mineral for nerve, muscle, and enzyme function. Measurements Trend: Flat - consistent results across varied reference scales. September 2024.0: 0.87 mmol/L
December 2024.0: 2.127 mmol/L (average of 2)
March 2025.0: 0.92 mmol/L. Clinical meaning Values indicate electrolyte homeostasis despite unit/reference scale changes. Action No action required. Sample source Blood.

Nicotinamide Riboside [in Blood - Quantitative] (percentile)

Loading chart...

Biomarker shows steady improvement within normal range suggesting effective supplementation or dietary intake.

Description Precursor to nicotinamide adenine dinucleotide (NAD+) essential for cellular energy metabolism. Measurements Trend: Rising fast - percentile increased nearly threefold over five months. - March 2025.0: 28.0 percentile - June 2025.0: 55.0 percentile - August 2025.0: 73.0 percentile. Clinical meaning - Consistent upward trend indicates improving NR availability. - Supports mitochondrial health and DNA repair. Action No action required as levels are within reference range and trending positively. Sample source Blood.

Riboflavin (Vitamin B2) [Quantitative] (percentile)

Loading chart...

Riboflavin levels have normalized effectively from previously low-baseline readings.

Description Water-soluble B vitamin required for energy production and enzyme function. Measurements Trend: Rising fast - significant jump in August following period of stability. - May 2025.0: 27.0 percentile - June 2025.0: 27.0 percentile - August 2025.0: 74.0 percentile. Clinical meaning - Recent increase moves status from borderline low to high-normal. - Reflects improved metabolic cofactor availability. Action Maintain current intake to keep levels in optimal upper-middle range. Sample source Unknown.

Vitamin A (Retinol) [Quantitative] (percentile)

Loading chart...

Vitamin A levels remain stable and optimal.

Description Fat-soluble micronutrient essential for vision, immune function, and cellular growth. Measurements Trend: Rising slightly - Gradual increase within optimal range. May 2025.0: 52.0 percentile. June 2025.0: 52.0 percentile. August 2025.0: 55.0 percentile. Clinical meaning - Patient maintains consistent, mid-range status across multiple reference intervals. - No evidence of deficiency or toxicity. Action No action required. Sample source Blood.

Vitamin K2 (Menaquinone-7) [in Stool - Quantitative] (%)

Loading chart...

Values currently within range despite recent downward trend.

Description Fat-soluble vitamin subtype produced by gut bacteria, crucial for bone and cardiovascular health. Measurements Trend: Falling fast - Significant drop from peak in late 2024. July 2024.0: 11.53 %. October 2024.0: 21.0 %. February 2025.0: 9.76 %. Clinical meaning - Current levels remain within reference range but show 53 percent decline from October peak. - Fluctuations may reflect changes in gut microbiome composition or dietary intake. Action Monitor gut health or dietary intake to stabilize downward trend. Sample source Stool.

Xanthurenic Acid [in Urine - Quantitative] (ug/gCR)

Loading chart...

Values remain within normal limits despite sharp downward trend.

Description

Urinary metabolite of tryptophan metabolism used as marker for Vitamin B6 status.

Measurements

Trend: Falling fast - Significant drop below baseline reference ranges in late 2024.

May 2024.0: 536.0 ug/gCR
November 2024.0: 656.0 ug/gCR
December 2024.0: 100.0 ug/gCR (Average of 2)

Clinical meaning

Current levels within low-normal range across updated references.
Significant downward shift suggests potential changes in B6 metabolism or dietary tryptophan intake.

Action

No action required as current values are within reference range.

Sample source

Urine

Cardiovascular

20 biomarkers

Triglycerides [in Blood - Quantitative] (mmol/L)

Loading chart...

Borderline and fluctuating values require consistent lifestyle management.

Description

Type of fat found in blood reflecting lipid metabolism cardiovascular risk.

Measurements

Trend: Rising slightly - Significant volatility with recent elevation

April 2024: 1.5 mmol/L
September 2024: 0.9 mmol/L
October 2024: 1.05 mmol/L
December 2024: 2.1 mmol/L (Average of 2 readings)
March 2025: 2.1 mmol/L (Average of 2 readings)
May 2025: 1.7 mmol/L
June 2025: 1.7 mmol/L
August 2025: 2.1 mmol/L
September 2025: 1.6 mmol/L
October 2025: 2.0 mmol/L
November 2025: 1.1 mmol/L

Clinical meaning

Frequent fluctuations above optimal thresholds.
Elevated levels linked to diet, lifestyle, or metabolic syndrome.

Action

Review dietary fat/sugar intake and consider cardiovascular risk assessment.

Sample source

Blood

SYMPHONY Age (Heart) [Quantitative] (Years)

Loading chart...

Cardiovascular biological age is elevated and shows an overall upward trajectory over time.

Description

Proteomic biological age clock reflecting heart system health and cellular aging.

Measurements

Trend: Rising - Biological age increased over 18 months.

March 2024.0: 53.4 Years
December 2024.0: 54.9 Years
January 2025.0: 56.1 Years
February 2025.0: 55.1 Years average (3 readings)
March 2025.0: 55.9 Years average (2 readings)
May 2025.0: 56.1 Years average (2 readings)
June 2025.0: 56.1 Years average (2 readings)
August 2025.0: 55.9 Years
September 2025.0: 55.5 Years

Clinical meaning

Biological heart age consistently exceeds reference limits.
Gradual upward trend indicates accelerating cardiovascular aging process.

Action

Evaluate cardiovascular risk factors including blood pressure, lipids, and lifestyle interventions to slow age progression.

Sample source

Blood

Homocysteine [in Blood - Quantitative] (umol/L)

Loading chart...

Results show high variability with frequent out-of-range elevations requiring nutritional monitoring.

Description

Amino acid marker for cardiovascular risk, B-vitamin status, and methylation efficiency.

Measurements

Trend: Rising - Significant fluctuations with overall increase since baseline.

May 2024.0: 10.4 umol/L
September 2024.0: 19.24 umol/L
December 2024.0: 16.14 umol/L average (2 readings)
March 2025.0: 13.415 umol/L average (2 readings)
May 2025.0: 19.34 umol/L
June 2025.0: 19.8 umol/L
July 2025.0: 15.32 umol/L
September 2025.0: 19.31 umol/L
November 2025.0: 9.1 umol/L

Clinical meaning

Recurrent elevations suggest intermittent hyperhomocysteinemia risk.
High levels associated with increased vascular inflammation and endothelial dysfunction.

Action

Assess B12, B6, and folate levels to address possible nutritional deficiencies contributing to elevations.

Sample source

Blood

Apolipoprotein A1 [in Blood - Quantitative] (G/L)

Loading chart...

Values are stable and healthy providing cardioprotective benefits.

Description Primary protein component of high-density lipoprotein (HDL) particles facilitating cholesterol clearance. Measurements Trend: Flat - Fluctuating within normal limits until brief spike. Sept 2024: 1.24 G/L; Dec 2024: 1.54 G/L (avg 2 readings); Mar 2025: 1.4 G/L
May 2025: 1.39 G/L; Oct 2025: 1.77 G/L; Nov 2025: 1.29 G/L. Clinical meaning High levels generally indicate good cardiovascular protection. Elevated Oct 2025 reading likely associated with specific liver panel testing. Action No action required as values remain largely optimal. Sample source Blood.

Apolipoprotein B [in Blood - Quantitative] (G/L)

Loading chart...

Persistent low values indicate excellent cardiovascular risk profile but require clinical correlation for underlying causes.

Description Primary protein constituent of LDL and VLDL particles representing total number of atherogenic lipoproteins. Measurements Trend: Falling slightly - Persistent low values often below reference ranges. Sept 2024: 0.55 G/L; Dec 2024: 0.64 G/L (avg 2 readings); Mar 2025: 0.67 G/L
May 2025: 0.46 G/L; Oct 2025: 0.63 G/L (avg 2 readings); Nov 2025: 0.49 G/L. Clinical meaning Consistently low levels indicate very low risk for plaque formation. Below-range values might warrant investigation for malabsorption or hypolipoproteinemia if clinical symptoms present. Action Evaluate for potential nutrient malabsorption or genetic hypolipidemia. Sample source Blood.

Apolipoprotein B to Apolipoprotein A1 Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Patient maintains optimal lipid balance with values consistently below high-risk thresholds.

Description

Lipid balance marker for cardiovascular risk assessment.

Measurements

Trend: Falling slightly - General decline since peak in March 2025.

September 2024.0: 0.44 Ratio
December 2024.0: 0.41 Ratio
March 2025.0: 0.48 Ratio
May 2025.0: 0.33 Ratio
October 2025.0: 0.36 Ratio (avg 2 readings)
November 2025.0: 0.38 Ratio

Clinical meaning

Low ratio indicates favorable balance between atherogenic and anti-atherogenic particles.
Consistently below reference threshold suggests low cardiovascular risk profile.

Action

No action required.

Sample source

Blood

SYMPHONY Age (Heart) [in Blood - Quantitative] (Years)

Loading chart...

Heart age shows steady increase over last year requiring monitoring of cardiovascular lifestyle factors.

Description

Biological cardiovascular age estimate based on proteomic markers.

Measurements

Trend: Rising slightly - Gradual increase following initial 2024 decrease.

March 2024.0: 54.75 Years (avg 2 readings)
February 2025.0: 54.9 Years
March 2025.0: 55.9 Years
June 2025.0: 56.1 Years

Clinical meaning

Values represent biological heart age rather than chronological age.
Recent upward trend suggests increasing biological aging of cardiovascular system.

Action

Review lifestyle interventions to address rising biological heart age.

Sample source

Blood

Heart Rate [Quantitative] (bpm)

Loading chart...

Wide variation from high-intensity exercise to resting bradycardia requires clinical correlation.

Description Clinical measure of cardiac cycles per minute. Measurements Trend: Falling slightly - Decreasing resting averages and high variability during stress tests. April 2024: 69.0 bpm. July 2024: 104.5 bpm (average, 11 readings). September 2024: 67.7 bpm (average, 6 readings). November 2024: 71.0 bpm (average, 15 readings). September 2025: 70.3 bpm (average, 27 readings). Clinical meaning Results show healthy chronotropic response to exercise and low resting heart rate. Occasional bradycardia noted in recent readings. Action Discuss resting heart rates below 60 bpm with physician if symptomatic. Sample source Unknown.

Cholesterol to High Density Lipoprotein Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Excellent cardiovascular risk profile with stable and optimal ratios.

Description Calculation of total cholesterol divided by HDL for cardiovascular risk assessment. Measurements Trend: Falling - Significant improvement since initial out-of-range reading. July 2024: 3.82 Ratio. September 2024: 2.5 Ratio. December 2024: 1.63 Ratio (average, 3 readings). March 2025: 2.6 Ratio (average, 2 readings). May 2025: 2.4 Ratio. June 2025: 2.3 Ratio. August 2025: 2.5 Ratio. September 2025: 2.5 Ratio. November 2025: 2.2 Ratio. Clinical meaning Ratio consistently below 3.5 target indicates low cardiovascular risk. Downward trend suggests improving lipid profile. Action No action required. Sample source Blood.

High Density Lipoprotein Cholesterol [in Blood - Quantitative] (mmol/L)

Loading chart...

Patient maintains healthy levels of cardioprotective cholesterol with stable long-term trajectory.

Description Lipoprotein transporting cholesterol from tissues to liver. Measurements Trend: Rising - Gradual increase over 18 months. April 2024: 1.42 mmol/L. September 2024: 1.1 mmol/L. October 2024: 1.16 mmol/L (Avg of 2). December 2024: 1.3 mmol/L (Avg of 3). March 2025: 1.39 mmol/L (Avg of 2). May 2025: 1.4 mmol/L. June 2025: 1.3 mmol/L. August 2025: 1.4 mmol/L. September 2025: 1.6 mmol/L. November 2025: 1.35 mmol/L. Clinical meaning - Values consistently within or near protective reference ranges. - Improving trend suggests reduced cardiovascular risk. Action No action required. Sample source Blood.

Low Density Lipoprotein Cholesterol [in Blood - Quantitative] (mmol/L)

Loading chart...

Excellent control of atherogenic cholesterol with values consistently below clinical risk thresholds.

Description Primary transporter of cholesterol to peripheral tissues. Measurements Trend: Falling - Significant reduction since initial peak. April 2024: 2.0 mmol/L. July 2024: 2.6 mmol/L (Avg of 2). September 2024: 1.2 mmol/L. October 2024: 0.96 mmol/L. December 2024: 1.4 mmol/L (Avg of 2). March 2025: 1.3 mmol/L (Avg of 2). May 2025: 1.2 mmol/L. June 2025: 1.0 mmol/L. August 2025: 1.3 mmol/L. September 2025: 1.8 mmol/L. November 2025: 1.2 mmol/L. Clinical meaning - All values since September 2024 well below aggressive target thresholds. - Excellent control of atherogenic particles. Action No action required. Sample source Blood.

Total Cholesterol [in Blood - Quantitative] (mmol/L)

Loading chart...

Total cholesterol levels remain stable and well within target range.

Description Sum of HDL, LDL, and VLDL particles in blood. Measurements Trend: Falling - Recent decrease from September peak. April 2024: 4.4 mmol/L
September 2024: 2.7 mmol/L
December 2024: 3.53 mmol/L average (3 readings)
March 2025: 3.6 mmol/L average (2 readings)
May 2025: 3.3 mmol/L
June 2025: 3.0 mmol/L
August 2025: 3.5 mmol/L
September 2025: 4.0 mmol/L
October 2025: 3.7 mmol/L average (2 readings)
November 2025: 3.0 mmol/L. Clinical meaning Consistent control within reference range. Fluctuations likely reflect lifestyle or dietary variations. Action No action required. Sample source Blood.

Non-High Density Lipoprotein Cholesterol [in Blood - Quantitative] (mmol/L)

Loading chart...

Non-HDL cholesterol is optimally managed and reflects low atherogenic burden.

Description Total cholesterol minus HDL; marker of all atherogenic lipoproteins. Measurements Trend: Falling - Recent downward shift since September. September 2024: 1.6 mmol/L
December 2024: 2.27 mmol/L average (3 readings)
March 2025: 2.2 mmol/L average (2 readings)
May 2025: 1.9 mmol/L
June 2025: 1.7 mmol/L
August 2025: 2.1 mmol/L
September 2025: 2.4 mmol/L
October 2025: 2.2 mmol/L
November 2025: 1.7 mmol/L. Clinical meaning Consistently below 3.4 mmol/L threshold. Low levels indicate reduced cardiovascular risk profile. Action No action required. Sample source Blood.

Lipoprotein (a) [in Blood - Quantitative] (mg/dL)

Loading chart...

All readings consistently below clinical threshold for high cardiovascular risk.

Description Genetic lipid marker linked to atherosclerotic cardiovascular disease risk. Measurements Trend: Rising - Recent uptick in values. May 2024: 0.912 mg/dL
September 2024: 10.0 mg/dL
December 2024: 5.14 mg/dL average (3 readings). Clinical meaning - Values remain well within optimal reference range (<30 mg/dL). - Low risk profile for genetically determined cardiovascular events. Action No action required. Sample source Blood.

High Density Lipoprotein Particle Size [in Blood - Quantitative] (percentile)

Loading chart...

Recent results show movement toward highly favorable large-particle HDL distribution.

Description Measure of diameter of HDL particles via NMR or precipitation. Measurements Trend: Rising fast - Sharp increase in latest reading. March 2025: 50.0 percentile
June 2025: 38.0 percentile
August 2025: 97.0 percentile. Clinical meaning - Significant shift from average to large particle size distribution. - Larger HDL particles generally associated with better cholesterol efflux capacity and lower risk. Action Continue current lipid management strategy. Sample source Blood.

Total Polyunsaturated Fatty Acids [in Blood - Quantitative] (percentile)

Loading chart...

Total PUFA levels improving steadily within normal range.

Description Essential fatty acids indicator for heart/brain health. Measurements Trend: Rising - Steady increase in percentiles. March 2025: 30.0 percentile. June 2025: 39.0 percentile. August 2025: 60.0 percentile. Clinical meaning - Improved intake/absorption of healthy fats. - Shift toward optimal cardiovascular protective range. Action Maintain current dietary habits including omega-3 and omega-6 sources. Sample source Blood.

Very Low Density Lipoprotein Particle Size [in Blood - Quantitative] (percentile)

Loading chart...

Biomarker values remain within normal limits despite high volatility in particle size distribution.

Description Lipoprotein subfraction indicating average size of VLDL particles. Measurements Trend: Falling fast - Significant decline from May peak. March 2025: 37.0 percentile. May 2025: 73.0 percentile. August 2025: 21.0 percentile. Clinical meaning Lower percentile reflects smaller VLDL particles. Correlates with triglycerides and cardiovascular risk profiles. Action No action required as values remain within reference range. Sample source Blood.

Hormones

57 biomarkers

Dehydroepiandrosterone Sulfate [in Blood - Quantitative] (umol/L)

Loading chart...

Persistent out of range low values indicate clinical attention required for adrenal health.

Description Adrenal androgen precursor measuring adrenal gland function. Measurements Trend: Falling fast - Sharp decline since March 2025. September 2024: 7.2 umol/L. December 2024: 6.0 umol/L average (3 readings). March 2025: 12.0 umol/L. May 2025: 2.1 umol/L. June 2025: 2.5 umol/L. July 2025: 1.9 umol/L. September 2025: 2.7 umol/L. November 2025: 3.1 umol/L. Clinical meaning Substantial drop below reference ranges suggests possible adrenal insufficiency. Low levels associated with chronic stress or HPA axis dysfunction. Action Evaluate adrenal function and investigate causes of recent decline. Sample source Blood.

Progesterone [in Blood - Quantitative] (nmol/L)

Loading chart...

Recent results show return to normal reference range after previous deficiency.

Description Steroid hormone regulating menstrual cycle and pregnancy. Measurements Trend: Rising - Recovery after drop below reference range. December 2024: 0.76 nmol/L (avg of 3), March 2025: 2.68 nmol/L, May 2025: <0.67 nmol/L, June 2025: 0.71 nmol/L, July 2025: 0.72 nmol/L, September 2025: 0.8 nmol/L, October 2025: 1.55 nmol/L. Clinical meaning - Recent return to normal range following period of suppression. - Values suggest cycle-dependent fluctuations or hormonal imbalance recovery. Action Monitor alongside menstrual cycle phase to confirm ovulation status. Sample source Blood.

SYMPHONY Age (Hormone) [Quantitative] (Years)

Loading chart...

Steady rise in biological hormone age suggests worsening endocrine health profile.

Description Biological age metric based on endocrine profiles. Measurements Trend: Rising - Increase of 5.9 years over 9 months. December 2024: 55.9 Years, February 2025: 55.9 Years, March 2025: 58.1 Years, June 2025: 62.3 Years, August 2025: 62.3 Years, September 2025: 61.8 Years. Clinical meaning - Upward trend indicates accelerating biological aging relative to hormone markers. - Slight stabilization noted in final reading. Action Evaluate lifestyle and endocrine stressors contributing to rapid biological age advancement. Sample source Unknown.

Norepinephrine [in Urine - Quantitative] (ug/gCR)

Loading chart...

Recent out-of-range low value suggests monitoring for sympathetic exhaustion.

Description

Catecholamine neurotransmitter reflecting sympathetic nervous system activity.

Measurements

Trend: Falling slightly - Decreasing levels from 2024 to mid-2025.

May 2024.0: 14.7 ug/gCR
November 2024.0: 17.1 ug/gCR
July 2025.0: 11.24 ug/gCR (avg of 5)

Clinical meaning

Low result on July 2025 indicates potential autonomic insufficiency or chronic stress fatigue.
Most readings remain within range but trend lower over time.

Action

Correlate low values with symptoms of fatigue or orthostatic hypotension.

Sample source

Urine

Epinephrine [in Urine - Quantitative] (ug/gCR)

Loading chart...

Recent elevated result requires clinical correlation with patient stress levels.

Description

Adrenal hormone measuring acute stress response and medullary function.

Measurements

Trend: Rising - Significant spike in latest reading.

May 2024.0: 4.0 ug/gCR
November 2024.0: 3.5 ug/gCR
July 2025.0: 4.17 ug/gCR (avg of 3)

Clinical meaning

High reading on July 2025 (9.0 ug/gCR) indicates acute stress, anxiety, or adrenal stimulation.
Previous 2024 levels were stable and mid-range.

Action

Investigate sources of acute stress or potential sympathoadrenal triggers.

Sample source

Urine

SYMPHONY Age (Hormone) [in Blood - Quantitative] (Years)

Loading chart...

Rising biological age trend indicates declining physiological resilience.

Description

Biological aging clock measuring hormone-driven senescence.

Measurements

Trend: Rising - Biological age increased over last 4 months.

March 2024: 60.4 Years average (2 readings)
February 2025: 55.9 Years
March 2025: 58.1 Years
June 2025: 62.3 Years

Clinical meaning

Recent upward trend suggests accelerating biological aging.
All readings remain flagged out of range.

Action

Review lifestyle interventions and hormonal balance to address rising age trend.

Sample source

Blood

2-Methoxyestrone to 2-Hydroxyestrone Ratio [in Urine - Quantitative] (Ratio)

Loading chart...

Estrogen methylation efficiency improving but remains below target range.

Description Urinary ratio measuring estrogen methylation efficiency. Measurements Trend: Rising - Moving toward reference range. May 2024: 0.11
September 2024: 0.19. Clinical meaning Low ratio suggests suboptimal Phase II COMT detoxification of estrogen metabolites. Improvement indicates better hormonal clearance. Action Support COMT enzyme activity with magnesium or methyl donors if clinically indicated. Sample source Urine.

Dopamine [in Stool - Quantitative] (%)

Loading chart...

Dopamine levels significantly low and showing downward trend.

Description Measurement of dopamine levels in gastrointestinal tract. Measurements Trend: Falling - Levels decreasing further from midpoint. July 2024: 0.985 average (2 readings)
October 2024: 0.05. Clinical meaning Low fecal dopamine may indicate gut microbiome imbalances or altered enteric nervous system signaling. Declining levels suggest worsening depletion. Action Evaluate gut-brain axis and consider probiotic or dietary support to optimize enteric neurotransmitter production. Sample source Stool.

Free Cortisol (Evening) [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Evening levels are stable but nighttime cortisol has fallen below the reference range.

Description

Quantitative urinary marker measuring unbound evening/night cortisol levels.

Measurements

Trend: Falling

September 2024: 15.55 µg/g Cr (Evening), 3.74 µg/g Cr (Night)
July 2025: 11.53 µg/g Cr (Evening), 2.07 µg/g Cr (Night)

Clinical meaning

Evening levels remain within reference range.
Nighttime levels dropped below range, suggesting potential nocturnal hypocortisolism.

Action

Evaluate for symptoms of fatigue or sleep disruption related to low nighttime cortisol.

Sample source

Urine

Free Cortisone (1st Morning) [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Significant rise observed with morning levels now trending above the reference limit.

Description

Inactive metabolite of cortisol used to assess morning adrenal output.

Measurements

Trend: Rising fast

September 2024: 25.16 µg/g Cr (1st Morning), 70.33 µg/g Cr (2nd Morning)
July 2025: 94.47 µg/g Cr (1st Morning), 114.16 µg/g Cr (2nd Morning)

Clinical meaning

Substantial increase in early morning cortisone production.
Current 1st morning value slightly exceeds upper reference limit.

Action

Monitor for signs of morning sympathetic dominance or stress response.

Sample source

Urine

Free Cortisone (Evening) [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Nighttime levels fell below range despite stable evening values.

Description

Inactive metabolite of cortisol representing evening/overnight glucocorticoid status.

Measurements

Trend: Rising (Evening); Falling (Night)

September 2024: 42.91 µg/g Cr (Evening); 19.97 µg/g Cr (Night)
July 2025: 48.62 µg/g Cr (Evening); 9.52 µg/g Cr (Night)

Clinical meaning

Evening levels remain within normal reference range.
Nighttime levels dropped below range suggesting low overnight adrenal output.

Action

Investigate potential adrenal insufficiency or circadian rhythm disruption affecting sleep cycle.

Sample source

Urine

Melatonin (Evening) [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Massive increase in results across both time points indicates significant clinical abnormality.

Description

Urinary metabolite measuring pineal gland hormone production for sleep-wake regulation.

Measurements

Trend: Rising fast

September 2024: 0.87 µg/g Cr (Evening); 1.39 µg/g Cr (Night)
July 2025: 32.09 µg/g Cr (Evening); 13.83 µg/g Cr (Night)

Clinical meaning

Extreme elevation in evening/night concentrations.
Values far exceed upper reference limits suggesting external supplementation or metabolic shift.

Action

Review dosage of melatonin supplements or evaluate for pineal hyperfunction.

Sample source

Urine

Leptin [in Blood - Quantitative] (Percentile)

Loading chart...

Progressive elevation in leptin percentiles indicates worsening satiety hormone resistance.

Description Adipose-derived hormone regulating energy balance and satiety. Measurements Trend: Rising - Sustained increase above reference range. March 2025.0: 83.0 Percentile
May 2025.0: 88.0 Percentile
August 2025.0: 94.0 Percentile. Clinical meaning - Elevated levels suggest leptin resistance and increased fat mass. - High values correlate with diminished satiety signaling. Action Evaluate body composition and metabolic markers to address potential leptin resistance.

Estradiol [in Blood - Quantitative] (pmol/L)

Loading chart...

Hormone levels remain stable and within normal limits across all timepoints.

Description Primary estrogen steroid hormone. Measurements Trend: Flat - Stable fluctuations within reference range. December 2024: 82.7 pmol/L (avg of 3), March 2025: 98.9 pmol/L, May 2025: 97.3 pmol/L, June 2025: 131.8 pmol/L, July 2025: 64.6 pmol/L, September 2025: 94.6 pmol/L, October 2025: 99.1 pmol/L (avg of 2), November 2025: 103.899 pmol/L. Clinical meaning Levels consistent with healthy reference limits. Indicates normal estrogenic activity and metabolic balance. Action No action required. Sample source Blood.

Testosterone [in Blood - Quantitative] (nmol/L)

Loading chart...

Testosterone levels have stabilized within normal range following a temporary decline.

Description Primary androgenic steroid hormone. Measurements Trend: Rising slightly - Rebound to mid-range after March dip. December 2024: 16.77 nmol/L (avg of 3), March 2025: 12.1 nmol/L, May 2025: 19.5 nmol/L, June 2025: 19.7 nmol/L, July 2025: 21.4 nmol/L, September 2025: 17.5 nmol/L, October 2025: 16.2 nmol/L, November 2025: 19.728 nmol/L. Clinical meaning March reading showed transient decrease. Subsequent results confirm recovery to robust physiological levels. Action No action required. Sample source Blood.

Cortisol [in Blood - Quantitative] (nmol/L)

Loading chart...

Patient maintains stable cortisol levels within normal limits across all timepoints.

Description

Glucocorticoid hormone measuring adrenal cortex function and stress response.

Measurements

Trend: Falling slightly - minor decline in latest reading compared to baseline.

September 2024: 358.0 nmol/L
March 2025: 307.0 nmol/L
May 2025: 298.0 nmol/L
June 2025: 397.0 nmol/L
July 2025: 323.0 nmol/L
September 2025: 361.0 nmol/L
November 2025: 201.402 nmol/L

Clinical meaning

All readings remain within laboratory reference ranges.
Fluctuations expected based on circadian rhythm and collection time.

Action

No action required.

Sample source

Blood

Melatonin MT6s [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Melatonin metabolite levels are healthy and within expected clinical ranges.

Description

Major urinary metabolite of melatonin reflecting pineal gland production and sleep-wake cycles.

Measurements

Trend: Falling - reduction in latest average compared to previous year.

May 2024: 11.33 µg/g Cr (average of 6 readings)
July 2025: 10.5 µg/g Cr (average of 2 readings)

Clinical meaning

Results consistently fall within normal reference ranges.
Multiple daily readings suggest assessment of diurnal variation.

Action

No action required.

Sample source

Urine

Sex Hormone-Binding Globulin [in Blood - Quantitative] (nmol/L)

Loading chart...

Biomarker stable within normal range despite recent downward trend.

Description Blood protein regulating bioavailability of sex steroids. Measurements Trend: Falling - Recent decline after mid-year peak. December 2024: 31.98 (avg of 3), March 2025: 35.62, May 2025: 40.21, June 2025: 50.73, July 2025: 53.8, September 2025: 38.19, October 2025: 36.16. Clinical meaning - Values remain within normal reference ranges. - Lower SHBG levels increase free (active) hormone availability. Action No action required. Sample source Blood.

Follicle Stimulating Hormone [in Blood - Quantitative] (IU/L)

Loading chart...

All values consistently within healthy reference limits.

Description Pituitary hormone governing reproductive function and gamete production. Measurements Trend: Rising slightly - Gradual increase over ten-month period. December 2024: 3.3, March 2025: 3.7, May 2025: 3.4, June 2025: 4.5, July 2025: 3.5, September 2025: 4.3, October 2025: 4.4. Clinical meaning - Consistent results indicate healthy pituitary-gonadal axis function. - Current levels support normal reproductive signaling. Action No action required. Sample source Blood.

Free Androgen Index [in Blood - Quantitative] (%)

Loading chart...

Patient maintains stable androgen status within normal reference limits.

Description Ratio of total testosterone to sex hormone binding globulin (SHBG) determining bioactive androgen levels. Measurements Trend: Flat - Stable fluctuations within reference range. Dec 2024: 52.7%, Mar 2025: 34.0%, May 2025: 48.5%, Jun 2025: 38.8%, Jul 2025: 39.8%, Sep 2025: 45.8%, Oct 2025: 44.8%. Clinical meaning - Bioavailable testosterone remains within optimal physiological bounds. - No evidence of androgen deficiency or excess. Action No action required. Sample source Blood.

Insulin-like Growth Factor 1 [in Blood - Quantitative] (ng/mL)

Loading chart...

Recent sharp downward trend requires observation despite values remaining within reference limits.

Description Hormone reflecting growth hormone activity and tissue anabolic state. Measurements Trend: Falling fast - Significant decline starting July 2025. Dec 2024: 164.0 ng/mL, Mar 2025: 158.0 ng/mL, May 2025: 165.0 ng/mL (Avg of 2), Jun 2025: 158.0 ng/mL, Jul 2025: 177.0 ng/mL, Sep 2025: 131.0 ng/mL, Oct 2025: 108.0 ng/mL (Avg of 2). Clinical meaning - Notable 39% reduction in IGF-1 levels over last four months. - Values remain within range but show downward trajectory potentially impacting metabolic recovery. Action Monitor for symptoms of growth hormone deficiency or nutritional changes. Sample source Blood.

Luteinizing Hormone [in Blood - Quantitative] (IU/L)

Loading chart...

Results show stable, healthy hormone levels.

Description Pituitary hormone regulating reproductive function. Measurements Trend: Flat - minor fluctuations within normal range. Dec 2024: 4.2 IU/L, Mar 2025: 3.2 IU/L, May 2025: 3.6 IU/L, Jun 2025: 3.5 IU/L, Jul 2025: 3.9 IU/L, Sep 2025: 3.7 IU/L. Clinical meaning Values consistently within reference range. Normal pituitary-gonadal axis signaling. Action No action required. Sample source Blood.

Prolactin [in Blood - Quantitative] (mIU/L)

Loading chart...

All values remain well within reference limits.

Description Pituitary hormone influencing reproductive health and stress response. Measurements Trend: Rising - slight upward shift since July. Dec 2024: 162.0 mIU/L, Mar 2025: 153.0 mIU/L, May 2025: 171.0 mIU/L (Avg of 2), Jun 2025: 164.0 mIU/L, Jul 2025: 153.0 mIU/L, Sep 2025: 196.0 mIU/L, Oct 2025: 214.0 mIU/L. Clinical meaning Levels currently normal but trending upward. May reflect physiological stress or normal variation. Action Monitor trend in next routine screen. Sample source Blood.

Homovanillic Acid [in Urine - Quantitative] (ug/gCR)

Loading chart...

Biomarker levels remain stable and within normal reference ranges across all data points.

Description Urinary metabolite of dopamine. Measurements Trend: Falling slightly - Values volatile but remaining within reference ranges. - May 2024: 3092.0 ug/gCR - November 2024: 5867.0 ug/gCR - December 2024: 1280.0 ug/gCR (avg of 2) - July 2025: 1400.0 ug/gCR. Clinical meaning - Indicates dopamine turnover is within physiological limits. - Recent stabilization suggests balanced catecholamine metabolism. Action No action required. Sample source Urine.

Tetrahydrocortisone [in Urine - Quantitative] (µg/g Cr)

Loading chart...

Cortisol metabolites are stable and within the reference range.

Description Urinary metabolite of cortisol reflecting total adrenal output. Measurements Trend: Rising - Moderate increase in metabolite excretion. May 2024.0: 576.0 µg/g Cr. September 2024.0: 752.0 µg/g Cr. Clinical meaning - Values remain within reference range. - Rising trend suggests increased cortisol production or metabolism over time. Action No action required as results are within normal limits. Sample source Urine.

Vanillylmandelic Acid [in Urine - Quantitative] (ug/gCR)

Loading chart...

Catecholamine metabolites are normal with a decreasing trend toward the lower range.

Description End-stage metabolite of catecholamines epinephrine and norepinephrine. Measurements Trend: Falling fast - Significant downward trajectory over 14 months. May 2024.0: 2360.0 ug/gCR. November 2024.0: 2235.0 ug/gCR (avg of 2). December 2024.0: 1340.0 ug/gCR (avg of 2). July 2025.0: 960.0 ug/gCR. Clinical meaning - All values within normal reference intervals. - Consistent decline indicates reduced sympathetic nervous system activity or catecholamine turnover. Action No action required. Sample source Urine.

Dopamine 3-O-Sulfate [in Blood - Quantitative] (Percentile)

Loading chart...

Recent sharp increase places value at upper threshold of normal range.

Description Major sulfated metabolite of dopamine in circulation. Measurements Trend: Rising - Significant increase to upper reference limit. March 2025.0: 67.0 Percentile
May 2025.0: 64.0 Percentile
August 2025.0: 94.0 Percentile. Clinical meaning - High levels suggest increased peripheral dopamine production or decreased renal clearance. - August reading near upper limit of normal. Action Monitor for symptoms of catecholamine excess or hypertension. Sample source Blood.

Dopamine 4-Sulfate [in Blood - Quantitative] (Percentile)

Loading chart...

Values fluctuate significantly but current measurement is within normal limits.

Description Secondary sulfated conjugate of dopamine metabolism. Measurements Trend: Rising - Recovery from sharp drop in May. March 2025.0: 82.0 Percentile
May 2025.0: 6.0 Percentile
August 2025.0: 77.0 Percentile. Clinical meaning - High volatility suggests transient metabolic shifts or dietary influences. - Current value remains within healthy reference bounds. Action No action required as latest result is stable. Sample source Blood.

Equol [in Stool - Quantitative] (%)

Loading chart...

Values remain within reference ranges despite downward trend.

Description

Stool metabolite derived from bacterial metabolism of soy isoflavones.

Measurements

Trend: Falling fast - consistent decline over eight months

July 2024: 2.23 %
October 2024: 1.28 %
February 2025: 0.74 % (Average of 2)

Clinical meaning

Indicates decreasing gut microbiome capacity for equol production.
Reflects potential shift in microbial diversity or reduced soy precursor intake.

Action

Increase intake of soy-based foods to support equol-producing bacteria.

Sample source

Stool

Gamma-Aminobutyric Acid [in Stool - Quantitative] (%)

Loading chart...

Biomarker remains stable and well within expected reference ranges.

Description

Stool measurement of inhibitory neurotransmitter relative abundance produced by gut microbiota.

Measurements

Trend: Falling - peaked in October followed by recent decline

July 2024: 18.54 %
October 2024: 27.95 %
February 2025: 20.52 %

Clinical meaning

Reflects current balance of GABA-producing versus GABA-consuming intestinal bacteria.
Levels currently stabilize near baseline within normal physiological range.

Action

No action required as current level is optimal and within reference limits.

Sample source

Stool

Norepinephrine [in Stool - Quantitative] (%)

Loading chart...

Biomarker remains within healthy reference range despite falling trend.

Description

Microbial relative abundance of norepinephrine-related metabolites in gut.

Measurements

Trend: Falling fast - Sharp decline since October 2024.

July 2024: 0.02%
October 2024: 0.02%
February 2025: 0.002%

Clinical meaning

Current levels within normal reference range despite recent drop.
Suggests potential shift in microbial neuroactive metabolite production.

Action

Monitor for changes in mood or gut motility if levels continue to decline.

Sample source

Stool

Serotonin [in Stool - Quantitative] (%)

Loading chart...

Recent sharp decline suggests unstable microbial serotonin production.

Description

Marker of serotonin production and abundance within gut microbiome.

Measurements

Trend: Falling fast - Significant decrease from 2024 peak.

July 2024: 0.07%
October 2024: 0.16%
February 2025: 0.019%

Clinical meaning

Current level borderline but above minimum threshold.
History of out-of-range high values in late 2024.

Action

Assess dietary precursors and probiotic support to stabilize serotonin-producing bacteria.

Sample source

Stool

Kidney Function

26 biomarkers

Creatinine [in Urine - Quantitative] (mmol/L)

Loading chart...

Volatile results with frequent out-of-range readings require clinical correlation.

Description

Waste product in urine used to assess sample concentration and kidney output.

Measurements

Trend: Rising - increasing volatility and higher values over time

May 2024: 13.551 mmol/L (avg of 6)
September 2024: 21.216 mmol/L
February 2025: 13.4 mmol/L (avg of 2)
March 2025: 2.99 mmol/L
July 2025: 15.205 mmol/L

Clinical meaning

Significant fluctuations suggest varied hydration levels or potential kidney filtration inconsistency.
Results frequently fall outside standard reference ranges.

Action

Investigate underlying causes for significant concentration variance across multiple tests.

Sample source

Urine

Estimated Glomerular Filtration Rate (CKD-EPI) [in Blood - Quantitative] (ml/min/1.73m^2)

Loading chart...

Recent values slightly below target range indicate need for continued monitoring.

Description

Calculated measure of blood volume filtered by kidneys per minute.

Measurements

Trend: Falling slightly - overall downward trajectory since initial high reading

October 2024: 102.0 ml/min/1.73m^2
December 2024: 80.0 ml/min/1.73m^2
June 2025: >90 ml/min/1.73m^2
August 2025: >90 ml/min/1.73m^2
September 2025: 87.0 ml/min/1.73m^2

Clinical meaning

Values dropping below 90 indicate mild reduction in kidney filtration efficiency.
Recent data shows shift from optimal to slightly sub-optimal levels.

Action

Monitor trend and assess for contributing factors like blood pressure or hydration.

Sample source

Blood

SYMPHONY Age (Kidney) [in Blood - Quantitative] (Years)

Loading chart...

Biological kidney age remains elevated and stable above reference norms.

Description

Biological age estimate based on kidney-specific proteomic markers.

Measurements

Trend: Flat - Minimal variance over 15 months

March 2024: 59.45 Years (Average of 2)
February 2025: 58.2 Years
March 2025: 60.3 Years
June 2025: 60.2 Years

Clinical meaning

Biological kidney age consistently exceeds chronological expectations.
Indicates potential accelerated renal aging or chronic stress.

Action

Evaluate renal function markers like GFR and albuminuria to correlate with proteomic aging.

Sample source

Blood

SYMPHONY Age (Kidney) [Quantitative] (Years)

Loading chart...

Persistent out-of-range kidney age shows recent modest improvement.

Description

Proteomic clock measurement reflecting renal system health and aging.

Measurements

Trend: Falling slightly - Gradual decrease in biological age since March 2025 peak

February 2025: 58.2 Years
March 2025: 60.3 Years
June 2025: 60.2 Years
August 2025: 57.8 Years (Average of 2)
September 2025: 57.8 Years

Clinical meaning

Values consistently out of range suggesting suboptimal kidney resilience.
Recent 2.5-year reduction in biological age suggests slight improvement in profile.

Action

Monitor metabolic factors and blood pressure to support continued downward trend in biological age.

Sample source

Unknown

Creatinine (Spot) [in Urine - Quantitative] (mmol/L)

Loading chart...

Urinary creatinine shows high variability and recently fell below reference range suggesting potential sample dilution.

Description Waste product from muscle metabolism excreted via kidneys used to normalize urine dilution. Measurements Trend: Falling slightly - Significant volatility with recent decline. November 2024: 2.8 mmol/L. February 2025: 15.6 mmol/L. October 2025: 10.055 mmol/L. November 2025: 6.66 mmol/L. Clinical meaning Low levels suggest dilute urine or reduced muscle mass. Fluctuating values affect accuracy of other urine-based ratio tests. Action Correlate with hydration status and repeat test to ensure concentrated sample. Sample source Urine.

Oxalic [in Urine - Quantitative] (mmol/mol creatinine)

Loading chart...

Oxalic acid levels have spiked significantly above the clinical reference range.

Description

Metabolic byproduct primarily associated with kidney stone risk and diet.

Measurements

Trend: Rising fast - Sharp increase above upper reference limit

December 2024: 4.61 mmol/mol creatinine (average of 2 readings)
July 2025: 173.0 mmol/mol creatinine

Clinical meaning

Current elevation suggests hyperoxaluria, increasing urolithiasis risk.
Potential causes include high-oxalate diet, malabsorption, or metabolic imbalance.

Action

Evaluate dietary oxalate intake and increase fluid consumption to mitigate stone risk.

Sample source

Urine

Creatinine [in Blood - Quantitative] (umol/L)

Loading chart...

Normal values with stable trend despite recent slight elevation.

Description

Waste product filtered by kidneys used to estimate filtration rate.

Measurements

Trend: Rising - increasing values toward upper limit.

April 2024.0: 80.0 umol/L
July 2024.0: 96.0 umol/L (average of 2)
September 2024.0: 89.0 umol/L
December 2024.0: 98.75 umol/L (average of 4)
March 2025.0: 81.5 umol/L (average of 2)
May 2025.0: 87.0 umol/L
June 2025.0: 78.0 umol/L
August 2025.0: 69.0 umol/L
September 2025.0: 86.0 umol/L
October 2025.0: 82.0 umol/L
November 2025.0: 109.0 umol/L

Clinical meaning

Fluctuating renal function with recent spike.
Most values within range despite single outlier.

Action

Monitor renal function trends and maintain adequate hydration.

Sample source

Blood

Calcium [in Blood - Quantitative] (mmol/L)

Loading chart...

Values remain consistently within normal range and stable.

Description

Mineral critical for bone health, nerve function, and muscle contraction.

Measurements

Trend: Flat - stable concentration across testing period.

April 2024.0: 2.39 mmol/L
July 2024.0: 2.3 mmol/L (average of 2)
September 2024.0: 2.29 mmol/L
November 2024.0: 2.365 mmol/L (average of 2)
December 2024.0: 2.41 mmol/L
March 2025.0: 2.38 mmol/L (average of 2)
May 2025.0: 2.44 mmol/L
June 2025.0: 2.4 mmol/L
August 2025.0: 2.18 mmol/L
September 2025.0: 2.47 mmol/L
October 2025.0: 2.4 mmol/L
November 2025.0: 2.24 mmol/L

Clinical meaning

Calcium homeostasis maintained within narrow physiological range.
Transient fluctuations clinically insignificant.

Action

No action required.

Sample source

Blood

Chloride [in Blood - Quantitative] (mmol/L)

Loading chart...

Values remain stable and predominantly within reference ranges.

Description

Serum electrolyte indicating acid-base balance and fluid status.

Measurements

Trend: Flat - values fluctuate within normal ranges over 19 months.

April 2024.0: 102.0 mmol/L
July 2024.0: 103.0 mmol/L
September 2024.0: 105.0 mmol/L
October 2024.0: 104.0 mmol/L
December 2024.0: 102.3 mmol/L (avg 3 readings)
March 2025.0: 106.0 mmol/L (avg 2 readings)
May 2025.0: 105.0 mmol/L
June 2025.0: 103.0 mmol/L
August 2025.0: 107.0 mmol/L
September 2025.0: 100.0 mmol/L
October 2025.0: 102.0 mmol/L
November 2025.0: 104.0 mmol/L

Clinical meaning

Patient maintains stable extracellular anion levels.
Rare minor elevation in September 2024 corrected quickly.

Action

No action required.

Sample source

Blood

Potassium [in Blood - Quantitative] (mmol/L)

Loading chart...

Potassium levels are well-regulated and stable across all measurement dates.

Description

Major intracellular cation essential for nerve and muscle function.

Measurements

Trend: Flat - stable concentration with minor physiologic variability.

April 2024.0: 4.4 mmol/L
September 2024.0: 4.2 mmol/L
October 2024.0: 4.4 mmol/L
December 2024.0: 4.35 mmol/L (avg 2 readings)
March 2025.0: 3.9 mmol/L (avg 2 readings)
May 2025.0: 4.2 mmol/L (avg 2 readings)
June 2025.0: 4.2 mmol/L
August 2025.0: 3.8 mmol/L
September 2025.0: 4.8 mmol/L
October 2025.0: 4.0 mmol/L (avg 2 readings)
November 2025.0: 4.2 mmol/L

Clinical meaning

Consistent normal electrolyte balance.
September 2024 out-of-range flag appears clinically insignificant given stable trend.

Action

No action required.

Sample source

Blood

Sodium [in Blood - Quantitative] (mmol/L)

Loading chart...

Sodium levels remain stable and within clinical norms.

Description Primary extracellular electrolyte for fluid balance and nerve function. Measurements Trend: Rising slightly - Slight upward trend with final stabilization. April 2024.0: 138.0 mmol/L
September 2024.0: 139.0 mmol/L
December 2024.0: 140.0 mmol/L (avg, 3 tests)
March 2025.0: 141.5 mmol/L (avg, 2 tests)
May 2025.0: 141.0 mmol/L
June 2025.0: 141.0 mmol/L
August 2025.0: 140.0 mmol/L
September 2025.0: 141.0 mmol/L
October 2025.0: 139.0 mmol/L
November 2025.0: 140.0 mmol/L. Clinical meaning - Values largely within normal range despite inconsistent reference intervals. - No evidence of significant hypernatremia or hyponatremia. Action No action required. Sample source Blood.

pH [in Urine - Quantitative]

Loading chart...

Urine pH values demonstrate normal physiological variation within reference ranges.

Description Measure of urine acidity or alkalinity. Measurements Trend: Falling - Recent downward shift toward more acidic readings. April 2024.0: 6.5
July 2024.0: 7.0
September 2024.0: 7.5
December 2024.0: 6.5
March 2025.0: 6.5 (avg, 2 tests)
May 2025.0: 7.5
June 2025.0: 6.5
July 2025.0: 7.5
September 2025.0: 6.0
October 2025.0: 5.0
November 2025.0: 6.5. Clinical meaning - Fluctuations reflect typical dietary and metabolic variability. - October reading at lower limit of normal. Action No action required. Sample source Urine.

Phosphate [in Blood - Quantitative] (mmol/L)

Loading chart...

Phosphate levels are stable and within normal limits.

Description

Serum mineral marker for bone health and kidney function.

Measurements

Trend: Rising - upward shift in final quarter.

April 2024.0: 1.07 mmol/L
July 2024.0: 1.1 mmol/L
September 2024.0: 1.04 mmol/L
December 2024.0: 1.14 mmol/L
March 2025.0: 1.17 mmol/L average (2 readings)
May 2025.0: 1.12 mmol/L
June 2025.0: 0.96 mmol/L
August 2025.0: 0.98 mmol/L
September 2025.0: 1.07 mmol/L
October 2025.0: 1.11 mmol/L average (2 readings)
November 2025.0: 1.33 mmol/L

Clinical meaning

Values remain within healthy reference range.
Stable maintenance of phosphorus homeostasis.

Action

No action required.

Sample source

Blood

Specific Gravity [in Urine - Quantitative]

Loading chart...

Urinary concentration remains within physiological range indicating healthy fluid balance.

Description

Ratio of urine density to water indicating kidney concentration ability.

Measurements

Trend: Rising - slight increase from mid-year lows.

April 2024.0: 1.013
September 2024.0: 1.024
October 2024.0: 1.005
December 2024.0: 1.016
March 2025.0: 1.0085 average (2 readings)
May 2025.0: 1.007
June 2025.0: 1.005
July 2025.0: 1.008
September 2025.0: 1.013
October 2025.0: 1.016
November 2025.0: 1.015

Clinical meaning

Fluctuations reflect normal changes in hydration and fluid intake.
Kidney concentration capacity appears intact.

Action

No action required.

Sample source

Urine

Uric Acid [in Blood - Quantitative] (mmol/L)

Loading chart...

Patient shows stable uric acid levels within healthy range despite minor reference interval fluctuations.

Description End product of purine metabolism excreted by kidneys. Measurements Trend: Flat - Stable readings within lower reference limit. April 2024: 0.246 mmol/L
July 2024: 0.35 mmol/L (Avg of 2)
September 2024: 0.31 mmol/L
October 2024: 0.27 mmol/L
December 2024: 0.28 mmol/L
March 2025: 0.255 mmol/L (Avg of 2)
May 2025: 0.28 mmol/L
June 2025: 0.27 mmol/L
August 2025: 0.23 mmol/L
September 2025: 0.28 mmol/L
October 2025: 0.26 mmol/L
November 2025: 0.27 mmol/L. Clinical meaning Values remain consistently low-normal. No risk for hyperuricemia or gout indicated. Action No action required. Sample source Blood.

Adjusted Calcium [in Blood - Quantitative] (mmol/L)

Loading chart...

Calcium levels demonstrate healthy stability and remain well-regulated over time.

Description Calcium concentration corrected for albumin levels. Measurements Trend: Rising slightly - Gradual increase from lower limit toward mid-range. July 2024: 2.2 mmol/L (Avg of 2)
September 2024: 2.21 mmol/L
November 2024: 2.27 mmol/L
December 2024: 2.35 mmol/L
March 2025: 2.36 mmol/L (Avg of 2)
May 2025: 2.44 mmol/L
June 2025: 2.36 mmol/L
August 2025: 2.22 mmol/L
September 2025: 2.33 mmol/L. Clinical meaning Levels consistently within normal physiological range. Efficient mineral homeostasis observed. Action No action required. Sample source Blood.

Urea Nitrogen [in Blood - Quantitative] (mmol/L)

Loading chart...

Biomarker remains stable and within normal clinical parameters across recent history.

Description Waste product of protein metabolism measured in serum to evaluate kidney function and protein intake. Measurements Trend: Flat - Stable values within normal limits after initial September 2024 low. September 2024: 3.9 mmol/L
December 2024: 5.3 mmol/L
March 2025: 4.8 mmol/L
May 2025: 5.3 mmol/L
June 2025: 5.1 mmol/L
August 2025: 4.1 mmol/L
September 2025: 4.1 mmol/L
October 2025: 4.2 mmol/L. Clinical meaning Consistent results suggest stable renal clearance and adequate protein balance. Recent readings align well with reference ranges. Action No action required. Sample source Blood.

Urea [in Blood - Quantitative] (mmol/L)

Loading chart...

Values are currently normal despite gradual upward trajectory.

Description Primary nitrogenous waste product reflecting liver protein synthesis and renal excretion efficiency. Measurements Trend: Rising - Gradual increase across observation period. April 2024: 3.4 mmol/L
December 2024: 4.7 mmol/L (Avg of 2)
March 2025: 5.1 mmol/L
November 2025: 6.2 mmol/L. Clinical meaning Upward trend noted but remains within normal laboratory limits. May reflect changes in dietary protein intake or hydration status. Action Monitor trend in next routine screening. Sample source Blood.

Creatinine (Evening) [in Urine - Quantitative] (mg/mL)

Loading chart...

Biomarker levels are stable and within normal limits.

Description Urinary byproduct of muscle metabolism used to normalize other urine markers. Measurements Trend: Falling - decrease from 2024 to 2025. September 2024: 1.35 mg/mL (average of 2 readings)
July 2025: 0.69 mg/mL (average of 2 readings). Clinical meaning - Values remain within reference range (0.3 - 2.0 mg/mL). - Lower levels may indicate higher urine dilution or lower muscle mass. Action No action required. Sample source Urine.

Cystatin C [in Blood - Quantitative] (mg/L)

Loading chart...

Results show stable kidney function over 14-month period.

Description Blood protein used as highly sensitive indicator of kidney filtration rate. Measurements Trend: Flat - consistent values across all timepoints. September 2024: 0.9 mg/L
March 2025: 0.82 mg/L
October 2025: 0.83 mg/L
November 2025: 0.85 mg/L. Clinical meaning - Readings consistently within standard range (0.64 - 1.23 mg/L) despite previous flags. - Stable trend suggests healthy, consistent glomerular filtration. Action No action required. Sample source Blood.

Kidney System Score [in Blood - Quantitative] (Score)

Loading chart...

Persistent low kidney scores indicate chronic renal impairment requiring further diagnostic investigation.

Description Composite metric evaluating renal filtration efficiency and health status. Measurements Trend: Falling slightly - minor decrease in composite score over 12 months. - January 2024.0: 60.3 Score - January 2025.0: 59.5 Score (Average of 3 readings). Clinical meaning - Persistent out-of-range scores indicate chronic kidney stress or diminished filtration capacity. - Stability between 2024 and 2025 suggests non-acute but ongoing renal dysfunction. Action Order comprehensive metabolic panel and urinalysis to investigate underlying causes of low scores. Sample source Blood.

Albumin (Microalbumin) [in Urine - Quantitative] (MG/L)

Loading chart...

Albumin levels remain stable and within healthy reference ranges across all time points.

Description Small amounts of protein in urine indicating potential glomerular basement membrane damage. Measurements Trend: Flat - consistent readings at baseline over 8 months. - March 2025.0: 3.0 MG/L - October 2025.0: 3.0 MG/L (Average of 2 readings) - November 2025.0: 3.0 MG/L. Clinical meaning - Values within normal physiological limits despite one early flag. - Consistently low levels suggest intact glomerular filtration barrier. Action No action required. Sample source Urine.

White Blood Cell Count (Urinalysis Microscopy) [in Urine - Quantitative] (10^6/L)

Loading chart...

WBC levels remain within normal limits with most recent result showing complete absence of urinary leukocytes.

Description Quantitative measure of leukocytes in urine indicating immune response. Measurements Trend: Falling - Recent decrease after slight rise. - April 2024: 2.0 10^6/L - October 2025: 5.0 10^6/L (Average of 2 readings) - November 2025: 0.0 10^6/L Clinical meaning - All values remained within healthy reference range. - Recent zero reading confirms absence of pyuria or inflammation. Action No action required. Sample source Urine.

Immune System

42 biomarkers

SYMPHONY Age (Inflammation) [Quantitative] (Years)

Loading chart...

Persistent out-of-range values and upward trajectory signal accelerated inflammatory aging.

Description

Epigenetic or glycan-based proxy measuring systemic biological inflammatory aging.

Measurements

Trend: Rising - Consistent increase from baseline 53.0 to peak 58.0.

March 2024.0: 53.0 Years
December 2024.0: 54.0 Years
January 2025.0: 58.0 Years
February 2025.0: 54.1 Years (Average of 3)
March 2025.0: 56.9 Years (Average of 2)
May 2025.0: 56.9 Years
June 2025.0: 58.0 Years (Average of 2)
August 2025.0: 58.0 Years
September 2025.0: 54.3 Years

Clinical meaning

Biological age consistently exceeds chronological expectations.
Persistent elevation indicates chronic systemic inflammatory burden.

Action

Investigate underlying triggers of systemic inflammation and review lifestyle interventions.

Sample source

Unknown

Rheumatoid Factor [in Blood - Quantitative] (IU/mL)

Loading chart...

Persistent elevations above threshold require ongoing clinical monitoring for inflammatory arthritis.

Description

Autoantibody targeting immunoglobulin G Fc region used in diagnosing autoimmune conditions.

Measurements

Trend: Falling slightly - General decline from 28.0 to 18.0 despite fluctuations.

May 2024: 28.0 IU/mL
July 2024: 23.0 IU/mL (average of 2)
September 2024: 27.6 IU/mL
December 2024: 29.4 IU/mL
March 2025: 22.5 IU/mL (average of 2)
May 2025: 19.9 IU/mL
October 2025: 22.7 IU/mL
November 2025: 18.0 IU/mL

Clinical meaning

Consistently elevated above reference range suggesting persistent systemic inflammation.
Improvement over 18 months may indicate response to treatment or reduced disease activity.

Action

Correlate levels with clinical symptoms of joint pain or stiffness to assess disease management.

Sample source

Blood

SYMPHONY Age (Immune) [in Blood - Quantitative] (Years)

Loading chart...

Recent data shows favorable trend toward lower biological immune age.

Description

Biologic age metric based on inflammatory and immune system protein profiles.

Measurements

Trend: Falling - Significant reduction from peak 66.3 to 59.0.

March 2024: 60.35 Years (average of 2)
February 2025: 66.3 Years
March 2025: 64.6 Years
June 2025: 59.0 Years

Clinical meaning

Recent decline suggests improved immune resilience or reduced chronic inflammation.
Initial rise followed by sharp drop indicates positive shift in biological aging markers.

Action

Maintain current lifestyle or therapeutic interventions contributing to immune age reduction.

Sample source

Blood

SYMPHONY Age (Immune) [Quantitative] (Years)

Loading chart...

Biological immune age showing consistent and significant improvement over seven-month period.

Description

Epigenetic metric estimating biological aging based on immune system profile.

Measurements

Trend: Falling fast - Significant reduction in biological age since February 2025.

Feb 2025: 66.3 Years
Mar 2025: 64.6 Years
Jun 2025: 59.0 Years
Aug 2025: 58.7 Years
Sep 2025: 58.7 Years

Clinical meaning

Higher-than-chronological age suggests accelerated immune senescence.
Rapid decline indicates effective intervention or system recovery.

Action

Monitor continued downward trend to reach target age.

Sample source

Unknown

SYMPHONY Age (Inflammation) [in Blood - Quantitative] (Years)

Loading chart...

Inflammatory biological age shows concerning upward trend over last fifteen months.

Description

Biological age calculation based on systemic inflammatory markers.

Measurements

Trend: Rising - Overall upward movement despite intermittent fluctuation.

Mar 2024: 55.5 Years (average of 2 readings)
Feb 2025: 54.0 Years
Mar 2025: 56.9 Years
Jun 2025: 58.0 Years

Clinical meaning

Increasing age suggests rising systemic inflammation levels.
Elevated results indicate higher biological stress compared to calendar age.

Action

Investigate underlying causes of rising inflammatory markers.

Sample source

Blood

CD4T to CD8T Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Ratio fell below reference range in latest reading indicating potential immune system imbalance.

Description Ratio of helper T-cells to cytotoxic T-cells measuring immune balance. Measurements Trend: Falling slightly - slight decline in primary ratio. - Jan 2025: 4.55 (avg of 2) - Jul 2025: 0.86. Clinical meaning - Low ratio suggests immune senescence or chronic activation. - Out-of-range July value indicates potential immune exhaustion. Action Monitor CD4/CD8 ratio trends alongside absolute lymphocyte counts. Sample source Blood.

Tumor Necrosis Factor Alpha [in Blood - Quantitative] (pg/mL)

Loading chart...

Significant downward trend from elevated to sub-normal levels requires monitoring.

Description Pro-inflammatory cytokine regulating immune response. Measurements Trend: Falling fast - consistent decline from elevated to low. May 2024: 15.8 pg/mL
July 2024: 7.17 pg/mL
January 2025: 5.8 pg/mL
July 2025: 3.63 pg/mL. Clinical meaning Initial systemic inflammation resolved. Current low value may indicate immune suppression or successful anti-inflammatory therapy. Action Investigate potential causes for below-reference levels if patient is symptomatic. Sample source Blood.

CD8 Positive T-Lymphocytes Percentage [in Blood - Quantitative] (%)

Loading chart...

CD8 levels successfully stabilized within normal limits after period of elevation.

Description Percentage of cytotoxic T-cells identifying infected or malignant cells. Measurements Trend: Falling - gradual normalization of elevated levels. January 2025: 41.0 %
July 2025: 37.0 %
November 2025: 36.0 %. Clinical meaning Resolution of previous immune activation or chronic viral response. Most recent value reached upper limit of normal. Action No action required as values have returned to reference range. Sample source Blood.

Histamine [in Stool - Quantitative] (%)

Loading chart...

Values shifted below normal range following downward trend.

Description

Marker of intestinal immune activation and microbial metabolism.

Measurements

Trend: Falling

July 2024: 0.09%
October 2024: 0.07%
February 2025: 0.013% (average of 2 readings)

Clinical meaning

Current levels below reference range suggest low histamine production.
May indicate shifts in gut microbiota composition or reduced allergic response.

Action

Investigate potential causes for low microbial histamine production or dietary intake.

Sample source

Stool

Echovirus Antibody Immunoglobulin A [in Blood - Quantitative] (U/mL)

Loading chart...

Markers indicate recovery from prior Echovirus exposure with currently stable, normal values.

Description

Serum marker of acute or mucosal immune response to Echovirus infection.

Measurements

Trend: Falling fast - Recent decline from abnormal to normal range.

July 2025.0: 11.91 U/mL (average of 2 readings)
August 2025.0: 8.774 U/mL

Clinical meaning

Elevated July levels suggest recent viral exposure.
August decline confirms immunity or clearance of active infection.

Action

No action required.

Sample source

Blood

Echovirus Antibody Immunoglobulin G [in Blood - Quantitative] (U/mL)

Loading chart...

Patient transitioned from elevated antibody levels to normal range within one month.

Description Serological indicator of past or recent exposure to echovirus group. Measurements Trend: Falling fast - Sharp decline from elevated baseline to normal range. July 2025: 14.06 U/mL (average of 2 readings), August 2025: 8.898 U/mL. Clinical meaning Elevated IgG suggests recent infection; subsequent drop to 8.898 U/mL indicates resolution and transition to seronegative or baseline status. Action No action required as latest value is within reference range. Sample source Blood.

Inter-alpha-trypsin Inhibitor Heavy Chain H3 [in Blood - Quantitative] (Percentile Rank)

Loading chart...

Rapid rise to out-of-range values indicates active inflammatory process.

Description Plasma protein associated with inflammation and extracellular matrix stabilization. Measurements Trend: Rising fast - Jump from 10th to 89th percentile. - January 2025: 10.3 Percentile Rank - August 2025: 89.0 Percentile Rank (avg of 2). Clinical meaning - Elevated levels suggest acute phase inflammatory response. - Significant increase over eight months indicates worsening systemic inflammation. Action Investigate potential sources of acute inflammation or connective tissue turnover. Sample source Blood.

Globulin [in Blood - Quantitative] (g/L)

Loading chart...

Globulin levels remain stable and within normal limits across all historical data.

Description Group of blood proteins involved in liver function and immune response. Measurements Trend: Flat - values consistently within reference ranges over 19 months. April 2024: 31.0, May 2024: 32.0, July 2024: 24.0, September 2024: 27.0, October 2024: 28.5 (avg of 2), December 2024: 31.3 (avg of 3), March 2025: 31.0 (avg of 2), May 2025: 30.0, June 2025: 32.0, August 2025: 31.0, September 2025: 35.0, October 2025: 33.0 (avg of 2), November 2025: 27.0. Clinical meaning - Normal liver synthesis and immune status. - Stable protein balance maintained. Action No action required. Sample source Blood.

High Sensitivity C-Reactive Protein [in Blood - Quantitative] (mg/L)

Loading chart...

Inflammatory markers are excellently controlled and show a favorable downward trend.

Description Highly sensitive marker for systemic low-grade inflammation and cardiovascular risk. Measurements Trend: Falling slightly - values shifted from low-normal to near-undetectable. September 2024: 1.3, December 2024: 0.36 (avg of 3), March 2025: <0.5 (avg of 3), May 2025: 0.5 (avg of 2), June 2025: <0.50, July 2025: 0.2, September 2025: 0.16, October 2025: 0.2, November 2025: <0.2. Clinical meaning - Results consistently indicate low clinical risk for inflammation. - Current levels signify optimal cardiovascular health profile. Action No action required. Sample source Blood.

Erythrocyte Sedimentation Rate [in Blood - Quantitative] (mm/hr)

Loading chart...

All results remain within normal limits across all time points.

Description Nonspecific marker of systemic inflammation. Measurements Trend: Flat - Stable within normal range. April 2024: 5.0 mm/hr. May 2024: 2.0 mm/hr. September 2024: 10.0 mm/hr. December 2024: 14.0 mm/hr. March 2025: 9.0 mm/hr (average, 2 readings). May 2025: 5.0 mm/hr. June 2025: 12.0 mm/hr. August 2025: 4.0 mm/hr. September 2025: 3.0 mm/hr. October 2025: 4.0 mm/hr (average, 2 readings). November 2025: 5.0 mm/hr. Clinical meaning Results consistently below reference thresholds. Suggests absence of significant active systemic inflammation. Action No action required. Sample source Blood.

Double-Stranded DNA Antibody IgG (ELISA) [in Blood - Quantitative] (IU/mL)

Loading chart...

Results stable and within normal limits indicating absence of dsDNA autoantibodies.

Description Specific autoantibody marker for Systemic Lupus Erythematosus (SLE) and disease activity monitoring. Measurements Trend: Falling slightly - Decreased from mid-range to below detection limit. October 2024: 14.4 IU/mL (average of 3), December 2024: <10 IU/mL, July 2025: <10 IU/mL. Clinical meaning - Values consistently within negative reference range. - Low/undetectable levels suggest no active double-stranded DNA autoimmune response. Action No action required. Sample source Blood.

Allantoin [in Blood - Quantitative] (percentile)

Loading chart...

Overall values remain within reference range but show recent upward volatility requiring observation.

Description Uric acid oxidation product used as biomarker for systemic oxidative stress. Measurements Trend: Rising - Recent spike to high-normal percentile. May 2025: 53.0 percentile, June 2025: 53.0 percentile, August 2025: 52.5 percentile (average of 15.0 and 90.0). Clinical meaning - Most recent measurement shows significant elevation in oxidative damage marker. - High percentile suggests increased free radical activity or antioxidant depletion. Action Evaluate lifestyle factors or underlying inflammation contributing to oxidative stress. Sample source Blood.

CD3 Positive T-Lymphocytes Percentage [in Blood - Quantitative] (%)

Loading chart...

T-cell levels are within healthy range and show stability over time.

Description Percentage of total T-lymphocytes expressing CD3 surface marker. Measurements Trend: Falling slightly - values decreased from high-normal to mid-normal range. - January 2025: 78.0 % - July 2025: 70.63 % (average of 3 readings) - November 2025: 72.0 % Clinical meaning - Indicates stable cellular immune capacity. - Values remain within established reference intervals despite minor fluctuation. Action No action required. Sample source Blood.

Immune System Score [in Blood - Quantitative] (Score)

Loading chart...

Declining immune score remains out of range and requires clinical investigation.

Description Composite metric evaluating overall immune health and function. Measurements Trend: Falling - score decreased significantly over 12-month period. - January 2024: 66.3 Score (average of 2 readings) - January 2025: 59.0 Score Clinical meaning - Lowering score suggests potential decline in immune system resilience. - Consistent out-of-range status indicates persistent vulnerability. Action Correlate with white blood cell differentials and clinical symptoms. Sample source Blood.

Neutrophil to Lymphocyte Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Critical rise in NLR indicates potential acute inflammatory process or severe physiological stress.

Description Calculation of innate versus adaptive immune balance. Measurements Trend: Rising fast - Sharp increase from baseline in 2025. - May 2024.0: 1.0 Ratio - October 2024.0: 1.06 Ratio (avg of 2) - January 2025.0: 17.6 Ratio (avg of 2) Clinical meaning - Massive elevation suggests acute systemic inflammation or significant physiological stress. - Previous results stable within range. Action Immediate clinical investigation required to identify source of acute inflammation. Sample source Blood.

CD3 Positive T-Lymphocytes Count [in Blood - Quantitative] (cells/µL)

Loading chart...

Immune cell levels remain within target range despite minor fluctuations.

Description

Total mature T-lymphocyte count in peripheral blood.

Measurements

Trend: Falling slightly - minor decrease after mid-year peak

January 2025.0: 1326.0 cells/µL
July 2025.0: 1522.0 cells/µL
November 2025.0: 1198.0 cells/µL

Clinical meaning

Values remain within healthy reference range
Reflects stable overall cellular immune competence

Action

No action required.

Sample source

Blood

CD4 Positive T-Lymphocytes Count [in Blood - Quantitative] (cells/µL)

Loading chart...

Helper T-cell levels are stable and within the normal clinical range.

Description

Helper T-cell count indicating adaptive immune system health.

Measurements

Trend: Falling slightly - mild decline from July peak

January 2025.0: 625.0 cells/µL
July 2025.0: 678.0 cells/µL
November 2025.0: 593.0 cells/µL

Clinical meaning

Concentrations consistently within normal physiological limits
Suggests adequate immune defense capability

Action

No action required.

Sample source

Blood

CD4 Positive T-Lymphocytes Percentage [in Blood - Quantitative] (%)

Loading chart...

CD4 percentage remains stable and within normal limits across all time points.

Description Percentage of total lymphocytes that are helper T-cells for immune coordination. Measurements Trend: Flat - fluctuating within normal range. January 2025: 37.0 %
July 2025: 32.0 %
November 2025: 36.0 %. Clinical meaning - Values remain within reference range. - Fluctuations suggest stable immune competence. Action No action required. Sample source Blood.

CD8 Positive T-Lymphocytes Count [in Blood - Quantitative] (cells/µL)

Loading chart...

CD8 absolute counts are well-regulated and fall within expected clinical ranges.

Description Absolute count of suppressor/cytotoxic T-cells involved in viral and tumor response. Measurements Trend: Falling slightly - decrease observed from July peak. January 2025: 700.0 cells/µL
July 2025: 783.0 cells/µL
November 2025: 599.0 cells/µL. Clinical meaning - Absolute counts consistently within reference intervals. - No evidence of significant immune activation or depletion. Action No action required. Sample source Blood.

Epstein Barr Virus Viral Capsid Antigen IgA [in Blood - Quantitative] (AU/ml)

Loading chart...

Patient shows stable, negative results for EBV VCA IgA antibodies over ten months.

Description Antibody marker used to screen for nasopharyngeal carcinoma or chronic EBV reactivation. Measurements Trend: Flat - Stable low-level detection within reference range. September 2024: 1.23 AU/ml
October 2024: 1.5 AU/ml
July 2025: 1.47 AU/ml. Clinical meaning Results consistently negative. No evidence of acute or chronic active EBV infection. Action No action required. Sample source Blood.

Glycoprotein Acetyls [in Blood - Quantitative] (Percentile)

Loading chart...

Inflammation levels have normalized following a temporary mid-year elevation.

Description Composite NMR marker of systemic inflammation and acute-phase reactants. Measurements Trend: Falling - Significant spike in June followed by decline. March 2025: 18.0 Percentile
June 2025: 75.0 Percentile
August 2025: 31.0 Percentile. Clinical meaning Transient increase in systemic inflammatory burden observed in June. Current levels suggest resolution of acute-phase response. Action Monitor for clinical symptoms of inflammation if values rise again. Sample source Blood.

Immunoglobulin G [in Blood - Quantitative] (g/L)

Loading chart...

IgG levels remain stable and within healthy reference limits.

Description

Primary antibody type providing long-term protection against bacterial and viral infections.

Measurements

Trend: Falling slightly - minor decrease within normal range

October 2024: 13.48 g/L
July 2025: 12.58 g/L (average of 2 readings)

Clinical meaning

Levels within normal range suggest adequate humoral immune capacity.
Stable values indicate no immediate signs of immunodeficiency or hypergammaglobulinemia.

Action

No action required.

Sample source

Blood

Lipid Peroxidation (Percentile) [Quantitative] (percentile)

Loading chart...

Rising trend and out of range values indicate increasing oxidative stress.

Description Indicator of oxidative stress and cellular membrane damage. Measurements Trend: Rising - June average exceeds February baseline. - February 2025.0: 51.0 percentile - June 2025.0: 51.0 percentile (average of 41.0 and 61.0 readings). Clinical meaning - Current levels suggest increasing oxidative damage to lipid structures. - June readings flagged out of range indicating potential inflammatory triggers. Action Investigate sources of oxidative stress or antioxidant deficiency. Sample source Unknown.

Progranulin [in Blood - Quantitative] (Percentile)

Loading chart...

Values remain within established reference ranges despite recent upward trend.

Description Glycoprotein modulating neuroinflammation and lysosomal function. Measurements Trend: Rising fast - Significant increase between May and August. - March 2025.0: 57.0 Percentile - May 2025.0: 45.0 Percentile - August 2025.0: 83.0 Percentile. Clinical meaning - Values remain within reference range but show high variability. - August peak suggests recent systemic or neurological inflammatory response. Action Monitor for emerging cognitive or inflammatory symptoms. Sample source Blood.

Serum Amyloid A-1 Protein [in Blood - Quantitative] (Percentile)

Loading chart...

Inflammatory marker shows healthy downward trend within normal limits.

Description

Acute-phase inflammatory protein reflecting systemic immune activation.

Measurements

Trend: Falling fast - Significant decline from moderate to low percentile range

March 2025.0: 46.0 Percentile
June 2025.0: 36.0 Percentile
August 2025.0: 7.0 Percentile

Clinical meaning

Indicates reduction in systemic inflammation levels
Values remaining within healthy reference range

Action

No action required.

Sample source

Blood

Systemic Immune-Inflammation Index [in Blood - Quantitative] (Percentile)

Loading chart...

Index remains within healthy limits with improving inflammatory profile.

Description

Integrated measure of inflammation combining platelet, neutrophil, and lymphocyte counts.

Measurements

Trend: Falling - Consistent decrease toward lower end of reference range

March 2025.0: 19.0 Percentile
June 2025.0: 15.0 Percentile
August 2025.0: 10.0 Percentile

Clinical meaning

Reflects low systemic immune-mediated inflammatory burden
Values currently stable at low-normal threshold

Action

Monitor for further decreases below reference range at next interval.

Sample source

Blood

Transforming Growth Factor Beta [in Blood - Quantitative] (Percentile)

Loading chart...

All results within normal range indicate stable immune and repair signaling.

Description Cytokine regulating cell growth, inflammation, and tissue repair. Measurements Trend: Flat - Fluctuating within normal range. - March 2025: 34.0 Percentile - May 2025: 84.0 Percentile - August 2025: 41.0 Percentile Clinical meaning - Values remain within reference intervals despite transient May peak. - No evidence of chronic inflammatory overactivation. Action No action required. Sample source Blood.

Liver Function

17 biomarkers

Fibrosis Score FIB4 [Quantitative]

Loading chart...

Persistent intermediate risk score requiring longitudinal monitoring of liver health.

Description Non-invasive index assessing liver fibrosis risk using age, AST, ALT, and platelets.

Measurements Trend: Falling slightly - Decreasing since August peak but remaining in intermediate risk category.

September 2024: 1.79
March 2025: 1.51
May 2025: 1.58
August 2025: 2.01
September 2025: 1.86
October 2025: 1.65 (avg of 2 readings)

Clinical meaning

Current values indicate intermediate risk for advanced fibrosis.
Recent decline suggests stabilization or mild improvement from peak.

Action Monitor AST/ALT levels and consider imaging if score trends toward 2.66.

Sample source Blood

SYMPHONY Age (Liver) [in Blood - Quantitative] (Years)

Loading chart...

Biological liver age remains elevated compared to baseline and shows upward volatility.

Description Biological age clock quantifying liver tissue health and functional decline.

Measurements Trend: Rising - Gradual increase in biological age over 15 months.

March 2024: 56.25 (avg of 2 readings)
February 2025: 55.5
March 2025: 59.0
June 2025: 57.1

Clinical meaning

Biological liver age consistently exceeds chronological age markers.
Volatility in results suggests sensitivity to metabolic or lifestyle factors.

Action Review metabolic markers and alcohol intake to mitigate accelerated aging.

Sample source Blood

Albumin [in Blood - Quantitative] (g/L)

Loading chart...

Albumin levels remain stable and within normal limits across all time points.

Description Primary liver-synthesized protein maintaining oncotic pressure and transporting molecules. Measurements Trend: Flat - Fluctuating within normal physiologic range. April 2024: 48.0 g/L
May 2024: 41.0 g/L
September 2024: 44.0 g/L
November 2024: 50.0 g/L
December 2024: 45.0 g/L (avg 3)
March 2025: 41.0 g/L (avg 2)
May 2025: 40.0 g/L
June 2025: 42.0 g/L
August 2025: 38.0 g/L
September 2025: 47.0 g/L
October 2025: 44.0 g/L
November 2025: 43.0 g/L. Clinical meaning Stable values indicate preserved hepatic synthetic function and adequate nutritional status. Action No action required as values remain consistently within reference limits. Sample source Blood.

Total Protein [in Blood - Quantitative] (g/L)

Loading chart...

Total protein levels remain within target range across all test dates.

Description Combined measurement of albumin and globulin in blood reflecting nutritional and liver/kidney health. Measurements Trend: Flat - Values consistently fluctuate within normal range. April 2024: 79.0 g/L
May 2024: 73.0 g/L
July 2024: 67.0 g/L
September 2024: 71.0 g/L
October 2024: 70.7 g/L (avg of 3)
December 2024: 77.0 g/L (avg of 3)
March 2025: 72.0 g/L (avg of 2)
May 2025: 70.0 g/L
June 2025: 74.0 g/L
August 2025: 69.0 g/L
September 2025: 82.0 g/L
November 2025: 70.0 g/L. Clinical meaning Consistent results indicate stable protein synthesis and fluid balance. Highest value at upper reference limit in September 2025. Action No action required. Sample source Blood.

Total Bilirubin [in Blood - Quantitative] (umol/L)

Loading chart...

Bilirubin levels are optimal with no signs of cholestasis or liver dysfunction.

Description Waste product from red blood cell breakdown used to evaluate liver function and bile duct health. Measurements Trend: Rising - Values demonstrate moderate upward trajectory within normal bounds. April 2024: 7.8 umol/L
May 2024: 7.0 umol/L
September 2024: 12.3 umol/L
October 2024: 8.0 umol/L
December 2024: 8.6 umol/L (avg of 3)
March 2025: 10.3 umol/L (avg of 2)
May 2025: 13.3 umol/L
June 2025: 7.6 umol/L
August 2025: 7.6 umol/L
September 2025: 14.5 umol/L
October 2025: 9.9 umol/L
November 2025: 14.0 umol/L. Clinical meaning All readings remain safely below upper reference limits. Variation suggests normal physiological fluctuation. Action No action required. Sample source Blood.

Albumin to Globulin Ratio [in Blood - Quantitative] (Ratio)

Loading chart...

Patient shows persistent low-normal or slightly sub-optimal A/G ratios requiring continued observation.

Description Proportion of albumin to total globulin proteins in serum. Measurements Trend: Flat - values fluctuate around low-normal range with intermittent out-of-range flags. - April 2024: 1.5 - September 2024: 1.63 - October 2024: 1.47 average (3 readings) - December 2024: 1.19 - March 2025: 1.34 average (2 readings) - May 2025: 1.33 - June 2025: 1.31 - August 2025: 1.23 - September 2025: 1.34 - October 2025: 1.33 - November 2025: 1.6 Clinical meaning - Low ratios may indicate chronic inflammation or liver/kidney issues. - Recent readings show slight recovery toward center of reference range. Action Monitor liver and kidney function markers at next routine screening. Sample source Blood

Alkaline Phosphatase [in Blood - Quantitative] (U/L)

Loading chart...

Alkaline phosphatase levels remain consistently normal and stable throughout monitoring period.

Description Enzyme found primarily in liver, bones, and bile ducts. Measurements Trend: Flat - stable within normal limits across all timepoints. - April 2024: 65.0 - September 2024: 77.0 - October 2024: 64.0 average (2 readings) - November 2024: 69.0 average (2 readings) - December 2024: 74.0 - March 2025: 59.5 average (2 readings) - May 2025: 52.0 - June 2025: 64.0 - August 2025: 58.0 - September 2025: 69.0 - October 2025: 71.0 - November 2025: 54.0 Clinical meaning - Normal levels suggest absence of active cholestasis or high bone turnover. - Stability indicates consistent liver and bone health status. Action No action required. Sample source Blood

Alanine Aminotransferase [in Blood - Quantitative] (U/L)

Loading chart...

ALT levels are stable and within normal limits.

Description Enzyme primarily in liver signaling hepatocellular injury. Measurements Trend: Falling slightly - Downward trajectory from December 2024 peak. April 2024: 24.0 U/L, September 2024: 31.0 U/L, October 2024: 27.0 U/L (avg of 2), December 2024: 38.0 U/L, March 2025: 26.0 U/L (avg of 2), May 2025: 22.0 U/L, June 2025: 21.0 U/L, August 2025: 18.0 U/L, September 2025: 21.0 U/L, October 2025: 25.0 U/L, November 2025: 16.0 U/L. Clinical meaning Values consistently within reference range. No evidence of active liver cell damage. Action No action required. Sample source Blood.

Aspartate Aminotransferase [in Blood - Quantitative] (U/L)

Loading chart...

AST levels remain healthy and stable.

Description Enzyme found in liver, heart, and muscle tissue indicating cell damage. Measurements Trend: Falling slightly - Stabilized after December 2024 peak. April 2024: 23.0 U/L, September 2024: 27.0 U/L, October 2024: 26.0 U/L (avg of 2), December 2024: 33.0 U/L, March 2025: 26.5 U/L (avg of 2), May 2025: 23.0 U/L, June 2025: 27.0 U/L, August 2025: 29.0 U/L, September 2025: 27.0 U/L, October 2025: 26.0 U/L, November 2025: 23.0 U/L. Clinical meaning All results within clinical reference ranges. December 2024 value was near upper limit but normalized. Action No action required. Sample source Blood.

Gamma-Glutamyl Transferase [in Blood - Quantitative] (U/L)

Loading chart...

GGT remains consistently within reference range showing excellent stability.

Description

Liver enzyme indicating biliary obstruction or alcohol consumption.

Measurements

Trend: Flat - stable within normal range.

April 2024: 20.0 U/L
September 2024: 22.0 U/L
October 2024: 17.0 U/L (avg 2 readings)
December 2024: 24.0 U/L
March 2025: 17.0 U/L
May 2025: 15.0 U/L
June 2025: 16.0 U/L
August 2025: 19.0 U/L
September 2025: 18.0 U/L
October 2025: 18.0 U/L

Clinical meaning

Low-normal values suggest healthy liver and bile duct function.
No evidence of cholestasis or hepatic injury.

Action

No action required.

Sample source

Blood

Urobilinogen [in Urine - Quantitative] (umol/L)

Loading chart...

Significant recent increase in values although still technically within reference limits.

Description

Bilirubin byproduct used to screen for liver disease or hemolytic anemia.

Measurements

Trend: Rising fast - sharp increase in October 2025.

September 2024: 3.2 umol/L
December 2024: 3.2 umol/L
March 2025: 3.2 umol/L
May 2025: 3.2 umol/L
June 2025: 3.2 umol/L
July 2025: 3.2 umol/L
September 2025: 3.2 umol/L
October 2025: 17.0 umol/L

Clinical meaning

Recent spike to high-normal range requires monitoring.
Elevated levels may indicate increased red cell breakdown or early hepatic stress.

Action

Repeat test in 4 weeks to monitor trend.

Sample source

Urine

SYMPHONY Age (Liver) [Quantitative] (Years)

Loading chart...

Biological liver age remains out of range but shows recent improvement and stabilization.

Description

Epigenetic or proteomic estimation of biological liver aging relative to chronological age.

Measurements

Trend: Falling slightly - Decreasing biological age from peak in March 2025.

February 2025: 55.5 Years
March 2025: 59.0 Years
June 2025: 57.1 Years
August 2025: 54.5 Years (average of 2 readings)
September 2025: 54.5 Years

Clinical meaning

Biological age exceeds chronological expectations during measurement period.
Recent stabilization suggests improved liver health markers.

Action

Monitor liver-related lifestyle factors to continue downward age trend.

Sample source

Unknown

Liver System Score [in Blood - Quantitative] (Score)

Loading chart...

Persistent abnormal scores require clinical correlation despite slight downward trend.

Description

Composite blood-based metric evaluating overall liver functional integrity.

Measurements

Trend: Falling slightly - Score reduced from 59.0 in 2024 to 2025 average.

January 2024: 59.0 Score (average of 2 readings)
January 2025: 55.4 Score (average of 4 readings)

Clinical meaning

Persistent out-of-range values indicate suboptimal liver system performance.
Minor year-over-year reduction in score indicates trending improvement.

Action

Correlate with standard hepatic enzymes and ultrasound if clinically indicated.

Sample source

Blood

Beta-Glucuronidase (Percentile) [in Stool - Quantitative] (percentile)

Loading chart...

Biomarker remains stable within optimal mid-percentile range.

Description Bacterial enzyme in gut reflecting detox capacity and microbiome health. Measurements Trend: Flat - Stable near median percentile. - July 2024: 46.0 percentile - October 2024: 44.0 percentile - February 2025: 48.0 average (2 readings). Clinical meaning - Elevated levels may indicate dysbiosis or impaired estrogen/toxin clearance. - Current readings consistently hover around mid-range despite flagged status. Action Monitor microbiome balance through diet and probiotic intake.

Lactate Dehydrogenase [in Blood - Quantitative] (U/L)

Loading chart...

Biomarker levels are stable and within normal reference ranges across all data points.

Description Enzyme involved in energy production; indicator of tissue damage or cell turnover. Measurements Trend: Flat - stable readings within optimal reference range. October 2024: 177.0 U/L. December 2024: 178.0 U/L. October 2025: 174.0 U/L. Clinical meaning Consistent values suggest no acute tissue injury or hemolysis. Levels remain centered within normal clinical limits. Action No action required. Sample source Blood.

Endocrine/Metabolic

43 biomarkers

Glucose [in Blood - Quantitative] (mmol/L)

Loading chart...

Overall stable glucose levels interrupted by a single low-range outlier.

Description Primary blood sugar energy source for cells. Measurements Trend: Falling slightly - General downward trajectory with recent hypoglycemia. - April 2024: 5.5 mmol/L - July 2024: 5.2 mmol/L - September 2024: 4.4 mmol/L - October 2024: 4.9 mmol/L (Avg of 2) - December 2024: 4.0 mmol/L - March 2025: 4.7 mmol/L (Avg of 2) - May 2025: 4.8 mmol/L - June 2025: 4.2 mmol/L - August 2025: 4.4 mmol/L - September 2025: 3.0 mmol/L - November 2025: 4.4 mmol/L Clinical meaning - Clinically significant hypoglycemia (3.0 mmol/L) noted September 2025. - Tight glycemic control overall but risk of low excursions exists. Action Investigate potential causes of symptomatic hypoglycemia and monitor fasting levels. Sample source Blood.

Insulin [in Blood - Quantitative] (uIU/mL)

Loading chart...

Rising insulin levels and recent out-of-range readings indicate developing metabolic dysfunction.

Description

Pancreatic hormone regulating blood glucose and lipid metabolism.

Measurements

Trend: Rising - increasing volatility and recent spike.

December 2024: 14.4 uIU/mL
March 2025: 15.2 uIU/mL
May 2025: 17.6 uIU/mL
June 2025: 28.0 uIU/mL
July 2025: 11.4 uIU/mL
September 2025: 30.2 uIU/mL

Clinical meaning

Recent values above reference range suggest hyperinsulinemia.
Fluctuating levels may indicate worsening insulin resistance.

Action

Investigate glycemic control with HgbA1c and assess dietary triggers for insulin spikes.

Sample source

Blood

SYMPHONY Age (Metabolic) [Quantitative] (Years)

Loading chart...

Metabolic age remains persistently elevated above the healthy reference threshold.

Description

Algorithm-derived estimation of biological aging based on metabolic biomarkers.

Measurements

Trend: Falling slightly - minor overall reduction from initial peak despite fluctuations.

January 2025: 58.2 Years
February 2025: 53.1 Years
March 2025: 57.6 Years
June 2025: 58.2 Years
August 2025: 55.9 Years
September 2025: 55.9 Years

Clinical meaning

Consistently exceeds chronological target of 54.4 years.
Indicates accelerated metabolic aging and underlying systemic stress.

Action

Implement metabolic optimization strategies focusing on weight management and aerobic fitness.

Sample source

Unknown

Acetate [in Stool - Quantitative] (%)

Loading chart...

Acetate levels remain within healthy range following previous fluctuations.

Description Major short-chain fatty acid produced by gut bacteria. Measurements Trend: Falling slightly - Decreased from peak level. July 2024: 43.09 %
October 2024: 43.41 %
November 2024: 51.3 %
February 2025: 39.28 %. Clinical meaning - Levels indicate presence and activity of primary carbohydrate fermenters. - Currently within expected reference range. Action Maintain dietary fiber intake to support healthy microbial production. Sample source Stool.

Butyrate [in Stool - Quantitative] (%)

Loading chart...

Persistent downward trend toward lower end of reference range warrants observation.

Description Gut-derived short-chain fatty acid critical for colonocyte energy and anti-inflammatory signaling. Measurements Trend: Falling fast - Significant decline from July 2024 baseline. July 2024: 46.83 %
October 2024: 33.78 %
November 2024: 25.5 %
February 2025: 46.41 %
November 2025: 17.4 %. Clinical meaning - Notable downward trend suggests reduced activity of butyrate-producing bacteria. - Low levels may impact intestinal barrier integrity. Action Review intake of prebiotic fibers and resistant starches to support butyrate producers. Sample source Stool.

Phenylacetylglutamine [in Blood - Quantitative] (Percentile Rank)

Loading chart...

Consistently elevated levels indicate worsening intestinal dysbiosis.

Description Gut-derived metabolite indicating phenylalanine breakdown by bacteria. Measurements Trend: Rising - Sustained elevation above reference. - March 2025.0: 82.1 - June 2025.0: 82.0 - August 2025.0: 89.1 (avg of 3 readings). Clinical meaning - High levels suggest intestinal dysbiosis or protein maldigestion. - Potential marker for renal and cardiovascular stress. Action Investigate gut microbiome composition and protein intake.

SYMPHONY Age (Metabolic) [in Blood - Quantitative] (Years)

Loading chart...

Metabolic age shows concerning upward trend after 2025 low.

Description Epigenetic biological age estimation based on metabolic health markers. Measurements Trend: Rising - Increase following initial improvement. - March 2024.0: 57.0 (avg of 2 readings) - February 2025.0: 53.1 - March 2025.0: 57.6 - June 2025.0: 58.2. Clinical meaning - Reflects rate of metabolic aging versus chronological age. - Recent five-year increase suggests metabolic decline. Action Review glycemic control and lipid panels to address metabolic aging.

5-Hydroxyindoleacetic Acid [in Urine - Quantitative] (ug/gCR)

Loading chart...

Recent value is significantly out of range following period of instability.

Description

Urine metabolite of serotonin.

Measurements

Trend: Rising fast - sharp increase from late 2024 to 2025

May 2024.0: 3898.0 ug/gCR
November 2024.0: 10186.0 ug/gCR
December 2024.0: 840.0 ug/gCR
July 2025.0: 9100.0 ug/gCR

Clinical meaning

Elevated levels may indicate neuroendocrine activity or serotonin overproduction
Recent result exceeds reference range significantly

Action

Evaluate for clinical symptoms and repeat testing under dietary restrictions.

Sample source

Urine

Glutaric Acid [in Urine - Quantitative] (mmol/mol creatinine)

Loading chart...

Dramatic increase to critically high levels requires immediate clinical correlation.

Description

Organic acid marker reflecting Riboflavin (B2) status and fatty acid metabolism.

Measurements

Trend: Rising fast - severe spike in most recent reading

December 2024.0: 0.1 mmol/mol creatinine
July 2025.0: 26.755 mmol/mol creatinine (average of 2 readings)

Clinical meaning

High levels suggest Riboflavin deficiency or metabolic dysfunction
Extreme elevation in latest sample suggests acute metabolic stress

Action

Assess B2 intake and investigate potential metabolic blockages.

Sample source

Urine

Palmitoylcarnitine [in Blood - Quantitative] (Percentile)

Loading chart...

Biomarker returned to normal range following a temporary elevation.

Description

Long-chain acylcarnitine marker of fatty acid oxidation and mitochondrial function.

Measurements

Trend: Falling fast - Significant reduction from peak after brief spike above reference limit.

March 2025: 78.0 Percentile
May 2025: 96.0 Percentile
August 2025: 66.0 Percentile

Clinical meaning

Elevated levels suggest incomplete beta-oxidation or mitochondrial stress.
Recent decline indicates improved metabolic processing of long-chain fats.

Action

Monitor lipid metabolism markers to ensure sustained stabilization within reference range.

Sample source

Blood

Vanillactic Acid [in Blood - Quantitative] (Percentile Rank)

Loading chart...

Levels remain chronically elevated above the 80th percentile threshold despite recent improvement.

Description

Catecholamine metabolite reflecting aromatic amino acid metabolism and neurotransmitter turnover.

Measurements

Trend: Falling - Consistent downward trajectory though remains above clinical threshold.

March 2025: 97.4 Percentile Rank
August 2025: 82.93 Average (3 readings)

Clinical meaning

Persistent elevation suggests altered dopamine turnover or metabolic bypass pathways.
Improving trend indicates partial resolution of underlying metabolic imbalance.

Action

Investigate potential cofactor deficiencies or neurochemical stressors contributing to persistent elevation.

Sample source

Blood

3-Hydroxykynurenine [in Urine - Quantitative] (ug/gCR)

Loading chart...

Persistent low values indicate metabolic insufficiency requiring investigation.

Description Tryptophan metabolite in kynurenine pathway indicating neuro-metabolic health. Measurements Trend: Rising slightly - mild increase but remains below reference range. May 2024.0: 71.0 ug/gCR. November 2024.0: 77.0 ug/gCR (avg of 2 readings). Clinical meaning Low levels suggest insufficient tryptophan metabolism or Vitamin B6 deficiency. Potential marker for reduced neuro-inflammatory signaling. Action Assess Vitamin B6 status and protein intake. Sample source Urine.

3-Ureidopropionate [in Blood - Quantitative] (Percentile Rank)

Loading chart...

Rising levels above reference range indicate metabolic dysfunction requiring further clinical investigation.

Description

Metabolite of uracil degradation and precursor to beta-alanine.

Measurements

Trend: Rising fast - significant increase above reference threshold

May 2025.0: 55.1 Percentile Rank
August 2025.0: 89.4 Percentile Rank (avg of 2 readings)

Clinical meaning

Elevated levels suggest potential impairment in pyrimidine metabolism pathway.
High values often correlate with dihydropyrimidinase enzyme deficiency or altered nitrogen balance.

Action

Investigate potential genetic enzyme variants or check for systemic pyrimidine metabolic blocks.

Sample source

Blood

4-Hydroxyphenyllactic [in Urine - Quantitative] (mmol/mol creatinine)

Loading chart...

Previous elevation has successfully resolved to within normal range.

Description

Organic acid metabolite of tyrosine catabolism.

Measurements

Trend: Falling fast - normalization from high baseline

December 2024.0: 5.29 mmol/mol creatinine (avg of 2 readings)
July 2025.0: 0.15 mmol/mol creatinine

Clinical meaning

Elevated levels indicate tyrosine malabsorption or vitamin C deficiency.
Recent result shows complete resolution to optimal range.

Action

No action required as levels have normalized.

Sample source

Urine

Hemoglobin A1c [in Blood - Quantitative] (percentile)

Loading chart...

Biomarker remains stable and within target reference ranges.

Description Percentile ranking of glycated hemoglobin reflecting average blood glucose over 3 months. Measurements Trend: Falling slightly - General downward movement within normal percentile range. - January 2025: 52.5 percentile - March 2025: 49.0 percentile - May 2025: 53.0 percentile - August 2025: 40.8 percentile (Average of 2) Clinical meaning - Patient maintains stable glycemic control. - Current readings fall within healthy population distributions. Action No action required. Sample source Blood.

Propionate [in Stool - Quantitative] (%)

Loading chart...

Propionate levels remain consistently within normal limits across all timepoints.

Description

Short-chain fatty acid (SCFA) produced by gut bacterial fermentation.

Measurements

Trend: Flat - Values fluctuating within reference ranges.

July 2024: 25.14%
October 2024: 39.34%
November 2024: 20.0%
February 2025: 29.45% (Avg, 2 readings)
November 2025: 23.1%

Clinical meaning

Reflects healthy fiber fermentation and microbial diversity.
Consistent levels suggest stable metabolic gut health.

Action

No action required.

Sample source

Stool

Hemoglobin A1c (IFCC) [in Blood - Quantitative] (mmol/mol)

Loading chart...

Patient maintains healthy glycemic control within target reference ranges.

Description

Standardized measure of long-term glycemic control via hemoglobin glycation.

Measurements

Trend: Rising slightly - Recent 1 mmol/mol increase.

July 2024: 37.0 mmol/mol
March 2025: 37.0 mmol/mol
May 2025: 38.0 mmol/mol

Clinical meaning

Values remain within normal range.
Indicates stable three-month blood sugar averages.

Action

No action required.

Sample source

Blood

Hemoglobin A1c (NGSP) [in Blood - Quantitative] (%)

Loading chart...

Values remain stable and within normal reference ranges indicating effective glucose regulation.

Description Long-term blood sugar average over 3 months. Measurements Trend: Rising slightly - small increase within normal limits. March 2025: 5.5 %, May 2025: 5.6 %, October 2025: 5.6 %. Clinical meaning Levels indicate healthy glycemic control. Values remain below pre-diabetic threshold. Action No action required. Sample source Blood.

Kynurenic Acid [in Urine - Quantitative] (ug/gCR)

Loading chart...

Significant downward trend requires clinical correlation despite staying within broad reference limits.

Description Metabolite of amino acid tryptophan involved in neuroprotection and inflammation. Measurements Trend: Falling fast - significant drop in latest reading. May 2024: 680.0 ug/gCR, November 2024: 585.0 ug/gCR, December 2024: 830.0 ug/gCR, July 2025: 20.0 ug/gCR. Clinical meaning Latest value is extremely low compared to previous baseline. Low levels may suggest altered tryptophan metabolism or nutritional deficiencies. Action Correlate very low July 2025 reading with B6 status and neurological symptoms. Sample source Urine.

Metabolic System Score [in Blood - Quantitative] (Score)

Loading chart...

Persistent low scores indicate worsening metabolic health requiring clinical review.

Description Composite metric evaluating metabolic efficiency and health. Measurements Trend: Falling slightly - persistent decline over twelve months. January 2024.0: 58.2 Score. January 2025.0: 57.03 Score (average of 3). Clinical meaning Consistent out of range values suggest chronic metabolic dysfunction. Decreasing trend indicates worsening metabolic state. Action Initiate comprehensive metabolic workup and lifestyle intervention. Sample source Blood.

Methionine Sulfone [in Blood - Quantitative] (Percentile)

Loading chart...

Rapid improvement in oxidative stress levels with current values within healthy range.

Description Marker of oxidative protein damage and systemic oxidative stress. Measurements Trend: Falling fast - sharp decline from June to August. March 2025.0: 54.0 Percentile. June 2025.0: 75.0 Percentile. August 2025.0: 7.0 Percentile (average of 2). Clinical meaning Recent significant reduction suggests decreased oxidative burden or improved antioxidant capacity. Current levels within normal reference range. Action No action required as values are within normal limits. Sample source Blood.

Quinolinic Acid [in Blood - Quantitative] (Percentile)

Loading chart...

Values remain within normal reference limits despite recent increase.

Description Neuroactive metabolite of tryptophan pathway linked to inflammation. Measurements Trend: Rising - significant increase from March followed by stabilization. March 2025.0: 15.0 Percentile. June 2025.0: 50.0 percentile. August 2025.0: 48.0 Percentile. Clinical meaning - Current levels represent average percentile ranking. - Move from low-normal to mid-range suggests shift in kynurenine pathway activity. Action Monitor for neurological symptoms if trend continues upward. Sample source Blood.

Thyroid

8 biomarkers

Free Thyroxine [in Blood - Quantitative] (pmol/L)

Loading chart...

Free T4 remains consistently normal and stable.

Description Unbound thyroxine fraction indicating metabolically active thyroid hormone. Measurements Trend: Rising slightly - Gradual increase over final four readings. May 2024: 17.3 pmol/L
July 2024: 15.1 pmol/L (average of 2)
September 2024: 14.9 pmol/L (average of 2)
October 2024: 15.2 pmol/L
December 2024: 16.8 pmol/L (average of 2)
March 2025: 16.75 pmol/L (average of 2)
May 2025: 16.7 pmol/L
June 2025: 15.9 pmol/L
August 2025: 15.4 pmol/L
September 2025: 18.0 pmol/L
November 2025: 16.6 pmol/L. Clinical meaning - Consistent euthyroid status across multi-year tracking. - Stable hormone availability supports normal metabolic function. Action No action required. Sample source Blood.

Free Triiodothyronine [in Blood - Quantitative] (pmol/L)

Loading chart...

Free T3 levels remain stable and within normal limits.

Description Unbound triiodothyronine hormone indicating metabolic activity. Measurements Trend: Flat - values stable within reference range across 18 months. May 2024: 5.3 pmol/L. July 2024: 4.6 pmol/L (avg of 2). September 2024: 5.6 pmol/L. December 2024: 5.07 pmol/L (avg of 3). March 2025: 5.25 pmol/L (avg of 2). May 2025: 5.2 pmol/L. June 2025: 4.8 pmol/L. August 2025: 4.8 pmol/L. September 2025: 5.0 pmol/L. October 2025: 4.8 pmol/L (avg of 2). November 2025: 5.0 pmol/L. Clinical meaning Consistent euthyroid status. No evidence of hormone deficiency or excess. Action No action required. Sample source Blood.

Thyroid Stimulating Hormone [in Blood - Quantitative] (mIU/L)

Loading chart...

TSH shows healthy fluctuations and remains within therapeutic range.

Description Pituitary hormone regulating thyroid gland function. Measurements Trend: Falling slightly - gradual decline from upper-normal toward mid-normal. May 2024: 3.77 mIU/L. September 2024: 3.12 mIU/L (avg of 2). October 2024: 3.76 mIU/L (avg of 2). December 2024: 2.94 mIU/L (avg of 2). March 2025: 3.2 mIU/L. May 2025: 3.52 mIU/L. June 2025: 2.39 mIU/L. August 2025: 2.17 mIU/L. September 2025: 2.07 mIU/L. October 2025: 2.62 mIU/L (avg of 2). Clinical meaning Normal pituitary-thyroid feedback loop. Slight downward trend remains well within clinical targets. Action No action required. Sample source Blood.

Thyroglobulin Antibody [in Blood - Quantitative] (IU/mL)

Loading chart...

Patient remains well within normal range with recent significant decrease in antibody presence.

Description Autoantibody targeting thyroglobulin, protein used for thyroid hormone production. Measurements Trend: Falling fast - Sharp decline in latest 2025 reading. May 2024: 12.3 IU/mL
September 2024: 13.0 IU/mL
October 2024: 14.38 IU/mL (average, 4 readings)
December 2024: 12.5 IU/mL (average, 2 readings)
May 2025: <1.3 IU/mL. Clinical meaning Values consistently within reference range. Falling levels suggest low risk of autoimmune thyroiditis or successful management. Action No action required. Sample source Blood.

Thyroid Peroxidase Antibody [in Blood - Quantitative] (IU/mL)

Loading chart...

Consistently normal and stable values indicate no evidence of thyroid auto-inflammation.

Description Autoantibody targeting enzyme responsible for thyroid hormone synthesis. Measurements Trend: Flat - Highly stable values across all dates. May 2024: 9.0 IU/mL
September 2024: 9.0 IU/mL
October 2024: 9.34 IU/mL (average, 4 readings)
December 2024: 9.3 IU/mL (average, 2 readings). Clinical meaning Results consistently negative for TPO antibodies. Stable baseline indicates absence of Hashimoto's thyroiditis markers. Action No action required. Sample source Blood.

Thyroid Stimulating Hormone Receptor Antibody [in Blood - Quantitative] (IU/L)

Loading chart...

Patient shows stable, normal antibody levels over seven months.

Description Autoantibody targeting TSH receptors; marker for Graves disease. Measurements Trend: Flat - constant value. May 2024.0: 0.8 IU/L
September 2024.0: 0.8 IU/L
October 2024.0: 0.8 IU/L (average of 2)
December 2024.0: 0.8 IU/L (average of 2). Clinical meaning - Result remains within reference range. - Suggests absence of TSH receptor-stimulating antibodies. Action No action required. Sample source Blood.

Free Triiodothyronine to Reverse Triiodothyronine Ratio (X 100) [in Blood - Quantitative] (Ratio)

Loading chart...

Ratio is borderline low after steady decline from May to December.

Description Ratio between active (FT3) and inactive (rT3) thyroid hormones. Measurements Trend: Falling - consistent decrease toward lower reference limit. May 2024.0: 1.872 Ratio
September 2024.0: 1.621 Ratio
December 2024.0: 1.201 Ratio (average of 2). Clinical meaning - Ratio remains within range but shows notable downward trend. - Lower ratio may indicate reduced conversion of T4 to active T3 or increased rT3 production. Action Monitor thyroid function tests closely to ensure ratio does not fall below 1.2. Sample source Blood.

Reverse Triiodothyronine [in Blood - Quantitative] (pmol/L)

Loading chart...

Biomarker remains within normal limits despite rising trend.

Description

Inactive form of T3 hormone measuring thyroid metabolism thyroid output.

Measurements

Trend: Rising - Consistent increase over seven months

May 2024: 282.0 pmol/L
September 2024: 343.0 pmol/L
December 2024: 422.0 pmol/L (Average of 2 readings)

Clinical meaning

Values remain within reference range.
Upward trend may indicate metabolic adaptation or stress response.

Action

Monitor trend alongside Free T3 and TSH levels.

Sample source

Blood

Uncategorized

88 biomarkers

SYMPHONY Age (Brain) [Quantitative] (Years)

Loading chart...

Brain biological age remains persistently elevated above reference limits despite fluctuations.

Description

Proteomic marker of neurological system biological age.

Measurements

Trend: Rising - fluctuating upward trajectory since 2024

March 2024.0: 55.5 Years
January 2025.0: 59.3 Years
February 2025.0: 53.0 Years (average of 2)
March 2025.0: 59.1 Years (average of 2)
May 2025.0: 59.1 Years
June 2025.0: 59.3 Years (average of 2)
August 2025.0: 59.3 Years
September 2025.0: 56.8 Years

Clinical meaning

Biological brain age consistently exceeds reference targets
Recent values indicate accelerated neurological aging compared to baseline

Action

Evaluate lifestyle factors and neuroprotective strategies to decelerate biological aging trend.

Sample source

Blood

C-Terminal Telopeptide of Type I Collagen (Beta-CrossLaps) [in Blood - Quantitative] (ng/ml)

Loading chart...

Bone resorption markers are currently stable and within normal clinical ranges.

Description

Serum marker of bone resorption and collagen breakdown.

Measurements

Trend: Rising - recent increase from previous low points

November 2024.0: 0.11 ng/ml (average of 3)
December 2024.0: 0.231 ng/ml
March 2025.0: 0.071 ng/ml
November 2025.0: 0.137 ng/ml

Clinical meaning

Current levels within normal limits suggesting stable bone turnover
Historical low values indicate minimal active bone breakdown

Action

No action required as current levels remain within healthy reference range.

Sample source

Blood

OMICm Age [Quantitative] (Years)

Loading chart...

Biological age shows overall downward trend reaching optimal range.

Description Epigenetic biological age estimation based on DNA methylation patterns. Measurements Trend: Falling slightly - Decreasing biological age over 18 months. March 2024: 59.0 Years. February 2025: 31.38 Years (Avg/2). March 2025: 56.7 Years. June 2025: 57.9 Years. August 2025: 54.0 Years. Clinical meaning Lower biological age suggests improved metabolic health or slowed cellular aging. Current value (54.0) sits just below reference threshold (54.7). Action Continue current health optimization protocols to maintain favorable epigenetic profile. Sample source Blood.

Bacteroidetes (Phylum) Percentage [in Stool - Quantitative] (%)

Loading chart...

Abundance levels recovered to normal reference ranges after historical fluctuations.

Description Proportion of Bacteroidetes phylum within gut microbiome. Measurements Trend: Falling - Significant decrease from peak levels late 2024. July 2024: 29.894%. October 2024: 47.608%. November 2024: 56.323%. February 2025: 36.543%. November 2025: 51.19%. Clinical meaning Fluctuating abundance levels often linked to dietary fiber intake and weight management. Recent 51.19% value within healthy commensal range. Action Maintain high-fiber diet to support stable commensal bacteria levels. Sample source Stool.

OMICm Age [in Blood - Quantitative] (Years)

Loading chart...

Persistent elevation above reference with recent positive downward trend toward target.

Description Epigenetic biological age estimation via blood proteomics. Measurements Trend: Falling slightly - General decline since February peak despite fluctuations. - January 2025.0: 57.9 Years - February 2025.0: 60.3 Years - March 2025.0: 56.7 Years - June 2025.0: 57.9 Years - August 2025.0: 54.0 Years Clinical meaning - Biological age consistently exceeds reference limit 54.4. - Recent decline suggests potential lifestyle or therapeutic efficacy. Action Monitor metabolic markers and lifestyle factors to sustain downward biological aging trend. Sample source Blood

Proteobacteria (Phylum) Percentage [in Stool - Quantitative] (%)

Loading chart...

Persistent out of range readings and rebound in recent measurement indicate ongoing gut microbiome imbalance.

Description Phylum-level gut microbiome marker often associated with inflammation or dysbiosys. Measurements Trend: Falling slightly - Significant reduction from baseline with recent moderate rebound. - July 2024.0: 11.376 % - October 2024.0: 7.766 % - November 2024.0: 2.214 % - February 2025.0: 7.615 % Clinical meaning - Levels frequently exceed 4.0% threshold indicating potential gut dysbiosis. - Extreme volatility suggests unstable microbial environment. Action Investigate gut health symptoms and consider prebiotic or dietary interventions to stabilize phylum levels. Sample source Stool

SYMPHONY Age (Brain) [in Blood - Quantitative] (Years)

Loading chart...

Brain biological age is trending upward and remains out of range.

Description

Proteomic biomarker estimating biological brain age via blood protein signatures.

Measurements

Trend: Rising - Biological age increased significantly since early 2025 nadir.

March 2024: 57.4 Years (Average of 2)
February 2025: 53.0 Years
March 2025: 59.1 Years
June 2025: 59.3 Years

Clinical meaning

Biological brain age exceeds chronological expectations.
Recent sharp increase suggests potential neurological stress or lifestyle factors.

Action

Evaluate sleep hygiene and cognitive support strategies to mitigate age acceleration.

Sample source

Blood

SYMPHONY Age (Lung) [in Blood - Quantitative] (Years)

Loading chart...

Lung biological age has risen sharply back to peak levels.

Description

Proteomic biomarker estimating biological lung age through systemic protein analysis.

Measurements

Trend: Rising fast - Biological age spiked back to baseline after temporary improvement.

March 2024: 57.1 Years (Average of 2)
February 2025: 51.4 Years
March 2025: 51.6 Years
June 2025: 57.9 Years

Clinical meaning

Significant reversal of lung health improvements seen in early 2025.
Current values indicate elevated biological aging relative to target.

Action

Investigate environmental exposures or respiratory irritants contributing to recent spikes.

Sample source

Blood

Telomere Length [in Blood - Quantitative]

Loading chart...

Telomere length remains stable and within normal limits.

Description Genetic marker of cellular aging and chromosomal stability. Measurements Trend: Flat - values stable over 12 months. January 2024: 6.8. January 2025: 6.8 (average of 4 readings). Clinical meaning Results within normal reference range indicate biological age consistent with chronological age. Cellular maintenance appears stable. Action No action required. Sample source Blood.

Acetylcholine [in Stool - Quantitative] (%)

Loading chart...

Acetylcholine levels dropped sharply to the lower limit of detection.

Description Neurotransmitter marker reflecting enteric nervous system activity and gut motility. Measurements Trend: Falling fast - significant decrease from initial measurement. July 2024: 0.1 (average of 2 readings). October 2024: 0.01. Clinical meaning Decline to low-normal/out-of-range levels suggests potential reduction in parasympathetic signaling or gut motility. Recent values at bottom of distribution. Action Investigate gut transit time or autonomic function. Sample source Stool.

Gram Negative Bacteria [in Stool - Quantitative] (%)

Loading chart...

Bacteria levels currently within optimal range after prior elevation.

Description

Quantitative measurement of stool bacteria with cell walls containing thin peptidoglycan layer.

Measurements

Trend: Falling - Decreased after October peak toward reference range

July 2024.0: 42.96 % (Avg of 2)
October 2024.0: 57.16 %
February 2025.0: 48.01 %

Clinical meaning

Recent values within normal thresholds suggest stable gut ecosystem balance.
High levels previously indicated potential microbial dysbiosis or inflammatory risk.

Action

Maintain current fiber intake to support healthy microbiome diversity.

Sample source

Stool

Gram Positive Bacteria [in Stool - Quantitative] (%)

Loading chart...

Gram positive populations stabilized within recommended parameters.

Description

Quantitative measurement of stool bacteria with thick peptidoglycan cell walls.

Measurements

Trend: Rising - Recovered from October low toward target levels

July 2024.0: 51.03 % (Avg of 2)
October 2024.0: 38.02 %
February 2025.0: 48.76 % (Avg of 2)

Clinical meaning

Current levels meet minimum threshold for healthy gut flora distribution.
October dip suggested transient loss of beneficial bacterial populations.

Action

Continue diverse whole food diet to maintain healthy bacterial proportions.

Sample source

Stool

Oxalobacter [in Stool - Quantitative] (%)

Loading chart...

Significant decline to sub-reference range levels indicates loss of protective gut commensals.

Description

Commensal gut bacteria metabolizing oxalate to prevent kidney stones.

Measurements

Trend: Falling fast - Sharp decline to undetectable levels.

July 2024: 0.028 %
October 2024: 0.007 %
February 2025: 45.0 Score (avg of 2), 0.0 % (avg of 2)

Clinical meaning

Depleted levels increase risk for hyperoxaluria and calcium oxalate stones.
Recent results indicate loss of oxalate-degrading capacity.

Action

Consider low-oxalate diet and probiotic support to mitigate stone risk.

Sample source

Stool

Pancreatic Elastase [in Stool - Quantitative] (ug/g)

Loading chart...

Borderline and unstable readings require monitoring despite recent recovery to normal range.

Description

Enzyme marker for exocrine pancreatic function and digestive sufficiency.

Measurements

Trend: Falling - Significant drop below threshold in late 2025 followed by recovery.

November 2024: 209.0 ug/g
November 2025: 211.0 ug/g (avg of 3)
December 2025: >200 ug/g

Clinical meaning

Fluctuating levels suggest transient exocrine pancreatic insufficiency.
Value of 85.0 ug/g indicates severe malabsorption risk.

Action

Investigate potential causes of temporary pancreatic insufficiency if symptoms persist.

Sample source

Stool

SYMPHONY Age [in Blood - Quantitative] (Years)

Loading chart...

Biological age remains above reference range and shows upward progression.

Description

Epigenetic clock measuring biological aging rate via blood biomarkers.

Measurements

Trend: Rising - Biological age increasing faster than chronological time.

January 2024: 54.7 Years
January 2025: 56.17 Years (Average of 3)

Clinical meaning

Biological age exceeds reference range.
Upward trend indicates accelerated systemic aging.

Action

Assess lifestyle factors and inflammatory markers to mitigate aging rate.

Sample source

Blood

Bilophila wadsworthia [in Stool - Quantitative] (%)

Loading chart...

Pathobiont levels successfully reduced to within healthy reference range.

Description

Sulfate-reducing gut bacterium associated with animal-fat diets and bile production.

Measurements

Trend: Falling fast - Steady decline toward normal range.

July 2024: 0.366 %
October 2024: 0.285 %
February 2025: 0.116 %

Clinical meaning

Value normalized from previously high levels.
High levels linked to intestinal inflammation and high-fat intake.

Action

No action required; maintain current dietary or therapeutic intervention.

Sample source

Stool

Blautia [in Stool - Quantitative] (%)

Loading chart...

Values have returned to healthy reference range after temporary dip.

Description Beneficial gut bacteria genus involved in fermentation and anti-inflammatory metabolic production. Measurements Trend: Rising - Recovery after drop below reference range. July 2024: 10.998%, October 2024: 4.445%, February 2025: 7.156%. Clinical meaning - Recent increase suggests improving microbiome diversity. - Low levels October 2024 linked to reduced short-chain fatty acid production. Action Monitor fiber intake to maintain current recovery trend. Sample source Stool.

Faecalibacterium [in Stool - Quantitative] (%)

Loading chart...

Consistently high levels of this protective biomarker represent excellent gut health status.

Description Primary butyrate-producing bacteria associated with intestinal mucosal health. Measurements Trend: Rising - Sustained elevation above reference range. July 2024: 23.826%, October 2024: 21.546%, February 2025: 26.203% (Avg 2 readings). Clinical meaning - Persistently high levels indicate strong anti-inflammatory potential. - Values significantly exceed 10-15% range across all timepoints. Action Maintain current diet and lifestyle supporting high levels of beneficial commensal flora. Sample source Stool.

Gut Wellness Score [Quantitative]

Loading chart...

Continuous decline in gut wellness score necessitates diagnostic follow-up.

Description Composite metric of microbiome health and gut barrier function. Measurements Trend: Falling slightly - score decreased 4 points over 7 months. July 2024: 79.98. October 2024: 76.47. February 2025: 75.95. Clinical meaning Persistent out-of-range scores suggest chronic dysbiosis or inflammation. Steady decline indicates worsening intestinal environment. Action Investigate diet and lifestyle factors impacting gut flora diversity.

Pathobiont Bacteria [in Stool - Quantitative] (Score)

Loading chart...

Elevated and rising pathobiont levels indicate significant gut microbial imbalance.

Description

Quantitative marker of potentially harmful gut bacteria.

Measurements

Trend: Rising - increasing bacterial load

October 2024: 79.01 (average of 2)
February 2025: 85.0 (average of 2)

Clinical meaning

Elevated levels suggest gut dysbiosis
Rising trend indicates worsening microbial imbalance

Action

Investigate potential gut inflammation or dietary triggers contributing to pathobiont overgrowth.

Sample source

Stool

Roseburia [in Stool - Quantitative] (%)

Loading chart...

Persistent low levels of beneficial Roseburia suggest compromised gut health and butyrate production.

Description

Beneficial commensal bacteria producing butyrate for gut health.

Measurements

Trend: Falling slightly - persistent deficiency

October 2024: 27.38% (average of 2)
February 2025: 2.28% (average of 2)

Clinical meaning

Values significantly below reference range
Deficiency impairs intestinal barrier and anti-inflammatory capacity

Action

Increase prebiotic fiber intake or resistant starches to support Roseburia growth.

Sample source

Stool

SYMPHONY Age (Lung) [Quantitative] (Years)

Loading chart...

Lung biological age remains elevated above reference range but shows recent stabilization and overall decrease.

Description Epigenetic biological age estimation based on lung-specific protein signatures. Measurements Trend: Falling - Lung age decreased 2.7 years. January 2025: 57.9 Years. August 2025: 55.2 Years. September 2025: 55.2 Years. Clinical meaning Results consistently exceed chronological reference range, though trend shows improvement. Elevated lung biological age suggests potential environmental stress or accelerated cellular aging. Action Monitor pulmonary function and assess environmental/lifestyle risk factors. Sample source Blood.

Enterococcus faecalis [in Stool - Quantitative] (x10^5 CFU/g)

Loading chart...

Biomarker transitioned from elevated to optimal range.

Description Gram-positive commensal bacteria in gut microbiota. Measurements Trend: Falling fast - Significant reduction below reference limit. - November 2024.0: 1.84 x10^5 CFU/g - November 2025.0: 0.26 x10^5 CFU/g (average of 2 readings) Clinical meaning - Resolution of prior overgrowth. - Normalized level indicates balanced intestinal flora. Action No action required. Sample source Stool.

Escherichia Species [in Stool - Quantitative] (x10^4 CFU/g)

Loading chart...

Results show successful stabilization within normal reference range.

Description Major aerobic component of normal intestinal flora. Measurements Trend: Falling fast - Sharp decline from elevated to mid-range. - November 2024.0: 4137.0 x10^4 CFU/g - December 2025.0: 400.0 x10^4 CFU/g (average of 2 readings) Clinical meaning - Previous mild dysbiosis corrected. - Current levels reflect healthy colonization density. Action No action required. Sample source Stool.

Gait Speed Percentile [Quantitative] (Percentile)

Loading chart...

Significant decline into bottom decile indicates urgent need for mobility intervention.

Description Functional mobility and frailty assessment. Measurements Trend: Falling fast - significant decline in walking velocity. - January 2025.0: 35.4 Percentile - August 2025.0: 10.2 Percentile (Average of 2 readings). Clinical meaning - Result below 10th percentile indicates high risk for mobility impairment. - Rapid decline suggests acute loss of musculoskeletal or neurological function. Action Conduct physical therapy evaluation and falls risk assessment immediately. Sample source Unknown.

OMICm Fit Age [Quantitative] (Years)

Loading chart...

Biological age remains over 6 years higher than chronological age despite slight downward trend.

Description Biological age estimate based on fitness-related biomarkers and methylation. Measurements Trend: Falling slightly - minor decrease in biological age estimate. - January 2025: 62.2 Years - August 2025: 60.9 Years (Average of 2 readings) Clinical meaning - Biological age exceeds chronological age (54.7), suggesting accelerated aging. - Marginal improvement noted but remains significantly above expectation. Action Optimize lifestyle interventions including physical activity and nutrition to align biological age with chronological age. Sample source Unknown

Veillonella [in Stool - Quantitative] (%)

Loading chart...

Persistent low Veillonella levels indicate gut dysbiosis requiring targeted microbiome support.

Description

Gram-negative anaerobic bacteria fermenting lactate in gut microbiome.

Measurements

Trend: Rising - Improvement but remains below reference range

October 2024.0: 0.021 %
February 2025.0: 0.059 % (average of 2 readings)

Clinical meaning

Low levels linked to reduced lactate metabolism and altered gut diversity
Persistent deficiency despite recent increase

Action

Consider prebiotic supplementation to support beneficial commensal bacteria growth.

Sample source

Stool

Alpha Fetoprotein [in Blood - Quantitative] (ug/L)

Loading chart...

Patient shows stable, normal protein levels over 14-month monitoring period.

Description Glycoprotein produced by liver and yolk sac used as tumor marker. Measurements Trend: Flat - Stable fluctuations within normal reference range. - September 2024: 5.0 ug/L - October 2024: 4.0 ug/L - December 2024: 5.9 ug/L - March 2025: 4.85 ug/L average (2 readings) - May 2025: 6.1 ug/L - June 2025: 6.0 ug/L - July 2025: 3.8 ug/L - September 2025: 5.4 ug/L - October 2025: 5.6 ug/L - November 2025: 4.8 ug/L Clinical meaning - Values remain consistently within normal limits. - No evidence of pathological elevation. Action No action required. Sample source Blood.

Cancer Antigen 19-9 [in Blood - Quantitative] (U/mL)

Loading chart...

All values consistently normal with favorable downward trend since peak.

Description Sialylated Lewis blood group antigen used as marker for pancreatic and biliary malignancies. Measurements Trend: Falling - Significant decrease from December peak followed by stable low values. - September 2024: 10.1 U/mL - October 2024: 4.0 U/mL - December 2024: 27.9 U/mL - March 2025: 6.55 U/mL average (2 readings) - May 2025: 5.7 U/mL - June 2025: 7.1 U/mL - July 2025: 6.6 U/mL - September 2025: 4.6 U/mL - October 2025: 2.9 U/mL - November 2025: 5.9 U/mL Clinical meaning - Transient elevation in December 2024 resolved without intervention. - All readings remain below clinical cutoff. Action No action required. Sample source Blood.

Carcinoembryonic Antigen [in Blood - Quantitative] (ug/L)

Loading chart...

Patient exhibits stable, normal tumor marker levels across 13 months.

Description Glycoprotein marker used for monitoring malignancy and treatment response. Measurements Trend: Flat - consistently low values within normal range. - September 2024: 0.5 ug/L - October 2024: 0.4 ug/L (Avg of 2) - December 2024: <0.50 ug/L - March 2025: 0.5 ug/L - May 2025: <0.50 ug/L - June 2025: <0.50 ug/L - July 2025: <0.50 ug/L - September 2025: 0.5 ug/L - October 2025: 0.5 ug/L (Avg of 2) Clinical meaning - Values remain significantly below clinical thresholds. - Stability suggests absence of new or recurring CEA-producing pathology. Action No action required. Sample source Blood.

Dunedin PACE of Aging [in Blood - Quantitative] (Years)

Loading chart...

Biological aging pace is currently optimal and shows improvement from earlier 2025 readings.

Description Epigenetic clock measuring biological rate of aging relative to chronological time. Measurements Trend: Falling slightly - recent decrease from 2025 peak toward lower biological aging rate. - January 2024: 0.8 Years - January 2025: 0.9 Years (Avg of 3) - February 2025: 0.915 Years (Avg of 2) - March 2025: 1.0 Years - June 2025: 0.7 Years - September 2025: 0.8 Years Clinical meaning - Result of 0.8 indicates biological aging 20 percent slower than average. - Recent decline from 1.0 peak indicates improvement in biological pace. Action Maintain current lifestyle interventions supporting longevity. Sample source Blood.

Cancer Antigen 15-3 [in Blood - Quantitative] (U/mL)

Loading chart...

All results remain well below threshold of 32.4 U/mL.

Description Tumor marker for breast tissue monitoring. Measurements Trend: Flat - Stable low-level fluctuations. September 2024.0: 8.8 U/mL, December 2024.0: 11.3 U/mL, March 2025.0: 8.2 U/mL, May 2025.0: 6.7 U/mL, June 2025.0: 8.1 U/mL, July 2025.0: 8.3 U/mL, September 2025.0: 8.1 U/mL. Clinical meaning Values consistently within reference range. No evidence of significant rising trend. Action No action required. Sample source Blood.

Corneal Keratometry (K1) [Quantitative] (Diopters)

Loading chart...

Results labeled out of range and show slight decline requiring ophthalmic review.

Description Measurement of corneal curvature power. Measurements Trend: Falling slightly - Decreasing diopters over time. January 2025.0: 40.93 Diopters (average of 2), November 2025.0: 40.47 Diopters (average of 4). Clinical meaning Results indicate flat corneal curvature. Lower diopter values suggest potential refractive error or corneal shape changes. Action Correlate with visual acuity and topography. Sample source Unknown.

Corneal Keratometry (K2) [Quantitative] (Diopters)

Loading chart...

Biomarker demonstrates stable corneal curvature over time.

Description Measure of steepest corneal curvature (steep meridian). Measurements Trend: Flat - Curvature remains stable across both eyes. Jan 2025: 41.53 D (avg 2), Nov 2025: 41.44 D (avg 4). Clinical meaning Consistent readings suggest corneal stability. Values indicate flat corneal profile or post-surgical state. Action Correlate with visual acuity and refractive error to assess surgical or diagnostic needs. Sample source Unknown.

Corneal Diameter (White-to-White) [Quantitative] (mm)

Loading chart...

Corneal diameter remains stable and within expected biometric parameters.

Description Horizontal distance between limbus borders (White-To-White). Measurements Trend: Flat - No significant change in corneal diameter. Jan 2025: 12.0 mm (avg 3), Dec 2025: 12.0 mm (avg 2). Clinical meaning Stable dimensions essential for intraocular lens (IOL) sizing. Readings reflect normal adult anatomical range. Action No action required; use values for pre-operative cataract or refractive planning. Sample source Unknown.

OMICm Age Difference from Chronological Age [Quantitative] (Years)

Loading chart...

Biological age gap improved significantly from +6.3 to -0.65 years over six months.

Description Epigenetic measurement of biological aging versus actual age. Measurements Trend: Falling - Significant reduction in biological age gap. - February 2025: 6.3 Years - March 2025: 2.5 Years - June 2025: 3.5 Years - August 2025: -0.65 Years (avg of 2) Clinical meaning - Biological age decreased from older than chronological age to slightly younger. - Positive response to lifestyle or clinical interventions. Action Continue current health optimization protocols to maintain youthful biological profile. Sample source Blood

Prostate Specific Antigen [in Blood - Quantitative] (ug/L)

Loading chart...

PSA levels remain stable and well below clinical thresholds for concern.

Description Blood protein produced by prostate gland cells. Measurements Trend: Rising slightly - Stable baseline with minor recent elevation. - October 2024: 0.71 ug/L - March 2025: 0.65 ug/L - October 2025: 0.81 ug/L - November 2025: 0.86 ug/L Clinical meaning - All values well within age-appropriate reference ranges. - Low risk for significant prostate pathology. Action No action required; continue routine annual screening. Sample source Blood

SYMPHONY Age (Musculoskeletal) [in Blood - Quantitative] (Years)

Loading chart...

Musculoskeletal age remains high but shows recent favorable decline.

Description Epigenetic clock estimate of biological musculoskeletal age. Measurements Trend: Falling - Recent improvement from peak. March 2024: 50.65 average (2 readings)
February 2025: 54.3
March 2025: 54.7
June 2025: 51.6. Clinical meaning Results consistently show biological age exceeding chronological age. Recent decline suggests positive response to intervention. Action Continue current musculoskeletal support protocols and monitor for further downward trend. Sample source Blood.

Anterior Chamber Depth [Quantitative] (mm)

Loading chart...

Measurements remain stable but outside expected range requiring specialist review.

Description Ocular measurement of distance between cornea and iris. Measurements Trend: Flat - Stable values across timeline. January 2025: 3.51 average (2 readings)
December 2025: 3.51 average (2 readings). Clinical meaning Stable out-of-range measurements indicate persistent anatomical deviation. Lack of change suggests no acute progression. Action Consult ophthalmology to evaluate risk of angle-closure glaucoma based on stable depth readings. Sample source Unknown.

Axial Length [Quantitative] (mm)

Loading chart...

Persistent out-of-range axial length indicates high myopia requiring specialist monitoring.

Description Distance from anterior corneal surface to retina. Measurements Trend: Flat - Mean values consistent across year. January 2025: 25.76 mm average (2 readings)
December 2025: 25.76 mm average (2 readings). Clinical meaning Measurements suggest high axial myopia. Increased length correlates with risk of retinal pathology. Action Monitor via comprehensive ophthalmology exams and retinal imaging.

Fusobacteria (Phylum) Percentage [in Stool - Quantitative] (%)

Loading chart...

Biomarker reflects healthy gut flora with undetectable levels of pathobionts.

Description Stool marker for opportunistic pro-inflammatory bacteria. Measurements Trend: Falling - Levels decreased to zero in latest samples. July 2024: 0.0015% average (2 readings)
October 2024: 0.002%
February 2025: 0.0% average (2 readings). Clinical meaning Low/zero levels typical and generally favorable. Prevents potential gut mucosal inflammation. Action No action required. Sample source Stool.

Lens Thickness [Quantitative] (mm)

Loading chart...

Persistent out-of-range lens measurements require clinical correlation via eye exam.

Description Axial thickness of crystalline lens in eye. Measurements Trend: Flat - values stable over 11 months. January 2025: 4.00 mm average (2 readings). December 2025: 4.00 mm average (2 readings). Clinical meaning - Values consistently out of range. - Potentially indicates lens changes or age-related biometric shifts. Action Schedule comprehensive ophthalmological exam to assess visual acuity and cataract progression. Sample source Unknown.

Lung System Score [Quantitative] (percentile)

Loading chart...

Lung function score remains out of range but shows recent positive trajectory.

Description Composite metric of pulmonary function relative to population. Measurements Trend: Rising slightly - moderate recovery after initial drop. March 2024: 56.3 percentile. February 2025: 51.4 percentile. March 2025: 51.6 percentile. June 2025: 57.9 percentile. Clinical meaning - Scores indicate function in lower half of population. - Recent upward trend suggests improving respiratory status. Action Monitor for continued improvement and perform spirometry if respiratory symptoms emerge. Sample source Unknown.

Metabolic System Score [Quantitative] (percentile)

Loading chart...

Persistent abnormal metabolic scores require continued monitoring and diagnostic workup.

Description Composite percentile score reflecting metabolic function and efficiency. Measurements Trend: Rising slightly - Improvement from baseline despite early dip. March 2024: 55.8 percentile
February 2025: 53.1 percentile
March 2025: 57.6 percentile
June 2025: 58.2 percentile. Clinical meaning Persistent out-of-range status suggests metabolic dysregulation. Recent trend indicates gradual stabilization. Action Investigate insulin sensitivity and lipid profile. Sample source Unknown.

Musculoskeletal System Score [Quantitative] (percentile)

Loading chart...

Abnormal musculoskeletal scores show recent downward trend requiring clinical attention.

Description Composite percentile score assessing musculoskeletal integrity and health. Measurements Trend: Falling slightly - Decline following peak in early 2025. March 2024: 49.7 percentile
February 2025: 54.3 percentile
March 2025: 54.7 percentile
June 2025: 51.6 percentile. Clinical meaning Scores consistently outside expected range. Recent decrease suggests potential loss of bone or muscle density. Action Evaluate physical activity levels and vitamin D/calcium intake. Sample source Unknown.

Bone Mineral Density T-Score [Quantitative]

Loading chart...

Patient maintains healthy bone mineral density above osteopenia threshold.

Description Bone density comparison to young healthy adult average. Measurements Trend: Rising - Improvement followed by slight stabilization. - July 2024.0: -0.9 (avg of 2) - March 2025.0: 0.7 - November 2025.0: -0.1 Clinical meaning - Values consistently within normal range (>-1.0). - Current density suggests low fracture risk. Action No action required. Sample Source: Unknown.

Citrobacter freundii [in Stool - Quantitative] (%)

Loading chart...

Results show no detectable levels of Citrobacter freundii across all test dates.

Description Gram-negative opportunistic enteric bacterium. Measurements Trend: Flat - consistently undetectable. - July 2024.0: 0.0 % - October 2024.0: 0.0 % - February 2025.0: 0.0 % (average of 2 readings). Clinical meaning - Absence indicates low risk for associated opportunistic infections. - Stable within reference range. Action No action required. Sample source Stool.

Clostridium histolyticum [in Stool - Quantitative] (%)

Loading chart...

Biomarker remains within healthy limits with a downward long-term trend.

Description Proteolytic gut bacterium associated with collagen degradation. Measurements Trend: Falling slightly - overall reduction from initial levels. - July 2024.0: 0.444 % - October 2024.0: 0.046 % - February 2025.0: 0.139 %. Clinical meaning - Levels remain within normal reference range. - Recent slight increase from October remains well below upper threshold. Action No action required. Sample source Stool.

Clostridium perfringens [in Stool - Quantitative] (%)

Loading chart...

Bacteria levels remain undetectable and within reference range.

Description

Quantitative marker of pathogenic anaerobic gut bacteria.

Measurements

Trend: Flat - stable at zero

July 2024.0: 0.0 %
October 2024.0: 0.0 %
February 2025.0: 0.0 %

Clinical meaning

No detectable overgrowth of C. perfringens.
Normal gut flora composition regarding this species.

Action

No action required.

Sample source

Stool

Desulfovibrio (Percentile) [in Stool - Quantitative] (percentile)

Loading chart...

Recent values show significant reduction to lower population percentile.

Description Percentile ranking of sulfate-reducing bacteria in gut microbiome. Measurements Trend: Falling fast - Significant drop from moderate to low percentile. - July 2024.0: 60.0 percentile - October 2024.0: 62.0 percentile - February 2025.0: 22.0 percentile (average of 2 readings) Clinical meaning - Recent shift suggests decreased hydrogen sulfide production potential. - Current level indicates low prevalence relative to reference population. Action Monitor for changes in digestive symptoms associated with sulfate metabolism. Sample source Stool.

Desulfovibrio [in Stool - Quantitative] (%)

Loading chart...

Biomarker remains stable and well within normal range.

Description Relative abundance of Desulfovibrio genus in gut microbiota. Measurements Trend: Falling fast - Sharp decrease in total percentage. - July 2024.0: 0.02 % - October 2024.0: 0.022 % - February 2025.0: 0.002 % (average of 2 readings) Clinical meaning - Low levels typically associated with reduced gut inflammation risk. - All readings remain within optimal clinical reference range. Action No action required as values remain within healthy limits. Sample source Stool.

Escherichia [in Stool - Quantitative] (%)

Loading chart...

Normal values with stable low-level abundance since October 2024.

Description

Quantitative assessment of Escherichia genus abundance within stool microbiota.

Measurements

Trend: Falling - Initial decrease followed by stabilization at low levels.

July 2024.0: 0.015 %
October 2024.0: 0.001 %
February 2025.0: 0.001 % (average of 2 readings)

Clinical meaning

Current levels well within reference range.
Significant reduction from 2024 indicates decreased pathobiont presence.

Action

No action required.

Sample source

Stool

Escherichia coli [in Stool - Quantitative] (%)

Loading chart...

Biomarker levels reflect healthy baseline and remain consistently within reference range.

Description

Quantitative stool marker for Escherichia coli species within gut microbiome.

Measurements

Trend: Flat - Minimal fluctuation at baseline.

July 2024.0: 0.0 %
October 2024.0: 0.001 %
February 2025.0: 0.0 %

Clinical meaning

Levels remain consistently near zero.
No evidence of E. coli overgrowth or pathobiont imbalance.

Action

No action required.

Sample source

Stool

Eubacterium [in Stool - Quantitative] (%)

Loading chart...

Values remain within reference range despite downward trend.

Description

Beneficial gut commensal bacteria producing short-chain fatty acids.

Measurements

Trend: Falling fast - Sharp decrease over seven months

July 2024.0: 0.777 %
October 2024.0: 0.078 %
February 2025.0: 0.045 % (average of 2 readings)

Clinical meaning

Low abundance suggests reduced metabolic support for intestinal lining.
Consistent decline indicates potential loss of microbial diversity.

Action

Increase intake of prebiotic fibers and resistant starches to support commensal growth.

Sample source

Stool

Faecalibacterium (Percentile) [in Stool - Quantitative] (percentile)

Loading chart...

High percentile indicates strong presence of beneficial anti-inflammatory bacteria.

Description

Major butyrate-producing bacteria used as marker for gut health and anti-inflammation.

Measurements

Trend: Rising - Rebounded to peak levels after slight dip

July 2024.0: 88.0 percentile
October 2024.0: 82.0 percentile
February 2025.0: 93.0 percentile

Clinical meaning

High percentile indicates robust anti-inflammatory capacity in gut environment.
Consistently high levels correlate with protective mucosal health.

Action

No action required as high levels of this beneficial microbe are generally favorable.

Sample source

Stool

Gram Negative Bacteria (Percentile Rank) [in Stool - Quantitative] (percentile)

Loading chart...

Gram-negative bacterial load has stabilized within normal percentile ranges.

Description Percentile rank of Gram-negative bacteria relative to reference population distribution. Measurements Trend: Flat - Significant fluctuation with return toward baseline. - July 2024: 38.0 percentile - October 2024: 71.0 percentile - February 2025: 48.0 percentile Clinical meaning - Recent value shows stabilization within middle quartiles. - Temporary spike in October suggests transient microbiome shift. Action No action required as current levels are within normal community distribution. Sample source Stool.

Gram Positive Bacteria (Percentile Rank) [in Stool - Quantitative] (percentile)

Loading chart...

Gram-positive levels remain stable and within reference ranges despite temporary decline.

Description Proportion of Gram-positive bacteria within gut microbiome community distribution. Measurements Trend: Rising - Recovery to mid-range after October dip. July 2024: 59.0 percentile
October 2024: 28.0 percentile
February 2025: 56.0 percentile (avg of 2). Clinical meaning Fluctuations suggest microbiome shifts but remain within expected community ranges. Maintains diversity of thick-walled bacterial taxa. Action No action required. Sample source Stool.

Klebsiella [in Stool - Quantitative] (%)

Loading chart...

Klebsiella levels are optimal and show a positive downward trend to zero.

Description Abundance of Klebsiella genus, potential opportunistic pathogen. Measurements Trend: Falling - Consistent decline toward zero. July 2024: 0.01 %
October 2024: 0.007 %
February 2025: 0.0 %. Clinical meaning Low to undetectable levels indicate minimal risk from this pathobiont. Gradual reduction shows favorable gut profile. Action No action required. Sample source Stool.

Methanobrevibacter [in Stool - Quantitative] (%)

Loading chart...

Biomarker stable and within normal limits across all time points.

Description Archaeon genus producing methane in gut environment. Measurements Trend: Flat - consistently undetectable levels. - July 2024: 0.0% - October 2024: 0.0% - February 2025: 0.0% (average of 2 readings). Clinical meaning - Absence indicates low risk of methane-related constipation or bloating. - Levels remain within optimal reference range. Action No action required. Sample source Stool.

Myrosinase [in Stool - Quantitative] (%)

Loading chart...

Levels remain healthy and significantly above reference minimums despite recent decline.

Description Enzyme converting glucosinolates into bioactive isothiocyanates like sulforaphane. Measurements Trend: Falling - significant decrease after October peak. - July 2024: 8.38% - October 2024: 19.2% - February 2025: 9.52%. Clinical meaning - Values remain well above minimum clinical thresholds. - Decline from October suggests shift in microbial enzyme production capacity. Action Monitor dietary cruciferous vegetable intake to maintain beneficial levels. Sample source Stool.

Neurogranin [in Blood - Quantitative] (Percentile)

Loading chart...

Biomarker values are stable and within the normal percentile range.

Description Blood protein marker indicating synaptic health and cognitive function. Measurements Trend: Flat - Fluctuating within normal range. March 2025.0: 58.0 Percentile
June 2025.0: 76.0 Percentile
August 2025.0: 54.0 Percentile. Clinical meaning - Values remain within reference range suggesting stable synaptic integrity. - No immediate evidence of neurodegenerative acceleration. Action No action required. Sample source Blood.

Prevotella (Bacteroidetes) [in Stool - Quantitative] (%)

Loading chart...

Bacteroidetes levels are rising healthily within normal clinical bounds.

Description Commensal gut bacteria associated with fiber-rich diets and gut health. Measurements Trend: Rising - Consistent increase over seven months. July 2024.0: 0.029 %
October 2024.0: 0.921 %
February 2025.0: 1.867 % (Average of 2). Clinical meaning - Increasing colonization indicates shifting gut microbiome composition. - Current levels remain within normal reference limits. Action Monitor dietary fiber intake to maintain healthy microbiome diversity. Sample source Stool.

Segmental Lean Analysis (Right Arm Percentage) [Quantitative] (%)

Loading chart...

Muscle mass has normalized and is now well within target range.

Description Ratio of muscle mass in right arm compared to ideal lean weight for sex and height. Measurements Trend: Rising - Significant improvement from below target to optimal. October 2024.0: 94.7 percent. November 2025.0: 103.1 percent. Clinical meaning - Current value demonstrates healthy lean mass distribution. - Resolved previous deficit identified in late 2024. Action Maintain current physical activity and nutritional intake to support muscle mass. Sample source Unknown.

Segmental Lean Analysis (Right Arm) [Quantitative] (kg)

Loading chart...

Right arm lean mass improved into healthy reference range over time.

Description

Assessment of localized muscle mass in right arm via bioimpedance or DXA.

Measurements

Trend: Rising - Slight increase in lean mass over 13 months

October 2024: 2.78 kg
November 2025: 2.96 kg

Clinical meaning

Value recovered to low-normal range from previous deficit
Suggests improved localized muscle retention or hypertrophy

Action

Maintain current resistance training and protein intake to move further into mid-reference range.

Sample source

Unknown

Sutterella (Percentile) [in Stool - Quantitative] (percentile)

Loading chart...

High variability in Sutterella abundance suggests inconsistent microbiome composition.

Description

Abundance ranking of Sutterella genus within gut microbiome.

Measurements

Trend: Falling - Significant drop following previous sharp spike

July 2024: 31.0 percentile
October 2024: 88.0 percentile
February 2025: 43.0 percentile

Clinical meaning

Fluctuating levels indicate instability in commensal gut flora
High levels sometimes associated with gastrointestinal inflammation or dysbiosis

Action

Monitor for GI symptoms and consider prebiotic fiber to stabilize microbial diversity.

Sample source

Stool

SYMPHONY Age (Musculoskeletal) [Quantitative] (Years)

Loading chart...

Musculoskeletal age stable but flagged out of range.

Description Epigenetic marker assessing musculoskeletal system biological age. Measurements Trend: Flat - minimal change across 2025. - January 2025: 51.6 Years - August 2025: 51.7 Years - September 2025: 51.7 Years Clinical meaning - Biological age remains stable. - Out-of-range flag in August suggests potential deviation from target benchmarks despite stable trend. Action Investigate lifestyle or supplement factors affecting musculoskeletal health. Sample source Blood.

Weight [Quantitative] (kg)

Loading chart...

Weight successfully stabilized within healthy clinical range.

Description Measure of total body mass. Measurements Trend: Falling - decrease of 2.7kg over 16 months. - July 2024: 62.83 kg (average of 3) - November 2025: 60.3 kg Clinical meaning - Weight moving lower within normal reference range. - Previous out-of-range status resolved by latest measurement. Action No action required as current weight is within reference range. Sample source Unknown.

Health Data Analysis

Health Timeline

Patterns of Concern

Healthy Patterns

Follow Up Tests

Blood/Hematology

Vitamins & Minerals

Cardiovascular

Hormones

Kidney Function

Immune System

Liver Function

Endocrine/Metabolic

Thyroid

Uncategorized